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ABSTRACT
Many studies have examined the association between corporate social responsibility (CSR) and
corporate financial performance, but scholars argue that the exact relationship between CSR and
corporate financial performance remains unclear. This quantitative study examines the impact of
CSR on corporate financial performance in the pharmaceutical industry. The study addresses the
research question: What is the financial performance in the pharmaceutical industry among
companies that have embraced CSR? The alternative hypothesis predicted positive correlations
between financial performance and CSR. The related null hypotheses predicted that there would
be no correlations between any of 8 dimensions of CSR and corporate financial performance.
Archival data from 18 leading global pharmaceutical companies ranked by Access to Medicine
Index were used to answer the research question.
In 4 of the 8 hypotheses tested, the results show partial support for a positive effect of
CSR on corporate financial performance in the pharmaceutical industry based on significant
correlations in 2014. Specifically, significant 2014 relationships with corporate financial
performance were observed for CSR general access to medicine management, CSR capacity
advancement in product development and distribution, CSR product donations and philanthropic
activities, and overall CSR. However, no significant 2014 relationships with corporate financial
performance were observed for CSR public policy and market influence, CSR research and
development, CSR pricing, manufacturing, and distribution, and CSR patents and licensing. In
the 8 hypotheses tested, the findings in 2012 did not show any effect of CSR on corporate
financial performance in the pharmaceutical industry. The results of this study suggest at the
minimum, that CSR does not negatively impact corporate financial performance in the
pharmaceutical industry. This study does not support arguments against product donations and

xiii
philanthropic activities. The partial support for a positive effect of CSR on corporate financial
performance and no negative impact of CSR on financial performance in the pharmaceutical
industry, could encourage corporate leaders to pay attention to, not only their corporate financial
profits, but also ethical, environmental, and social issues such as improving the access to
medicines; and contributing to improving society.
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Chapter 1: The Problem
Our world is threatened by serious global climate changes and socioeconomic concerns.
Most climate scientists agree that the major cause of the current global warming is the heat
entrapped by the atmosphere, which is radiating from the earth into space; a phenomenon called
the greenhouse effect (D. Lee & Brenner, 2015). Researchers have warned that carbon dioxide
and other greenhouse gas emissions (water vapor, methane, and nitrous oxide) are at their highest
level worldwide ever (Burney, Kennel, & Victor, 2013). The burning of fossil fuels such as coal
and oil throughout the past century has increased the atmospheric concentration of carbon
dioxide. The amount of these gases released into the atmosphere in 2010 was 31% higher than
the 1990. The increase in global temperatures as a result of climate change has far-reaching
consequences for human beings and the earth’s ecosystems. Many scientists believe that there is
a relationship between man-made carbon dioxide emissions and rising global temperatures.
Extreme atmospheric temperatures can cause health issues for the sick and elderly. Unusually
high temperatures and socioeconomic factors were reported to have caused the death of more
than 14,947 individuals in France, between August 4 and 18, 2003 (Poumadère, Mays, Le Mer,
& Blong, 2005). Extreme weather conditions such as the severe drought in California can reduce
available water resources, reduce agricultural yields, and affect human health and well-being.
In addition to the extreme climatic changes, the world population has more than doubled
from 3 billion in 1960 to about 6.7 billion in 2009 (Leisinger, 2009, 2012). The number of
people living in Africa quadrupled during the same period to about 944 million, while the
population of Asia increased to more than 4 billion people. Some estimate that about 20% of
people in the developing countries (more than a billion human beings) still live on less than
$1.25 per day (Arnold & Valentin, 2013). Another 1.5 billion people are projected to live on $2
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or less a day (Arnold & Valentin, 2013; Leisinger, 2009). Together they constitute more than 2.6
billion people who are struggling daily to meet their basic needs. Poverty in these
underprivileged countries prevents patients from accessing the medical care and medicines they
need. About 14 million people die every year from infectious diseases, and more than 2 billion
people lack access to medicines for treatable health conditions (M. Lee & Kohler, 2010).
Researchers have reported that in 2003, more than 35 million people were infected with the HIV
virus globally, and 95% of these people lived in Africa (Margolis & Walsh, 2003). Some people
have suggested that pharmaceutical companies owe a moral obligation to society to make their
drugs more affordable to people, especially the poor (Nussbaum, 2009), because access to
medicine is recognized by some in the international community as a fundamental human right
(Ravi Shankar, 2013). Thus, when the pharmaceutical corporations neglect their corporate social
responsibility (CSR), they can become targets for criticism from different advocacy groups that
insist that pharmaceutical products should be more available, affordable, and accessible,
especially to the poor (Nussbaum, 2009).
Critics of the pharmaceutical industry have even gone as far as accusing the industry of
many crimes, including “high prices, immoral marketing, presents to medical doctors,
abandoning the poor, no money-no cure attitude,…and industry-government alliances”
(Nussbaum, 2009, p. 68). Pharmaceutical companies have also been blamed for recruiting
volunteers in the third world and enrolling them in clinical trials without informed consent.
These test subjects are used as inexpensive guinea pigs to test drugs that have not yet been
approved for testing in the U.S. These clinical trial subjects are poorly paid for their services, and
they are unable to afford the drugs under trial because the drugs are developed for Western
markets. Many researchers believe that the CSR of the pharmaceutical industry is providing
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affordable drugs for everyone (Esteban, 2008; K. M. Leisinger, 2009; Nussbaum, 2009). There is
a mounting surge of demands being placed upon the pharmaceutical industry to contribute to
improved access to medicines for poor patients in developing countries (K. M. Leisinger, 2009,
2012). One criteria used to define CSR of the pharmaceutical industry in this study is the
philanthropic initiative of pharmaceutical companies to increase global access to medicines.
Background of the Study
CSR, also called corporate conscience, corporate citizenship, or sustainable responsible
business (Wood, 1991), is a form of corporate self-regulation assimilated into a business model.
CSR involves responsibility for corporate actions whereby a business continuously monitors and
ensures that its actions encourage a positive impact on the environment and stakeholders,
including consumers, employees, investors, and communities. CSR and corporate sustainability
management include the evaluation of the impact of the company’s economic, social, and
environmental policies, and taking necessary actions to improve the impact according to the
stakeholders’ requirements (T. Katsoulakos & Y. Katsoulakos, 2007).
Some have argued that discovering and developing new drugs and vaccines is the
primary CSR of pharmaceutical companies, while others argue that recognizing the need for new
products for neglected diseases is a clear example of CSR in pharmaceutical companies
(Leisinger, 2005, 2009). The pharmaceutical industry is considered one of the most appreciated
industries because it develops therapeutic products that cure people’s ailments (Nussbaum,
2009). Researchers have argued that the same industry is one of the most criticized because it
does not provide everyone access to its therapeutic products. Leisinger (2009) contends that
pharmaceutical companies should contribute to improving access to medicine for poor people.
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Numerous studies have investigated the impact of CSR on corporate financial
performance. Nevertheless, many researchers have reached different conclusions about the
relationship between CSR and corporate financial performance (Robins, 2011). Some studies
found that greater participation in CSR was associated with better corporate financial
performance in consumer industries, while the opposite was true for industrial businesses. While
results of these studies were mixed, overall, the findings showed a positive but weak correlation
between CSR and corporate financial performance.
Debates have continued to rage about the relationship between CSR and corporate
financial performance since Milton Friedman proposed that making a profit is the social
responsibility of a corporation (Griffin & Mahon, 1997). On one hand, economic arguments
suggest that managers should make decisions that maximize the wealth of their firm’s equity
holders. On the other hand, some scholars have argued that firms have a duty to society that goes
well beyond simply maximizing the wealth of corporations (Mackey, Mackey, & Barney, 2007).
Mackey et al. argue that such a narrow focus on the company’s bottom line can compel the
management to ignore other important stakeholders, including employees, suppliers, customers,
and the society at large. Some believe that corporations would embrace CSR if they perceive that
at least some forms of CSR initiatives may improve the present value of a firm’s future cash
flows; thus, integrating CSR may be consistent with maximizing the wealth of the firm’s
shareholders (McWilliams & Siegel, 2000). CSR proponents posit that socially responsible
behavior can enable a firm to differentiate its products in the market. Advocates argue that
corporations increase long-term profits by operating with a CSR perspective, while critics argue
that CSR distracts from business’s economic role (Nussbaum, 2009). CSR critics argue that there
is no business case for CSR, and that CSR conscious companies underperform financially, or at
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least do not perform better than CSR-unconscious companies. CSR advocates contend that
corporate leaders may increase their CSR efforts and help address some global socioeconomic
challenges such as reducing poverty and improving the access to medicine if the leaders are
convinced that CSR is positively linked to financial performance (McWilliams & Siegel, 2000).
The myriad views about the impact of CSR on financial performance calls for more research
because most executives are only now warming up to the notion that CSR can improve profits
(Edmans, 2012; Robins, 2011).
These corporate executives understand that CSR can promote respect for their company
in the marketplace, which can result in higher sales, enhance employee loyalty, and attract better
personnel to the firm (Edmans, 2012; Robins, 2011). Public corporations realize that aggressive
CSR activities may help them gain a possible listing in the Dow Jones Sustainability Indexes,
Access to Medicine Index, or other similar CSR rating indexes (Robins, 2011). These
corporations realize that listing in the indexes may enhance the company’s stock price, making
executives’ stock and stock options more profitable and shareholders happier. A study by the
Economist Intelligence Unit found that “corporate citizenship is becoming increasingly
important for the long-term health of companies even though most struggle to show a return on
their investment from socially responsible activities” (as cited by Robins, 2011, p. 1). Many
researchers and industries differ in their views on the impact of CSR on financial performance.
This study differs from previous studies because it examines the impact of CSR on financial
performance in one industry: the pharmaceutical industry. Each industry is unique because each
industry has different competencies and internal and external pressures. Therefore, the internal
and external pressures in an industry, such as governmental regulations and consumer issues, are
likely to be similar within each industry (Griffin & Mahon, 1997). Researchers have argued that
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a study should focus on a single industry to allow the scholar to determine if similar issues
within the industry are treated in a like manner (Griffin & Mahon, 1997). In view of the public
perception that the high cost of pharmaceutical drugs denies the poor access to medicines
(Leisinger, 2009, 2012), and the complex regulations placed on the industry by the government
(Griffin & Mahon, 1997), the pharmaceutical company is an ideal model for studying the impact
of CSR on corporate financial performance.
The public is calling on the pharmaceutical industry to care for not only corporate profits,
but also to provide willingly affordable medicines to everyone. The public outcry is supported by
the stakeholder theory that argues that a company should be operated not only to maximize
shareholder value, but also for the benefits of its stakeholders (Freeman, Wicks, & Parmar,
2004). A company is perceived as being sustainable when its business strategy balances the wellbeing of all its stakeholders with profit maximization (Cheng, Ioannou, & Serafeim, 2014).
Cheng et al. argue that by aligning their business strategies with the global social needs,
companies can generate benefits for all their stakeholders.
Berete’s (2011) research has identified CSR factors that impact financial performance in
the pharmaceutical industry. This study builds on Berete’s study by testing the strength of the
correlations between CSR and corporate financial performance as predictors of value creation for
stakeholders. Many studies have examined the relationship between the financial performance
and CSR, but no consensus has been reached about CSR demonstrating either value creation or
value erosion for stakeholders. For this study, corporate financial performance is the dependent
variable while CSR is the independent variable. The study examined the correlation of the same
seven independent variables used in Berete’s study: general access to medicine management,
public policy and market influence, research and development conducted on neglected diseases,
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the company’s pricing, manufacturing and distribution practices, patents and licensing policies,
capacity advancement in product development and distribution, drug donations, and
philanthropic activities against the dependent variable: financial performance.
Public financial data from the 20 pharmaceutical companies the CSR activities of which
are rated by the Access to Medicine Index were used to assess the impact of CSR on the
pharmaceutical industry’s financial performance. The Access to Medicine Foundation publishes
its ranking of 20 of the largest global pharmaceutical companies in seven major categories every
two years. The 2012 and 2014 Access to Medicine Index data were extracted for this study. The
Access to Medicine Index was first published and used to measure CSR in the pharmaceutical
industry in 2008 (Iyer, 2014). The Access to Medicine Index assesses and ranks 20 of the largest
global pharmaceutical companies’ performance on seven CSR categories. The seven categories
are: (a) general access to medicine management; (b) public policy and market influence; (c)
research and development conducted on neglected diseases; (d) pricing, manufacturing, and
distribution practices; (e) patent and licensing policies; (f) capacity advancement in product
development and distribution; and (g) drug donations and philanthropic activities.
The study measured the financial performance of the pharmaceutical companies using the
Economic Value Added (EVA). EVA also described as economic profit, is an internal
management performance measure that compares net operating profit to total cost of capital.
Stern Stewart & Co. is credited with devising this trademarked concept (Poornima, Narayan, &
Reddy, 2015; Venanzi, 2012). EVA is computed by deducting the cost of capital from the net
operating profit after tax. EVA = Net Operating Profit After Tax - (Capital Invested x the
weighted average cost of capital). As presented in the formula, there are three elements necessary
to calculate EVA: net operating profit after tax, invested capital, and the weighted average cost
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of capital. Net operating profit after tax can be calculated but can also be found on the
corporation’s income statement. The capital invested is the amount of money that was used to
fund a project. The weighted-average cost of capital can be calculated if the information is not
provided on the corporation’s income statement (Berete, 2011; Venanzi, 2012). The reason for
multiplying the weighted-average cost of capital and capital investment is to evaluate the charge
for using the invested capital (Venanzi, 2012). This charge is the amount that investors need to
make their investment worthwhile. EVA is important because it is used as an indicator of how
profitable company projects are and it serves as a reflection of management performance.
Problem Statement
CSR has been studied for decades, with interest greatly increasing in the last decade in
both scholarship and practice (Glavas & Kelley, 2014). In their content analysis of the CSR
literature, Glavas and Kelley found that 181 CSR articles have been published in top-tier
management journals, with about half being published since 2005. Moreover, at least 20 peerreviewed journals are specifically focused on CSR. Although numerous studies have investigated
the relationship between CSR and corporate financial performance there remain mixed results
about the relationship between CSR and corporate financial performance (Cheng et al., 2014).
This study contributes to the body of literature on CSR by advancing the comprehension of the
impact of CSR on financial performance in the pharmaceutical industry. This study builds on
earlier studies and differs from prior studies by analyzing the association between eight
dimensions of CSR and corporate financial performance in one industry.
Statement of Purpose
The purpose of this quantitative study is to analyze the impact of CSR on financial
performance in the pharmaceutical industry. The aim of the study is to ascertain if CSR leads to
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better financial performance in the pharmaceutical industry. Therefore, correlations were
computed to examine the relationship between CSR (independent variables), and the 2011–2014
financial performance (dependent variable). The strength of association between the dependent
variable and independent variables was assessed through linear correlation (using the Spearman
correlation coefficient) to determine whether a significant correlation exists. This study intended
to analyze the CSR performance of the 20 global pharmaceutical companies that are rated by the
Access to Medicine Index. However, the researcher studied 18 of the 20 pharmaceutical
companies that participated in the 2012 and 2014 Access to Medicine CSR rating because: (a)
Only 19 of the 20 pharmaceutical companies participated in both the 2012 and 2014 Access to
Medicine CSR ranking. The 20th company rated by the Access to Medicine in 2012 was
different from the 20th company rated in 2014; (b) One of the 19 companies that was rated by
the Access to Medicine in both 2012 and 2014 is a private and not a publicly traded company.
The financial data of this company are not publicly available unlike the financial data of the
publicly traded pharmaceutical companies. This study is designed to evaluate the world’s largest,
publicly traded pharmaceutical companies so that the findings of the study could be generalized
to other publicly traded pharmaceutical companies. The study is expected to influence change in
pharmaceutical companies’ contribution to society’s welfare by inspiring global pharmaceutical
industry leaders to invest in CSR to generate positive collective benefits for society.
Importance of Study
About 93% of the world’s largest 250 companies publish annual corporate responsibility
reports, almost 60% of which are independently audited (Nelson, 2014). That means companies
from sectors as diverse as financial services, information technology, consumer goods, gas, and
mining are making billions of dollars of public commitments to help solve societal challenges.
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Furthermore, the recent global financial crisis, concerns about corporate tax practices, and
challenges such as youth unemployment and climate change have forced corporations to lift their
sights above their economic bottom line and judge their performance against wider social goals.
Economic growth must be more inclusive and more sustainable. The burden is on corporations to
produce more jobs, products, services, and infrastructure for more people, while putting more
emphasis on decent work and fairness, and less strain on natural resources.
Although the study of CSR and its impact on corporate financial performance is growing,
it is still unknown whether high profits enable greater spending on CSR, or if CSR creates higher
profits (Robins, 2011). Berete’s (2011) study found positive correlation between CSR and
financial performance in the pharmaceutical industry. Because of the inconsistency that still
exists about the economic impact of CSR on financial performance, this study contributes to the
body of literature on CSR by advancing the comprehension of the impact of CSR on financial
performance in the pharmaceutical industry. This study is one of a small number of studies that
examined the relationship between CSR and financial performance in one industry. This study’s
findings could inspire pharmaceutical companies to invest in CSR, which would be beneficial to
society. If doing good, in terms of transparency in business practices and addressing social ills,
could be associated with doing well in corporate financial performance, then companies might be
persuaded to integrate CSR into their businesses (Margolis, Elfenbein, & Walsh, 2009; Porter &
Kramer, 2006). Businesses would be encouraged to do good even if it means sustaining
additional costs, so that they can improve their bottom lines and society’s well-being.
Definition of Terms
CSR is a business’s commitment to improve community well-being through discretionary
business practices and contributions of corporate resources (M. Lee & Kohler, 2010).
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CSR: The business policy that focuses on the pressures from stakeholders that were
negatively affected by the firm’s business processes, or the action taken voluntarily by a firm to
alleviate the stakeholder pressures and improve its profit and reputation (Jackson &
Apostolakou, 2010).
CSR is defined by the World Business Council for Sustainable Development (1998) as,
“the continuing commitment by business to behave ethically and contribute to economic
development while improving the quality of life of the workforce and their families as well as of
the local community and society at large” (p. 3).
Corporate citizenship (Googins, Mirvis, & Rochlin, 2007) is defined as being a,…good
company…taking serious steps to minimize the harms of business activity and maximize
the benefits not only to shareholders but also to a broader set of stakeholders… being
responsive to the needs of society and being accountable to stakeholders and the public
about corporate conduct. (p. 21)
CSR is defined as “The social responsibility of business encompasses the economic,
legal, ethical, and discretionary expectations that society has of organizations at a given point in
time” (Carroll, 1979, p. 500).
For the purpose of this study, CSR is defined as the voluntary commitment of business to
contribute not only to its economic development, but also to the advancement of the health and
well-being of the society.
Stakeholders: Stakeholders are groups that can affect or be affected by the actions of a
corporation such as customers, employees, government, shareholders, suppliers, and the
communities from which the corporation performs its business (Freeman, 1984).
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Pharmaceutical industry: The pharmaceutical industry is the business sector that
develops therapeutic products to cure life-threatening ailments (Nussbaum, 2009).
In studies on the economic impact of CSR, the terms CSR and corporate social
performance are usually used synonymously (von Arx & Ziegler, 2014). Corporate social
performance is a set of corporate activities and their impact and outcomes for the corporation,
society, and other stakeholders (Wood, 1991). This study consistently uses CSR instead of
corporate social performance. The definition of CSR most frequently cited by scholars is
Carroll’s (1979) definition, which states, “The social responsibility of business encompasses the
economic, legal, ethical, and discretionary expectations that society has of organizations at a
given point in time” (p. 500). Wood’s (1991) definition of CSR, which has gained popularity, is,
CSR is “a business organization’s configuration of principles of social responsibility, processes
of social responsiveness and polices, programs, and observable outcomes as they relate to the
firm’s societal relationships” (p. 693).
Theoretical Framework
This study uses the Global Leadership Network Framework to assess the impact of
corporate responsibility on the financial performance in the pharmaceutical industry. The Global
Leadership Network comprises 10 leading global companies, prominent U.S. and U.K. CSR
research centers, The Center for Corporate Citizenship at Boston College, and AccountAbility, a
U.K.–based research institute (Googins et al., 2007). Berger (2013) recently used the Global
Leadership Network Framework in a qualitative study of the development of CSR among U.S.
Fortune 500 global companies. The Global Leadership Network Framework comprises four
areas shown in Figure 1. In the first domain, called business strategy, companies evaluate their
business priorities and their CSR and consider alignment of their business strategy with CSR.
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Theoretical Framework

Learning, development,
and change through
direct involvement with
stakeholders

Business
Strategy

Alignment of social,
environmental, and
economic performance to
long-term business
strategy and performance

Engaged
Learning
Innovative initiatives
to address social,
environmental, and
economic challenges

Leadership

Operational
Excellence

Embedding
strategically aligned
corporate citizenship
in systematic
sustainable manner

Figure 1. Global Leadership Network Framework. Reprinted from Beyond Good Company: Next
Generation of Corporate Citizenship (p. 125), by B. K. Googins, P. H. Mirvis, & S. A. Rochlin,
2007, New York, N Y: Palgrave Macmillan. Copyright 2007 by Palgrave Macmillan. Reprinted
with permission.
The second domain, named engaged learning, deals with how companies interact with
their stakeholders to define their policy on CSR through a process of consultation with their
stakeholders. The third domain, termed leadership, is the commitment of the corporation to take
leadership on social and environmental issues that are important to the business. The fourth
domain, termed operational excellence, deals with how companies embed corporate citizenship
through coordination of processes, practices, policies, and relationships among the companies
and their multiple stakeholders to ensure alignment between the business strategy and the path
that will lead to the achievement of the desired corporate goal (Googins et al., 2007).
Research Questions
For more than three decades, many researchers have been trying to figure out if
companies that have integrated CSR in their business policy perform better financially than
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companies that have not integrated CSR (Cheng et al., 2014; Robins, 2011). This study examines
the impact of CSR on financial performance in the pharmaceutical industry. CSR is measured by
ratings form the Access to Medicine Index, and corporate financial performance is measured by
EVA. The research question that this study answers is: What is the financial performance in the
pharmaceutical industry among companies that have embraced CSR?
Hypothesis
This study uses EVA as measure of financial performance and Access to Medicine Index
scores as a measure of CSR. The study tests the following hypotheses:
Null Hypothesis (Ho):
1. There is no correlation between incorporation of general access to medicine
management (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
2. There is no correlation between incorporation of public policy and market influence
(independent variable) in the business strategy, and financial performance (dependent
variable) in the pharmaceutical industry.
3. There is no correlation between incorporation of research and development conducted
on neglected diseases (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
4. There is no correlation between incorporation of pricing, manufacturing, and
distribution practices (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
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5. There is no correlation between incorporation of patent and licensing policies
(independent variable) in the business strategy, and financial performance (dependent
variable) in the pharmaceutical industry.
6. There is no correlation between incorporation of capacity advancement in product
development and distribution (independent variable) in the business strategy, and
financial performance (dependent variable) in the pharmaceutical industry.
7. There is no correlation between incorporation of product donations and philanthropic
activities (independent variable) in the business strategy, and financial performance
(dependent variable) in the pharmaceutical industry.
8. There is no correlation between incorporation of CSR (overall independent variables)
in the business strategy, and financial performance (dependent variable) in the
pharmaceutical industry.
Alternative Hypothesis (H1):
1. There is a positive correlation between incorporation of general access to medicine
management (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
2. There is a positive correlation between incorporation of public policy and market
influence (independent variable) in the business strategy, and financial performance
(dependent variable) in the pharmaceutical industry.
3. There is a positive correlation between incorporation of research and development
conducted on neglected diseases (independent variable) in the business strategy, and
financial performance (dependent variable) in the pharmaceutical industry.
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4. There is a positive correlation between incorporation of pricing, manufacturing, and
distribution practices (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
5. There is a positive correlation between incorporation of patent and licensing policies
(independent variable) in the business strategy, and financial performance (dependent
variable) in the pharmaceutical industry.
6. There is a positive correlation between incorporation of capacity advancement in
product development and distribution (independent variable) in the business strategy,
and financial performance (dependent variable) in the pharmaceutical industry.
7. There is a positive correlation between incorporation of product donations and
philanthropic activities (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
8. There is a positive correlation between incorporation of CSR (overall independent
variables) in the business strategy, and financial performance (dependent variable) in
the pharmaceutical industry.
In a quantitative research, the alternative hypothesis is a statement that speculates about
the relationships between two or more relationships. The alternative hypothesis indicates the
changes in the dependent variable that can be ascribed to the independent variable (Martin &
Bridgmon, 2012). The null hypothesis is the hypothesis that presumes that there is no difference
between two sets of data in respect to some factor. The null hypothesis is usually tested
statistically and its nullification is considered as evidence in support of the alternative
hypothesis. When the null hypothesis is rejected, it indicates that there is a significant difference
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between the means of the samples in the study. The researcher has an inconclusive decision if the
sample means are not different, and he or she cannot reject the null hypothesis.
Assumptions
There are three assumptions in this study:
1. The CSR ranking by the Access to Medicine Index is an accurate evaluation of the
CSR of the pharmaceutical companies.
2. The annual financial reports provided by the pharmaceutical companies are accurate
public data.
3. The findings from the study of the 20 global pharmaceutical companies rated by the
Access to Medicine Index can be generalized to the whole pharmaceutical industry.
Limitations
The study measures CSR using scores provided by the Access to Medicine Index, but
there are only 20 participating pharmaceutical companies on the Access to Medicine Index. CSR
data for companies not on the Access to Medicine Index are not available for measurement.
However, the companies in this study represent 20 of the world’s largest pharmaceutical
companies and more than 50% of the global pharmaceutical market (Iyer, 2014).
Organization of the Study
Chapter 1 introduces the subject, the problem, purpose of the study, significance of the
study, theoretical framework, research questions, limitations, delimitations, and assumptions of
the study. Chapter 2 presents, first, a review of the literature on the pharmaceutical industry;
second, a literature review of CSR in the pharmaceutical industry; and third, a literature review
of studies that examined the relationship between CSR and corporate financial performance.
Chapter 3 explains the methodology and rational of this study, the research design, population,
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sample and sampling procedures, instruments, validity and reliability, study limitations, human
subject consideration, data collection, data management, and analysis.
Summary
The purpose of this quantitative study is to determine the degree to which CSR influences
changes in financial performance in the pharmaceutical industry. Many researchers have
investigated the association between CSR and corporate financial performance, but they have
differed in their findings about this relationship (Robins, 2011). The divergent views about the
impact of CSR on financial performance call for more research especially because most
executives are only now warming up to the notion that CSR can improve profits (Edmans, 2012;
Robins, 2011). The study expects to influence a change in the contribution of pharmaceutical
companies to the welfare of society at large by inspiring global pharmaceutical industry leaders
to invest in CSR to generate positive collective benefits for society.
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Chapter 2: Literature Review
The Pharmaceutical Industry
The pharmaceutical industry had its origin in the mid-19th century when the therapeutic
effects of synthetic dyes were first exploited in Germany and Switzerland. The dye-drug
connection precipitously initiated the way to discover drugs. The pioneering firms were Swiss
and German chemical companies such as Ciba, Sandoz, Bayer, and Hoechst. In the U.S., the
pharmaceutical industry had its beginning toward the end of the 19th century with the entrance
of firms such as Wyeth (American Home Products), Eli Lilly, Pfizer, and Warner-Lambert
(Grabowski, 2011; Malerba & Orsenigo, 2001, 2015). The German companies produced up to
80% of the world’s drug output and dominated the pharmaceutical industry until World War II.
The pharmaceutical industry did not engage in intensive research and development (R & D) until
the need for antibiotics and large-scale development of penicillin during World War II led to the
increasingly research-intensive pharmaceutical industry.
Major therapeutic advances were made by the industry a few decades after World War II
such as the discovery and manufacture of several antibiotics, including synthetic penicillin,
streptomycin, tetracycline, and many new vaccines for children’s diseases. This era was called
the golden age of the pharmaceutical industry (Grabowski, 2011; Malerba & Orsenigo, 2001,
2015). Because of the technical experience gained while developing penicillin during the war, as
well as the recognition that enormous profits could be made from drug development,
pharmaceutical companies started to invest heavily in R & D (Malerba & Orsenigo, 2001). The
development of the pharmaceutical industry in the U.S. and Europe was driven by increased
demand for drugs, growth in population, increased standards of living, and unmet medical needs.
The development of the industry was further augmented by the growth of the U.S. health care
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insurance and the welfare state in some European countries, which gave rise to organized
profitable market for drugs (Malerba, & Orsenigo, 2015). Consequently, the pharmaceutical
industry has been one of the most profitable manufacturing sectors since the late 19th century
(Liebenau, 1988).
As the pharmaceutical industry grew, so did the regulation of the industry. Government
testing and certification of pharmaceutical products was initiated between 1896 and 1926. Drug
regulation started in Germany, then the United States initiated similar testing and certification
requirements, and Britain followed at a much later time (Liebenau, 1988). Regulation of drugs
was a way to control the safety of drugs sold to the public to assure safety and ethical business
transactions of the manufacturers. The Food, Drug, and Cosmetic Act of 1938 was the first
legislation that required pharmaceutical companies to prove the safety of their drugs or products
before the Food and Drug Administration (FDA) would approve them for sale to the public. This
legislation was passed after 107 people died from taking a Sulfanilamide drug (Valverde, 2013).
An important regulation called the Orphan Drug Act was enacted in 1983 to compensate for the
loss of earnings of companies involved in developing drugs for rare diseases such as Malaria and
African Trypanosomiasis (sleeping sickness). Under the Orphan Drug Act, companies that
developed drugs for neglected diseases get tax breaks and sponsorships.
Developing a new drug is very time consuming, complex, and a highly risky venture that
does not guarantee that a new product might succeed and bring in revenues even after massive
investment of time and money. Pharmaceutical R & D requires a substantial amount or
investment of time and money, and a high proportion of drug development projects fail. The
drugs that eventually succeed take many years and billions of dollars in cost before they generate
sales revenues (Chit, Papadimitropoulos, Krahn, Parker, & Grootendorst, 2015; Harris, 2004). It
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takes many years to bring a drug candidate from discovery to preclinical development, through
three clinical trial phases, and to the market. There is a 1:1,000 probability of a product making it
to the market (Basavaraj & Betageri, 2014; Chit et al., 2015; Liu, Constantinides, & Li, 2014).
The cost of making a new drug has increased from $100 million in 1979 to $ 2.6 billion in 2014,
making outsourcing a cheaper and more attractive option for several key activities (Basavaraj &
Betageri, 2014).
A new product or compound (potential drug) must first be studied in laboratory animals
to determine toxicity and efficacy before it can be tested on human beings. In clinical trials, or
clinical studies, the new product is tested in human volunteers to see if the new product is safe
and potent enough to be approved for use in the general population. However, until the clinical
trials are complete, it is not known if the new product or compound is beneficial to patients. The
FDA’s Center for Drug Evaluation and Research evaluates new drugs for safety and
effectiveness before they can be sold to the American people. In clinical trials phase 1, a new
drug or product is tested on a small population to evaluate the safety and safe dosage range of the
drug, and to identify any potential side effects. In phase 2, the drug or product is tested on a
larger number of people to determine its efficacy and safety. In phase 3, the drug or product is
administered to several groups of people to confirm the efficacy of the drug and to monitor any
side effects. The drug is compared to other commonly used drugs, and information is gathered to
aid in the safe usage of the drug or product. Phase 4 starts after the drug has been marketed. Data
are collected on the effects of the drug in various populations to determine if there are any side
effects as a result of long-term drug use. Clinical trials are required by the FDA and they play a
key role in the discovery and development of a drug (U.S. FDA, 2012; Yang, 2012).
Pharmaceutical products or drugs are the main drivers for industry growth. Pharmaceutical
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companies compete intensely on the characteristics of their products to gain a competitive edge,
and they invest heavily in marketing their products to patients as well as to doctors (Valverde,
2013).
There are two major categories for pharmaceutical drug sales: branded and generic drugs
(similar in composition and function to brand, but not advertised as brand). Brand-name drugs
accounted for 92% of the sales volume but accounted for only half of the dispensed prescription
volume in the United States in 2001, according to IMS Health, a technology and information
services company (Grabowski, Long, & Mortimer, 2013). Branded pharmaceutical drug sales
have decreased because of the release of generics. The percentage of generic products in the total
prescriptions in the United States has increased from 36% in 1994 to 84% in 2012. Hence, the
introduction of these generics has caused pressure on pharmaceutical firms to develop more
blockbuster drugs with high profit margins. The increase in generic sales is largely a result of the
expiration of patents on branded drugs. When a branded-drug patents expire, it only takes six to
eight weeks for a generic to take a 50% share of the branded drug’s market compared with six
months historically.
The introduction of the Abbreviated New Drug Application process, which was the result
of the Hatch-Waxman Act, has been the most significant regulatory development for generics
(Grabowski et al., 2013; Malerba, & Orsenigo, 2015; Valverde, 2013). The Hatch-Waxman Act
provisions facilitated the approval of generic drugs by the FDA, thus encouraging the entry of
generic drugs into the market (Grabowski et al., 2013). One of the primary provisions of the act
decreased the cost of completing an FDA application for the approval of a generic drug. A new
mitigation strategy by biopharmaceutical companies includes the use of a less intensive R & D
method, outsourcing, and leveraging existing products by concurrently developing generics of
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branded drugs still covered by patents; more aggressive protection of intellectual property; and
developing product-line extensions with longer patent life.
The pharmaceutical industry is highly regulated (Adobor, 2012; Valverde, 2013). Before
bringing a product to market, companies must show that the drug is safe and offers measurable
benefits to patients. After the drug is approved, the FDA requires companies to investigate and
monitor side effects. The FDA also investigates patient complaints, and continues to monitor
companies for compliance with manufacturing standards. Failure to comply with legal
commitments leads to fines by the FDA. The FDA can withdraw drugs from the market for
safety reasons related to the drug or its manufacturing process. Any drug withdrawal by the FDA
can impact a company’s image and economic status. The industry is also dependent on the
government for revenue because it participates in U.S. Federal government–funded health
programs. For example, most drugs sales come from government-funded programs such as
Medicare, so that changes in government policies could dramatically impact revenue. The U.S.
government historically increases regulations on pharmaceutical companies, including enforcing
strict safety and compensation requirements (Langer, 2013). Legislators in the U.S. have recently
adopted many laws aimed at curtailing the undue influence of the gifts pharmaceutical
companies use to entice physicians to prescribe their drugs. For example, a new federal
government law called the Physician’s Financial Transparency Reports (the Sunshine Act),
mandates drug and medical device makers to report payments or gifts to teaching hospitals and
physicians (American Medical Association, 2013; Kessel, 2014; Valverde, 2013). Legislators
passed the Sunshine Act to counter the corrupt practices that have been attributed to
pharmaceutical companies. For example, Kessel’s (2014) study reported many dubious
marketing practices by pharmaceutical companies.
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Kessel (2014) found that the pharmaceutical industry spent $27 billion on drug promotion
in 2012 and $24 billion of the total expenditure was used for marketing to physicians. Out of the
$24 billion, approximately $15 billion was spent on promotional sales and activities geared
toward doctors and for entertaining doctors. Free drug samples given to physicians to induce
doctors to prescribe the drug being promoted amounted to $5.7 billion. The industry also spent
$2.1 billion on doctors’ educational and promotional meetings. The reporting system mandated
by the Sunshine Act leaves no room for pharmaceutical companies to use gifts as rewards to
motivate health care providers to buy their products. The Sunshine Act allows companies to
compete fairly on the merit of their products instead of how many gifts they can afford. Most
countries have national codes that guide the pharmaceutical industries, for example, codes
established by the Association of the British Pharmaceutical Industry and the Pharmaceutical
Research and Manufacturers of America. Organizations such as Pharmaceutical Research and
Manufacturers of America and Association of the British Pharmaceutical Industry monitor the
marketing activities of pharmaceutical companies and disallow companies from using gifts or
money to persuade doctors to prescribe their products or medical equipment (Valverde, 2013).
The pharmaceutical industry is admired because it provides medicines that cure lifethreatening diseases, but the industry is also much criticized because it does not provide
everyone a cure at affordable prices (Nussbaum, 2009). The pharmaceutical industry is criticized
for high drug prices, dubious marketing practices, and offering gifts to physicians and clinical
trials coordinators (Valverde, 2013). The pharmaceutical industry was once considered one of
the most respected and admired industries in the United States, but consumer attitudes have since
changed and consumers equate the industry’s reputation to that of the tobacco companies. The
pharmaceutical industry is different from other industries because it is in a business designed to
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improve the health of people while concurrently increasing shareholders’ profits. It can be
argued that pharmaceutical companies are primarily loyal to shareholders and not to their
products’ consumers (Kessel, 2014). The decline in reputation can be attributed to strategic
business issues to which pharmaceutical companies need to adjust their business model. The
issues include increasing R & D costs, patent expirations on blockbuster drugs, competition from
generic drugs, and pressure to meet Wall Street earnings expectations. These issues have caused
pharmaceutical companies to place greater importance on a return on investment and increasing
shareholder value, and less emphasis on patients’ needs (Kessel, 2014; Valverde, 2013).
The pharmaceutical industry cannot afford to deemphasize patients’ needs. Whereas
access to medications in the early 20th century was considered a luxury that only the affluent
could afford, today access to medicine is regarded as a human right (Kessel, 2014). High drug
prices, which have made needed drugs unaffordable to low-income groups and people in
underdeveloped countries, have fostered the view that the pharmaceutical industry has turned
away from caring for human beings and is only concerned with maximizing its profits. The
public perceives the pharmaceutical industry differently from other sectors, because the industry
provides medications. Sick patients do not compare buying a drug to buying an iPhone. A sick
patient could die from lack of access to medicine. A sick patient can live happily without an
iPhone but with access to drug treatment.
With the advancement of technology, the Internet, and Twitter, any consumer complaints
or information about a pharmaceutical firm’s regulatory violations, lack of ethical business
practices, or product failures can travel around the world in a few minutes. Lawyers have
increasingly turned their attention to pharmaceutical companies and are soliciting clients over
drug-safety issues. Consequently, the pharmaceutical industry has become susceptible to
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frivolous lawsuits from people claiming to have been injured using their drugs. Class-action tort
lawyers buy primetime television advertising spots inviting calls and promising rewards for
anyone apparently harmed by prescription drugs (Kessel, 2014). These advertisements often list
the millions of dollars they have won for clients in previous lawsuits against pharmaceutical
companies.
To rebuild trust, it behooves the pharmaceutical firms to include CSR activities in their
business strategies because businesses are not measured on their profitability alone (Kessel,
2014). CSR is a firm’s voluntary performance that goes above and beyond the requirements of
the law to improve not only shareholders’ value but also the well-being of society. Since the
beginning of the 20th century, there has been a growing awareness of the imbalance between the
medical needs of the large mass of poor people in the world and the pharmaceutical industry’s
economic priorities (Lezaun & Montgomery, 2015). The imbalance has motivated a proliferation
of programs that solicit public and private R & D organizations to accelerate the discovery of
new medicines to treat neglected diseases. For example, in 2012, the U.K. and U.S. governments,
the Bill Gates Foundation, the World Bank, 13 pharmaceutical companies, and representatives
from countries with neglected diseases signed an agreement on neglected tropical diseases. The
agreement, called the London Declaration, pledged to coordinate innovative actions to develop
drugs that will eliminate or control 10 neglected tropical diseases by the end of the decade. Many
scholars have called for participants with the relevant academic expertise, academic institutions,
governments, philanthropic organizations, and the pharmaceutical industry to collaborate and
form product development partnerships to develop drugs for neglected diseases of the poor
(Lezaun & Montgomery, 2015).
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CSR in the pharmaceutical industry. CSR has become a strategic business practice for
many firms in the pharmaceutical industry. Many scholars advocate pharmaceutical companies
investing in CSR to remain profitable while satisfying the needs of its various stakeholders (West
& Dobson, 2011). Others argue that it is important for pharmaceutical companies to be engaged
in CSR performance because the pharmaceutical industry is different from other sectors since its
business decisions have direct impact on human lives (Droppert & Bennett, 2015). The
pharmaceutical industry is different from other industries because its business is drugs that can
save human lives. Therefore, the pharmaceutical industry is perceived as having a distinct ethical
responsibility to the public such as providing access to drugs to all patients.
CSR is still a new business domain, and yet the pharmaceutical industry has come to
realize that CSR is an important concept that must be considered in its business practices
(Esteban, 2008). In a study that asked managers about the impact of CSR on their companies, the
unanimous answer was that a company’s business is at risk if CSR is not embedded in the firm’s
business processes. Hank McKinnell, former CEO of Pfizer, articulated the responsibility of the
industry succinctly when he said, “Because we have the ability to help in so many ways, we have
a moral imperative to do so” (as cited in Nussbaum, 2009, p. 67). The danger and risks to the
pharmaceutical industry for neglecting CSR include outrage from the public, loss of reputation,
government sanctions, and litigation from class-action tort lawyers.
The pharmaceutical industry was once among the most respected sectors in the U.S. For
example, the headline on Fortune magazine’s 1990 reputational survey ran with “America’s
most admired corporations: Merck leads the pack for the fifth year running” (as cited in Juliano,
2013, p. 393). The pharmaceutical companies were proud of their reputations as depicted by a
slogan from Squibb pharmaceuticals stating, “The priceless ingredient in every product is the
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honor and integrity of its maker” (Juliano, 2013, p. 393). Many people distrust the
pharmaceutical industry and the glowing public image of the industry has been tarnished by
various reports in the media of unethical and illegal behavior such as not disclosing negative
results in clinical trials, high drug prices, and companies enticing doctors with gifts to use their
drugs (Nussbaum, 2009).
Pharmaceutical companies are often blamed for the lack of access to medications in
developing countries and many scholars agree that pharmaceutical firms need to adopt CSR
practices to address such issues as public trust and access to medications (Esteban, 2008; Sobrio
& Keller, 2007). For example, in 2006, the Stanford University Medical Center announced a new
policy that banned pharmaceutical sales representatives from entering into the medical school
facilities and patient care areas. The university allowed pharmaceutical sales representatives into
those areas only on very specific occasions under extremely controlled conditions. In addition,
Stanford University Medical Center medical doctors were banned from accepting gifts from
pharmaceutical companies (Esteban, 2008). This shows how the decline in trust can negatively
impact the economics and relationships of the pharmaceutical industry. The pharmaceutical
industry has a highly complex set of stakeholders to balance, including patients; government
regulators; the health and scientific community; patient advocates; the media; activists, including
antivivisectionists; politicians; and the public at large. The development of CSR strategies that
focus on transparent policies and procedures for drug development and clinical trials, drug
pricing, and marketing will go a long way toward helping the industry balance its responsibilities
to its stakeholders. Some authors have also called for the industry to engage in more efficient
environmental, waste, and water management, especially because pharmaceutical processes as
with all manufacturing require large amounts of water (Esteban, 2008).
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To regain a good public image, the industry must balance shareholder profit
maximization with CSR objectives. The traditional reasons that companies had for CSR
activities included paying for a firm’s negative deeds and philanthropic contribution to the
community because of some social benefits obtained by the company (Pérez-Bustamante, 2013).
Companies no longer perceive CSR as contrition for misdeeds but as a corporate strategic
activity that should be incorporated into their business practices. Incorporating CSR into
business practices must create shared value for both the firm and the society; hence, CSR should
be treated as an investment and not a cost because CSR can be incorporated in business practices
such as drug development, innovation, clinical trials, advertising, sales, and marketing (PérezBustamante, 2013; Porter & Kramer, 2006).
Providing affordable drugs to patients in need is a fundamental component of CSR for
pharmaceutical companies (Peukert & Fuggenthaler, 2009). Pharmaceutical companies should
invest in researching and developing drugs for neglected diseases as a CSR. An example of a
successful drug-development program for neglected diseases is Novartis’s effort to develop
antimalaria drugs. Although malaria is not common in Novartis’ core markets, Novartis initiated
a malaria research program to provide low-priced drugs for patients. The goal behind this
initiative is clearly corporate responsibility, because Novartis is aware of the fatalities of malaria
in the third world. The Novartis’s malaria program is a CSR investment with high potential for
positive financial returns. The low drug prices could easily be compensated for by the large
market for antimalaria drugs in the third world. Developing drugs for neglected diseases is a
shared value for all shareholders because it improves the health of people in malaria-infested
countries, and the investment could be profitable for the companies. Developing research
programs for neglected diseases can potentially enhance the reputation of pharmaceutical firms,
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and the cost of investing in the CSR could be offset by sales revenue from the large market for
neglected diseases. Advocates of CSR argue that although the cost-benefit ratio of different CSR
activities may differ, a high level of CSR improves a firm’s reputation, image, and financial
performance (Longest & Lin, 2004; Waddock & Graves, 1997).
The impact of CSR on corporate financial performance has been widely studied and
debated for many decades (Griffin & Mahon, 1997; Longest & Lin, 2004). One of the most
comprehensive studies that showed a positive relationship between CSR and corporate financial
performance evaluated 67 firms throughout a period of 11 years. The study’s authors concluded
that having employed “the largest longitudinal database used to date in this type of research, we
find overwhelming evidence of a positive relationship between social and financial performance
indicators in a sample of large and important U.S. corporations” (Preston & O’Bannon, 1997, p.
428). Many pharmaceutical companies are developing and restructuring their CSR strategies as a
result of increasing public pressure demanding that they engage in socially responsible business
activities in a changing globalized world (Droppert & Bennett, 2015). A recent study of CSR in
six highest earning multinational pharmaceutical firms by Droppert and Bennett, found that CSR
meant different things for each firm. Each firm defined CSR differently, managed CSR
differently, was involved in different CSR activities, and had different motivations for engaging
in CSR. In spite of the different interpretations or understanding of CSR by these firms, the
common factors that motivated engagement in CSR activities included reputation, rankings in
sustainability indices, entry into new markets, financial performance, employee recruitment and
satisfaction, and improvement of the health of the public. Studies have found that firms engage
in CSR activities for various reasons. Some researchers have proposed the following four reasons
that motivate companies to implement CSR initiatives: (a) CSR improves corporate image; (b)
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CSR helps in employee recruitment, motivation, and retention; (c) CSR increases corporate
financial performance; and (d) CSR positively influences the opinions of investors and analysts
(Fort, 2014; Nussbaum, 2009). Companies do not necessarily incorporate CSR for all four
reasons, but each company may engage CSR for one or more of these four benefits (Nussbaum,
2009).
A critical domain of CSR that the pharmaceutical industry is required to incorporate in its
business practices is the human rights obligation of the industry (Gruskin & Raad, 2010; Hunt &
Khosla, 2010; Ritter, 2010). There are different and often contradictory opinions about the
debate on the human rights obligations of pharmaceutical companies. Some global
pharmaceutical companies claim that they support human rights because of their drug donation
programs or CSR agendas that promote nondiscrimination in the workplace. Conversely,
activists argue that pharmaceutical companies violate health-related human rights by focusing
more on their drug patents and shareholder profits over access to medicines for patients in need
(Gruskin & Raad, 2010). The following are a few of the human rights guidelines for
pharmaceutical companies regarding access to medicines that were outlined in the 2008 United
Nations report: governments have a key responsibility to increase access to medicines, the
pharmaceutical industry saves lives, pharmaceutical companies have a responsibility to enhance
shareholder value, and pharmaceutical companies have human rights responsibilities (Hunt &
Khosla, 2010). These guidelines should help pharmaceutical companies to formulate CSR
policies that would both value human rights to health and improve shareholder value.
The 2008 United Nations report stresses that a pharmaceutical company is granted a drug
patent as a reward for developing a life-saving drug, an important medical and public health
function. However, a patent is granted to a company under explicit and implicit conditions.
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Under these conditions, society has legitimate expectations of a company granted a patent for a
life-saving drug. The understanding between the holders of a drug patent and society grants
monopoly privileges to the patent holder, but also places social responsibilities on the patent
holder (Hunt & Khosla, 2010). The United Nations report acknowledges government’s
responsibility to ensure human rights protection but encourages pharmaceutical firms to engage
in businesses activities that are consistent with enjoyment of human rights (Gruskin & Raad,
2010; Hunt & Khosla, 2010; Ritter, 2010).
Although many pharmaceutical companies contribute to improving access to medicines,
those companies are not fulfilling their human rights responsibilities as numerous studies suggest
(Hunt & Khosla, 2010). In 2008 and 2010, the Access to Medicine Index ranked 20
pharmaceutical companies on their performance on access to medications. The companies were
scored and ranked by the Access to Medicine Index on measures such as public policy influence
and advocacy, pricing, patents and licensing, and drug donation. The study found Glaxo Smith
Kline ranked highest in 2008, followed by NovoNordisk, Merck & Co., and Novartis. The lowest
ranked companies were Pfizer, Wyeth, Teva Pharmaceutical, and Schering-Plough (Hunt &
Khosla, 2010). The authors concluded that although the Access to Medicine Index “does not
explicitly adopt a human rights framework, the Index reflects aspects of the Guidelines and the
right to the highest attainable standard of health, highlighting where companies are doing well in
addition to some of their shortcomings” (Hunt & Khosla, 2010, p. 2).
The major role played by the pharmaceutical industry in helping human beings to realize
their rights to health is through utilizing its core competencies in research, development of drugs
and vaccines for unmet medical needs, and in facilitating the distribution of its products ( Hunt &
Khosla, 2010). The industry has saved or improved the quality of life of many people for more
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than a century. For example, the pharmaceutical industry developed and distributed the vaccine
that has brought measles disease close to elimination in many parts of the world (Ritter, 2010).
Ritter urges the pharmaceutical industry to leverage its competencies and coordinate with
governments to remove barriers to the health care that patients need and deserve. Such efforts by
the pharmaceutical industry amount not only to doing good for society, but can also enhance the
long-term profitability of pharmaceutical companies.
CSR
The body of literature on CSR contains myriad definitions of the CSR concept (Swaen &
Chumpitaz, 2008), and as such, some have termed CSR a tortured concept (Godfrey, Hatch, &
Hansen, 2010). Carroll (1999) discussed more than 25 different ways that CSR has been defined
in the academic literature. The search for a common definition of CSR is still elusive. Meijer and
Schuyt (2005) indicated that scholars most frequently cite Carroll’s (1979) CSR definition,
which states, “The social responsibility of business encompasses the economic, legal, ethical,
and discretionary expectations that society has of organizations at a given point in time” (p. 500).
CSR is sometimes defined as a voluntary approach undertaken by a company as presented in the
following examples:
1. CSR is a company’s commitment to implement discretionary initiatives and increase
access to medicine resulting in improving its community’s welfare (Kotler & Lee,
2005).
2. CSR represents corporate actions that improve society’s welfare above and beyond
the company’s own interests or legal obligations (McWilliams & Siegel, 2001).
Other times, CSR is viewed as an obligation that signifies the social contract between a
corporation and the society, as seen in the following examples:
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1. CSR is the economic, legal, ethical, and discretionary expectations that society has of
a company (Carroll, 1979).
2. CSR is a process in which companies assume the economic, legal, ethical, and
discretionary responsibilities that stakeholders have imposed on its corporate actions
(Maignan, Ferrell, & Hult, 1999).
Last, CSR is considered in terms of the groups to which companies are considered to be
responsible. For example, CSR is described as a mechanism of using resources and
implementing activities directed exclusively to maximize profits for a firm, as long as the firm
obeys the government’s rules and regulations (Friedman, 1962).
Most CSR definitions emphasize the voluntary actions of business designed to improve
society’s social or environmental conditions (Mackey et al., 2007; Margolis & Walsh, 2001).
Many CSR definitions are based on the concept that firms engage in responsible actions that go
well beyond profit making or simply obeying the law, and corporate responsibility that applies
not only to its shareholders but also to all its stakeholders (Swaen & Chumpitaz, 2008).
Therefore, some authors consider a firm socially responsible as long as the firm’s actions are
voluntary and designed to improve society’s social or environmental conditions (Mackey et al.,
2007).
According to stakeholder theory, in economic decisions or in its social life, a company
has a responsibility to all those who contribute directly or indirectly to its existence,
development, and survival, including suppliers, customers, employees, investors, and the local
community (Freeman et al., 2004). The different components of stakeholder theory are
highlighted in the definition of CSR proposed by the Commission of the European Communities,
which regards CSR as a company’s voluntary integration of social and environmental policies
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into its business strategies and relationships with its stakeholders, including shareholders,
nongovernmental organizations, suppliers, customers, and the community at large (Swaen &
Chumpitaz, 2008).
The concept of CSR has been evolving since the early 1930s (Carroll, 1979), and
throughout the past decades, CSR has grown from a marginalized concept into a complex one
that is increasingly becoming central in business decision making (Cochran, 2007). Many
authors have asserted that the modern era of social responsibility was marked by Bowen’s (1953)
publication Social Responsibilities of the Businessman, which many consider to be the first book
on CSR (Carroll, 1979; Ghobadian, Money, & Hillenbrand, 2015; Schwartz & Carroll, 2008;
Swaen, & Chumpitaz, 2008). Bowen is credited as being the first to offer a definition of the
social responsibilities of businessmen (Carroll, 1999; Pérez-Bustamante, 2013). Carroll (1999)
called Bowen the “Father of Corporate Social Responsibility” (p. 270). In his book, Bowen
posited that CSR “refers to the obligations of businessmen to pursue those policies, to make
those decisions, or to follow those lines of action which are desirable in terms of the objectives
and values of our society” (Bowen, 1953, p. 6). Bowen argued that although social responsibility
is no magic bullet, it must guide the business strategies of every corporation. However, the lack
of consensus on what CSR means has been one of the factors that has for a long time,
contributed to the concept’s ambiguity. CSR has been conceptualized in myriad ways: profit
making only; going beyond profit making; going beyond economic and legal responsibilities;
performing voluntary activities; incorporating economic, legal, and voluntary activities in
business; concern of a business for the broader social system; and responsibility of a business in
a number of social problem areas (Carroll, 1979).
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For many years, academics, practitioners, and corporate executives have debated the
responsibility of a corporation to its society. Some have argued that the corporation’s sole
responsibility is to provide maximum financial return to its stockholders. Others advocate that
corporations have social responsibilities to their stakeholders, including the firm’s employees,
customers, suppliers, and the communities in which the corporations operate (Alexander, 2015;
Carroll, 1991). Columbia University professor Adolf A. Berle and Harvard professor E. Merrick
Dodd are credited as being among the first to debate the topic of CSR in several articles featured
in the Harvard Law Review in the 1930s (Cochran, 2007).
In his review of the evolution of CSR, Cochran (2007) wrote a detailed account of Adolf
Berle’s argument that a business is responsible only to its shareholders, while Merrick Dodd
contended that in addition to economic responsibilities to shareholders, a business also has social
responsibilities to society. Dodd posited that a business has responsibility to the society because
a corporation is approved to operate by the law because of the service the firm provides to the
community, and not necessarily because the firm is a cash cow to its shareholders. Businesses as
such, were created as economic enterprises intended to provide goods and services to society.
The debate about what CSR means was intensified by Milton Friedman’s argument that the
doctrine of social responsibility is subversive. Friedman insisted, “Few trends could so
thoroughly undermine the very foundations of our free society as the acceptance by corporate
officials of a social responsibility other than to make as much money for their stockholders as
possible” (Friedman, 1962, p. 133).
Richard Eells, Clarence Walton, Keith Davis, and Archie Carroll were among the notable
academics in the 1970s whose views of CSR countered that of Milton Friedman (Carroll, 1999).
In denouncing the notion that a corporation owes an obligation only to its stockholders, Eells and
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Walton argued that a firm must pay attention to the needs and goals of the society that surpass
merely economic needs (as cited in Carroll, 1999). Keith Davis agreed with Paul Samuelson,
another distinguished economist, who proposed that corporations must integrate social
responsibility into their business. Davis defined CSR as a firm’s decision to undertake issues that
go beyond economic, technical, and legal requirements of the business (as cited in Carroll,
1999).
Sethi (1975) authored one of the early studies that specifically addressed CSR. He
developed a three-layer model to classify three states of corporate behavior that are based on
social obligation (including compliance to legal regulations), social responsibility (related to the
norms, values, and expectations of the society), and social responsiveness, which includes
anticipating and adapting to the prevailing social needs. In his publication, Carroll (1979)
presented a conceptual model of CSR that categorized the social obligations of a business into
four groups: economic, legal, ethical, and discretionary responsibilities. Subsequently, Carroll
(1991) framed the components of CSR in a pyramid that he called the “pyramid of corporate
social responsibility” (p. 39). Gupta (2012) argued that Carroll’s (1979) study built on Sethi’s
(1975) model of CSR. Carroll’s (1991) pyramid of CSR is a hierarchical model of CSR in
decreasing order of importance: economic (be profitable), legal (obey the law), ethical (do what
is right and fair and avoid harm), and discretional-philanthropic (be a good corporate citizen).
The pyramid of CSR Carroll proposed provides a framework for understanding how a firm can
reconcile its role of maximizing shareholders’ profits with its social responsibilities to
stakeholders.
In his pyramid of CSR in Figure 2, Carroll (1991) suggested that CSR consists of four
components or categories of CSR in order of decreasing importance: economic, legal, ethical,
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and philanthropic. The pyramid of CSR proposed that in addition to economic and legal
obligations, a corporation also has ethical and philanthropic responsibilities. The first level in the
CSR pyramid is Economic Responsibilities. Businesses were designed as economic enterprises
that provide goods and services to society. Maximizing profits became the primary motive and
incentive for entrepreneurs to start any business. Economic responsibility is highest on the
hierarchy of the CSR framework, and thus, the pyramid of CSR acknowledges that a firm must
be committed to being consistently profitable, competitive, and highly efficient in its operations.

Philanthropic
Responsibilities
Be a good corporate citizen.
Contribute resources to the
community; improve quality of life.
Ethical Responsibilities
Be ethical
Obligation to do what is right, just, and fair. Avoid harm.
Legal Responsibilities
Obey the law
Law is society’s codification of right and wrong. Play by the rules of the game.
Economic Responsibilities
Be profitable
The foundation upon which all others rest.

Figure 2. Pyramid of CSR. Adapted from “The pyramid of corporate social responsibility:
Toward the moral management of organizational stakeholders” by A. B. Carroll, July/August
1991, Business Horizons, p. 42. Copyright 1991 by Elsevier.
According to the pyramid of CSR, economic responsibility is the foundation on which all
other business responsibilities rest, because without efficient financial performance, a company
cannot perform all of the other social responsibilities (Carroll, 1991). Legal Responsibilities, the
next hierarchy on the pyramid, states that in addition to pursuing its economic goals, a business
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must comply with federal, state, and local laws and regulations because it was the society or
government that certified the business to operate. The next layer of the pyramid is the Ethical
Responsibilities. The ethical responsibility component advocates that corporations must integrate
into their business strategies, good corporate citizenship, integrity, and ethical behavior that go
beyond mere compliance with the laws and regulations. Corporate ethical responsibilities must
minimize harm to stakeholders and embrace standards, strategies, or norms that indicate what the
stakeholders would consider as fair and just.
The final layer of the pyramid is the Philanthropic Responsibilities. The concept of
philanthropic responsibility proposes that corporations must consistently be involved in
voluntary activities, programs, or projects that promote the welfare of human beings and improve
the quality of life for society (Carroll, 1991). In summary, the overall CSR of a business depicted
in the pyramid involves execution of corporate strategies so that the business is economically
profitable, law abiding, ethical, and philanthropic.
The array of corporate responsibilities proposed in the pyramid is remarkably a rebuttal
to the classical economic argument that the only social responsibility of a firm is to maximize the
profits of its owners or shareholders. Friedman (1962), an economist and the most famous
proponent of this classical economic argument, posited:
There is one and only one social responsibility of business to use its resources and engage
in activities designed to increase its profits so long as it stays within the rules of the
game, which is to say, engages in open and free competition, without deception or fraud.
(p. 133)
Carroll (1991) suggested that an evaluation of the separate components can help a business
leader understand the constant tension involved in fulfilling the different categories of CSR,
although the four components of CSR depicted in the pyramid are not mutually exclusive.

40
Carroll argued that a business is obligated to perform these responsibilities not only to improve
society, but also for the economic and intangible benefits of the corporation.
Carroll’s (1991) pyramid of CSR has been tested over time and proved to be a valid
concept (Bruyaka, Zeitzmann, Chalamon, Wokutch, & Thakur, 2013). The pyramid of CSR has
been used in several studies, including those by Wartick and Cochran (1985), Wood (1991), and
Bruyaka et al. (2013), as a framework to explain the concept of CSR. The CSR pyramid is an
accepted concept that has been used in many textbooks to evaluate social and ethical issues in
business and management (Bruyaka et al., 2013).
Aupperle, Carroll, and Hatfield (1985) were the first to test the CSR model of Carroll in a
survey of 241 chief executive officers (CEOs), in Forbes’s 500 list of CEOs. Its study supported
Carroll’s weighting of the four components of CSR in the pyramid, and affirmed that the CSR
components are interconnected but independent conceptually (Gupta, 2012). Another survey of
top managers in 591 multinational chemical companies (located in England, France, Germany,
Japan, Sweden, Switzerland, and the U.S.) also confirmed that as proposed by Carroll, there are
four interrelated but independent components of CSR (Gupta, 2012). The results of these surveys
supported the relative weightings assigned by Carroll to each of the four components, except in
Germany and Sweden, where legal responsibilities were ranked the highest followed by
economic, ethical, and philanthropic components respectively. Carroll’s (1991) four-part CSR
pyramid complements the current trend in corporate management where there is a growing
acceptance of the relationship between the economic role of the firm and its obligations to
society (Gupta, 2012). Decades of debates on CSR have resulted in a substantial amount of
information, and despite the different perceptions of firms about the components of the CSR
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pyramid, there is a common understanding that corporations have an obligation to work for
social improvement (Geva, 2008).
While the debate about CSR was still going on, the Vietnam War of the 1960s and early
1970s ushered in an era of activist groups and nongovernmental organizations engaged in social
movements concerning businesses and business practices. In advocating a broader notion of
CSR, activists and the media have become more aggressive and effective at putting public
pressure on corporations to run their businesses in socially responsible ways (Cochran, 2007;
Porter & Kramer, 2006). These social groups are becoming more empowered, creating a
relatively complex environment. At the same time, they pressure companies to behave
responsibly and to create a corporate social climate in which they can enhance the welfare of the
communities where they do business and the society at large (Andonov, Mihajloski,
Davitkovska, & Majovski, 2015). Social activist movements often focus media attention on
business practices that they consider to be irresponsible or unethical. Consequently, in the
current business environment, many firms embrace CSR to avoid unwanted media attention that
can damage their corporate image or result in legal action against the firm (Cochran, 2007).
Increased pressure by different social groups is one of the most important reasons that
companies are paying attention to social needs and how their corporate operations affect society
(Andonov et al., 2015). Corporations did not voluntarily pay attention to CSR, but they were
surprised by public responses to issues they had not considered their corporate responsibilities.
For example, there was a public outcry and call to boycott Nike products after the New York
Times and other media outlets reported the horrible labor practices at Nike’s Indonesia
warehouses (Porter & Kramer, 2006). Nike had to acknowledge its mistakes and take necessary
steps to rectify its business practices.
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Corporations cannot be held responsible for all the problems in the world and, indeed,
they do not have the resources to solve all of the world’s problems. Many have called on each
corporation to identify the societal problems it is best suited to solve and from which it can
benefit (Porter & Kramer, 2006). By putting its resources and expertise in solving a societal
problem in which the firm has a benefit, the firm understands it can create a major social benefit.
Perceiving CSR as a shared value between society and corporations requires businesses to think
differently about the consequences of their activities on society.
In recent years, there is increasing pressure on organizations worldwide to practice and
demonstrate their commitment to CSR. In spite of the confusion about the myriad definitions of
CSR and the varying findings about the link between CSR and corporate financial performance,
CSR continues to gain importance in corporate strategy and management (Godfrey et al., 2010).
Many nongovernmental organizations, including the World Resources Institute, AccountAbility,
Global Reporting Initiative, International Standards Organization, and the United Nations,
emphasize measuring and improving the CSR and performance of businesses worldwide.
CSR is becoming an increasingly popular element in corporate marketing strategies. In
recent years, successful corporations have integrated CSR into their business strategies as a key
aspect of their corporate management policies (Gupta, 2012; Swaen & Chumpitaz, 2008). The
major driving forces for the change in the business strategies of these corporations can be
partially explained by government and public pressure, demands from investors and consumers,
the need for greater transparency, and media coverage of financial scandals, social problems, and
environmental disasters.
Companies are increasingly being pressured to embrace social responsibility, partly
because of the scandals associated with major companies. In the beginning of the 21st Century,
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the world economic system witnessed the largest level of financial fraud, accounting
manipulations, and unethical behavior in corporate history. The ethical crises spread across
industries and countries and are considered the greatest economic scandals and failures since the
1920s (Guerra, 2004; Rockness & Rockness, 2005). Large corporations such as Enron,
WorldCom, HealthSouth, Adelphia, Parmalat, Elan, and Andersen were involved in these
scandals. In response to the crisis, the U.S. Congress enacted the Sarbanes-Oxley (SOX) Act in
July, 2002. The SOX Act mandated ethical behavior for both publicly traded companies and their
auditing firms. Furthermore, the SOX Act demanded full transparency, reliability, and accuracy
standards in financial reporting. The act emphasized that conflicts of interest that were pervasive
in securities market transactions would no longer be tolerated.
In addition to the SOX Act’s effect, there is an increasing level of corporate scrutiny by
shareholders, the public, and governmental agencies; consequently, CSR fast becoming a slogan
in corporate meetings (Castka, Bamber, & Sharp, 2005). Companies are pressured to embrace
social responsibility because of the increasing number of independent evaluating and ranking
corporations such as Fortune’s Most Admired Companies, KDL Socrates, and Access to
Medicine Index. These agencies’ guidelines encourage firms to engage in transparent practices
because CSR initiatives can benefit a firm’s bottom line (Pirsch, Gupta, & Landreth-Grau, 2007).
An online survey of 179 firms showed that, especially for marketing companies,
employing a strategic corporate business policy that goes beyond making profits can help a firm
to make important connections with its consumers, and fulfill the firm’s moral and social
obligations to society (Pirsch et al., 2007). The survey also found that the CSR initiatives of a
business can help to differentiate a firm from other firms in the marketplace, and consequently,
lead to increased purchase of the products sold by the firm (Pirsch et al., 2007).
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Apart from public outcry over high-profile corporate scandals, the prevalence of
reporting organizations such as the Organization for Economic Cooperation and Development
initiatives, the Global Reporting Initiative, and the increased regulatory oversight by the SOX
Act have increased the expectation for transparent financial and CSR disclosure from firms
(Dawkins & Fraas, 2013). Disclosure is defined as providing relevant information that enables a
transparent and accurate picture of the financial performance, governance, and operations of the
corporation. For example, the Securities Exchange Commission mandates disclosure of financial
information that is likely to be considered significant by an intelligent investor (Dawkins &
Fraas, 2013).
The United Nations initiatives, including the Global Reporting Initiative, support CSR
performance (Gupta, 2012). The United Nations initiatives defined the goal and principles for
corporate social responsibility performance in the areas of human rights, labor standards,
environment, health, anticorruption, and economic responsibility (Gupta, 2012). The Global
Reporting Initiative founded in 1997, is an international standards organization that provides
guidelines to businesses, governments, and other organizations to help them appreciate their
impacts on social issues such as human rights and environmental and climate changes. Global
Reporting Initiative guidelines are used by organizations worldwide, businesses, and
nongovernmental organizations for reporting sustainability. Sustainability reporting is used to
standardize and quantify social issues such as carbon dioxide emissions, financial transparency,
and employee rights. The focus of the Global Reporting Initiative on sustainability practices has
put CSR in the forefront of corporate business policies.
Although many agencies are working hard to help businesses, organizations, and
nongovernmental organizations integrate CSR into their practices, debate continues to persist
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about whether corporations should include socially responsible initiatives in their business
strategies (Mackey et al., 2007). Traditional economic arguments posit that managers should
only make decisions that maximize the wealth of their firm’s shareholders (Friedman, 1962).
Friedman emphasized:
Few trends would so thoroughly undermine the very foundations of our free society as
the acceptance by corporate officials of a social responsibility other than to make as much
money for their stockholders as they possibly can. This is a fundamentally subversive
doctrine. (p. 133)
However, the discussion of CSR has greatly progressed since Milton Friedman, a Nobel laureate
economist, outright rejected CSR in a New York Times article (Friedman, 1970). In the
publication, Friedman stressed his argument that the only social responsibility of a business is to
maximize the profits of the shareholders, and managers were not justified spending shareholders’
money for other purposes than increasing shareholder profits (Friedman, 1970). Other scholars
have argued that companies have a duty to society that goes beyond simply maximizing the
wealth of shareholders. These scholars argue that a narrow focus on maximizing the wealth of
the firm’s shareholders can lead the management to ignore other stakeholders, including
employees, suppliers, customers, and the society (Mackey et al., 2007). For example, some
studies showed that socially responsible initiatives can allow a firm to differentiate its products
in the market (McWilliams & Siegel, 2001; Waddock & Graves, 1997). These socially
responsible initiatives can potentially increase the value of a firm’s future cash flows and are,
therefore, consistent with the notion of maximizing the wealth of the firm’s shareholders.
Therefore, engaging in CSR practices could be a valuable strategic business decision for a firm.
Businesses are no longer considered only as economic entities, but they are also
recognized as inseparable part of society (Mittal, 2007). CSR is fast becoming a strategic
business item on corporate agendas. Some firms use CSR as a valuable public relationship tool,
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others as a means to manage risk, including reputation, ensure financial sustainability, and
improve relationship with stakeholders (Peukert & Fuggenthaler, 2009). Some have argued that
CSR has become a brand for organizational success in the new global economy (Mittal, 2007).
The proponents of CSR argue that a company can’t be healthy and be linked in an unhealthy way
with the society in which it is working. In like manner, a society can’t be healthy if the economy
is unhealthy. In a 2002 study of global CEOs by Pricewaterhouse Coopers (an auditing firm),
70% of the CEOs agreed that CSR is vital for the profitability of a company (as cited in Mittal,
2007).
Another study of CEOs in 50 countries by Environics International in 2002 showed that
80% of the CEOs agree that CSR enhances product innovation and profitability (as cited in
Mittal, 2007). It is no longer enough for businesses to look only after shareholders, but they
should also be concerned with all the stakeholders who can be affected by the corporation’s
operations or activities (Isaksson, Kiessling, & Harvey, 2014). A research study of 34 industries
in Sweden, found that corporations engage in CSR to increase their reputation, reduce their
market risk, or gain competitive advantages in attracting and retaining customers (as cited in
Isaksson et al., 2014). The study showed that the companies, including ABB (industrial
equipment), Ericsson (telecom), Swedbank, and Electrolux, that demonstrated high CSR (ranked
high on CSR index) also had high corporate performance (as cited in Isaksson et al., 2014).
As companies begin to integrate CSR into their businesses, they are confronted with a
host of similar constructs related to doing good for stakeholders. The concepts of CSR, corporate
citizenship, and sustainability have become commonplace not only in business, but they have
also gained importance with corporate leaders, and CSR concepts are driving developments of
new business strategies (Ghobadian et al., 2015). For example, Ban Ki-moon, the Secretary-

47
General of the United Nations, argued that sustainable development is the key to the future we
want for all because it provides a framework to generate economic growth, achieve social justice,
and implement environmental protection (as cited in Ghobadian et al., 2015). CSR has been a
prominent issue in political and business debates since the 1990s, partly in response to corporate
scandals (Enron and WorldCom), but also because of the realization that companies need to
partake in the development processes aimed at balancing the economic growth of the
communities in which they are located (Castka et al., 2005; Gupta, 2012). CSR and corporate
sustainability have become ways companies address the concerns and expectations of their
stakeholders (Gupta, 2012).
The compelling argument of Porter and Kramer (2002) in favor of corporate philanthropy
also encourages businesses to incorporate strategies that will help develop projects with both
social and financial returns. Porter and Kramer argued that CSR and economic responsibility are
not in conflict but are mutually connected because there are some economic investments that
have social returns, and similarly, there are some social investments with economic returns. They
surmised that organizations should align their corporate expertise with relevant social needs
(Porter & Kramer, 2002). For example, pharmaceutical companies should align drug
manufacturing and sales with drug donations and access to medicines.
Margolis and Walsh (2001) examined more than 90 studies in an attempt to determine the
relationship between CSR and improved firm financial performance, but they concluded that the
evidence of a relationship is inconclusive. Another study by Cheng et al. (2014) evaluated how
superior CSR performance can facilitate easy financing for a company’s operations and new
investments. They hypothesized that excellent CSR performance improves transparency, and
therefore, reduces borrowing costs (Cheng et al., 2014). These authors found that firms with
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strong CSR performance have lower borrowing costs and easy financing of capital (Cheng et al.,
2014). Many studies suggest that firms that incorporate CSR initiatives in their business
strategies are rewarded with higher financial performance (Seong, Cheol, & Park, 2012).
Using future stock returns as measure of firm value in his study, Edmans (2012) showed
that job satisfaction is positively related to firm value. Furthermore, he found that from 1984
through 2011, companies listed under the category of the 100 Best Companies to Work For in
America had 2.3% to 3.8% higher stock returns each year than their peers not listed the 100 Best
Companies to Work For in America (Edmans, 2012). These best companies consistently beat
earnings reports, and the investigation indicates that CSR can improve stock returns.
Many have argued that a high level of CSR performance can be a strategic investment
that could ultimately increase a firm’s profits and thus lead to an increase in shareholder returns
(Nollet, Filis, & Mitrokostas, 2016). Jensen (2001) argued that telling employees in an
organization that the sole purpose of the organization is to maximize the firm’s profits, might not
achieve maximization of the organization’s value. However, if employees are given a vision or
strategy that they can buy into, such as building the safest, most cost-efficient drugs or making a
fun movie that will delight people of all ages for centuries, the corporation stands a better chance
of achieving its purpose of maximizing value. This strategy is what Jensen calls “enlightened
value maximization” (p. 308) because it is consistent with value maximization. The multitude of
arguments in favor of incorporating CSR into a firm’s business strategy has led to a public outcry
for corporations to provide innovative solutions to human problems, even though economists
such as Friedman advocate that managers should focus on maximizing their shareholders’ value
(Pava & Krausz, 1996).
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Companies are increasingly using philanthropy to enhance their public relations and
promote the image of their corporations. For example, the U.S. corporate charitable expenditures
increased from $125 million in 1990 to $828 million in 2002 (Porter & Kramer, 2002). Some
have questioned if corporations should be involved in philanthropy especially after the economic
arguments by Milton Friedman in a 1970 New York Times article and in his 1962 book
Capitalism and Freedom. Friedman (1962) wrote in his book that the corporation is owned by its
stockholders. The corporation should not make any charitable contributions. If the corporation
makes a charitable contribution, it denies the individual stockholders the right to decide how to
use his or her funds. Any charitable contributions should, therefore, be made not by the firm but
by the stockholders if the stockholders desire to make a donation. Many have questioned the
rationale of Friedman’s statement because of the underlying assumptions. One major assumption
by Friedman is that goals directed to helping society and economic goals are quite different, so
that when a corporation spends on social issues, the corporation is depriving itself of its
economic goals (Friedman, 1962, 1970).
Many scholars have challenged Friedman’s assumption and have argued that charitable
contributions can be a competitive advantage when a corporation supports a right cause in the
correct manner (Porter & Kramer, 2002). For example, Cisco Systems Corporation started to use
focused charitable contributions to realize social as well as economic gains. Cisco Systems
invested in an education program called Cisco Networking Academy. The networking academy
is a global information technology program that trains network administrators and provides
career opportunities for trainees. Cisco Systems Corporation provides high paying jobs to high
school graduates who complete the Cisco Networking program. In this way, Cisco Systems
Corporation gives young people a bright future and provides well-trained employees for the
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company and its customers and ultimately promotes the growth of the company. The Cisco
Networking Academy has helped to increase customer demand for services because customers
have access to properly trained network administrators. As a result, Cisco Systems increased the
size of its market while advancing the knowledge and interest of Cisco Systems users. Cisco
Systems has validated the potential value of corporate philanthropy of a firm that is focused on a
social need and uses its unique competencies to meet societal needs. Cisco Systems has a high
level of CSR (providing training and career opportunity and advancing the knowledge of the
customers) while expanding the size of Cisco System’s market.
Entrepreneurs as well as large corporations are increasingly embracing CSR as a business
strategy. Peterson and Jun (2009) examined entrepreneurial commitment to CSR as a business
philosophy and showed that the respondents had strong affiliation to CSR initiatives. Many of
the entrepreneurs studied, most of whom ran small businesses, understood that failure to include
CSR initiatives in their business strategies could result in negative effects on their businesses,
including penalties from government regulatory agencies, adverse publicity, and activism by the
public and nongovernmental organizations. Other studies have shown that entrepreneurs are an
influential component of business in society because entrepreneurial organizations contribute to
the creation of wealth in any society (Peterson & Jun, 2009). Far more than 10 million
entrepreneurs are actively engaged in starting new businesses in the United States each year.
A study by Aguinis and Glavas (2012) reported the following reasons firms engage in
CSR: First, firms engage in CSR primarily for expected financial outcomes. Second, firms
engage in CSR as a result of the firm’s ethical values about doing the right thing. Third, there is a
small but positive relationship between CSR initiatives and financial outcomes. Fourth, there are
many nonfinancial outcomes from implementing CSR such as improved management practices,
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product quality, operational efficiencies, attractiveness to investors, and enhanced diversity of
employees.
As companies begin to embrace CSR, various constructs have been developed about how
businesses should relate to society to be considered socially responsible. CSR, stakeholder
management, sustainability, and corporate citizenship are concepts that have grown in
prominence to the point where they are pervasive in business and society (Schwartz & Carroll,
2008). Although these concepts have gained popularity, understanding what each construct really
means, or how each might relate to the others, remains difficult.
Stakeholder theory has shed much light on the social responsibility of corporations to
society by proposing the importance of the relationship of a corporation to the many groups that
affect and or are affected by the decisions of the corporation (Freeman, 1984). The fundamental
framework for stakeholder theory is attributed to the work of Edward Freeman from his 1984
book Strategic Management: A Stakeholder Approach (Gama Boaventura, Santos da Silva, &
Bandeira-de-Mello, 2012). The most commonly used definition for the term stakeholder was the
definition proposed by Freeman (1984), which states that the stakeholder is any person or
community that may be affected by the organization’s decisions or that can affect the realization
of the organization’s goals. By integrating stakeholder concepts into a coherent management
construct, Freeman is credited with moving stakeholder theory to the forefront of academia, and
it has become a dominant construct in management circles for more than 20 years (Schwartz &
Carroll, 2008).
The concept of sustainable development has captured unprecedented attention of
researchers and business leaders (Chabowski, Mena, & Gonzalez-Padron, 2011). Firms are
increasingly adopting sustainability approaches to manage their businesses, thus the
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sustainability construct has changed established standards and business policies worldwide. The
1987 landmark report titled Our Common Future, also known as The Brundtland Report issued
by the United Nation World Commission on Environment and Development (1987) is said to be
the incentive for the rapid growth of the body of literature on sustainability (Kassel, 2012;
Rogers & Hudson, 2011; Schwartz & Carroll, 2008). More than ever, companies are
emphasizing not only attaining economic benefits, but they also strive to promote environmental
and social benefits (Chabowski et al., 2011). The term sustainable development was an outcome
of the United Nations Conference on the Human Environment, which led to the Brundtland
Report that was later published as a book: Our Common Future (World Commission on
Environment and Development, 1987). The World Commission on Environment and
Development’s definition of sustainable development, which is widely used, is “development
which meets the needs of the present without compromising the ability of future generations to
meet their own needs” (p. 42). The main attributes of the construct are: (a) sustainability is a
global problem with global responsibilities; (b) growth must be managed to prevent
environmental damage; (c) social equity should be given priority, specifically to enable
economic and social advancement for the underdeveloped countries; and (d) major significance
should be assigned to long-term thinking about leaving a viable future for the next generations.
Others have defined corporate sustainability as a company’s voluntary activities that incorporate
social and environmental interests in operating its business and in corporate interactions with
stakeholders (Schwartz & Carroll, 2008).
The concept of sustainability development has gained such significance in business that
there is a proliferation of companies that evaluate and rank firms on sustainability. For example,
Business Ethics magazine’s 100 Best Corporate Citizens ranks firms on corporate social
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responsibility, Newsweek’s America’s Greenest Companies ranks firms on environmental
performance, and Fortune’s World’s Most Admired Companies ranks firms on corporate
reputation (Chabowski et al., 2011).
The concept of the triple bottom line (TBL) was later introduced to management
practices and linked to the notion of sustainability by John Elkington in 1999 (Schwartz &
Carroll, 2008). Elkington included the social, environmental, and economic elements of
sustainable practices into the concept of TBL (Rogers & Hudson, 2011; Slaper & Hall, 2011).
The TBL is an accounting framework that incorporates social, environmental, and financial
aspects of corporate performance. The TBL concept proposes that firms should pay attention not
only to maximizing their wealth or financial bottom line, but also to the welfare of all their
stakeholders (Meijer & Schuyt, 2005; Rogers & Hudson, 2011; Slaper & Hall, 2011). The
components of the TBL are often called the three Ps: people, planet, and profits (Meijer &
Schuyt, 2005; Slaper & Hall, 2011). In addition to measuring profits, return on investment, and
shareholder value, the TBL concept added environmental and social dimensions to management
practices (Rogers & Hudson, 2011; Slaper & Hall, 2011).
According to Elkington, sustainable development is the simultaneous pursuit of economic
prosperity, environmental quality, and social equity (Rogers & Hudson, 2011; Slaper & Hall,
2011). Elkington argued that to be sustainable, companies must perform not against a single
financial bottom line but against a TBL (economic, environmental, and social). The TBL
measures the impact of an organization’s activities (including the corporation’s economic
pursuit, shareholder values, and social and environmental resources) on the world. The TBL and
sustainability have become compelling business tools worldwide because of mounting evidence
of long-term profitability. For example, many firms, including General Electric, Unilever,
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Proctor and Gamble, 3M, and Cascade Engineering, have found that reducing waste from
packaging can also cut costs (Slaper & Hall, 2011). The TBL concept has changed the way
businesses evaluate the ramifications of their strategic business policies and performance.
A recent study was performed on Ben & Jerry’s ice cream company, from its founding
through its acquisition and integration into Unilever, to evaluate how successive CEOs perceived
and implemented the TBL concept instituted by the founders (Bayle-Cordier, Mirvis, &
Moingeon, 2015). The study examined the perceptions of the CEOs and employees throughout a
30-year period (Bayle-Cordier et al., 2015). The authors reported that the three CEOs that came
after the founders had different perceptions about what would make the business successful even
though the founders of Ben & Jerry’s ice cream company had emphasized strong linkages among
the economic, product, and social components of the company’s TBL (Bayle-Cordier et al.,
2015). The varying perceptions of the three subsequent CEOs caused the firm to go through
successive periods of diminished profitability. Ben & Jerry’s ice cream did not gain the superior
financial performance it enjoyed under the founding fathers until a fifth CEO took charge,
embraced the TBL concept, and reintegrated the firm’s TBL.
Corporate citizenship is the newest construct in the business and society literature, but it
is quickly becoming very popular (Schwartz & Carroll, 2008). Corporate citizenship was
categorized as “one of the latest frameworks to talk about the relationship between business and
society” (Waddell, 2000, p. 107). Corporate citizenship is defined as the voluntary corporate
actions and business strategies deployed in identifying, analyzing, and responding to the
company’s social, political, and economic responsibilities (Schwartz & Carroll, 2008).
An analysis by Schwartz and Carroll (2008) of each of the four frameworks—CSR,
stakeholder management, sustainability, and corporate citizenship—showed that despite their
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differences, each of the constructs consistently held three basic concepts. The three core concepts
include value, balance, and accountability. The notion of value implies that firms have an
obligation to improve the welfare of society. The constructs are concerned with corporate
initiative creating value or benefit to society. The concept of balance suggests that businesses
must take appropriate steps to achieve a balanced strategy or decision when addressing and
responding to potentially conflicting stakeholder interests. The concept of balance is
incorporated in all four frameworks. For example, CSR requires corporations to balance
economic gains against the cost of achieving those gains (Carroll, 1979). In addition, the World
Business Council for Sustainable Development posits that sustainable development demands the
integration of social, environmental, and economic issues to develop balanced decisions for longterm thinking and future viability (World Business Council for Sustainable Development, 1998).
In fulfilling its economic, legal, and ethical responsibilities, an accountable business must
be responsible for its actions and decisions and should develop processes for correcting its
failures to avert similar future mistakes (Kassel 2012; Schwartz & Carroll, 2008; WECD, 1987).
The regulatory initiatives that require greater corporate accountability in disclosure of financial
information (for example, U.S. Sarbanes-Oxley Act), as well as the disclosure of social
performance information (for example, U.K. Pensions Act), highlight the importance of
accountability (Schwartz & Carroll, 2008). The value, balance, and accountability framework
proposed by Schwartz and Carroll argues, “All organizations and individuals operating within a
business context have a responsibility as good citizens to (a) contribute to sustainable societal
value and (b) appropriately balance stakeholder interests, including shareholders or owners
and/or moral standards, while (c) demonstrating sufficient accountability” (p. 173).
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Some have argued that a corporation must determine what the obligations or expectations
of the stakeholders are to communicate effectively with the stakeholders and society, whether the
firm views CSR as an obligation or as a voluntary process (Athanasopoulou & Selsky, 2015). In
their study, Athanasopoulou and Selsky proposed that CSR studies should include how an
organization can efficiently manage its CSR initiatives to align them with the expectations of the
stakeholders and society. The authors argue that such consideration of CSR initiatives
management is important so that CSR research can realistically reflect the ongoing call for
organizational strategies to be more deliberate in creating shared values between the firm and
society (Athanasopoulou & Selsky, 2015). For example, the 2010 British Petroleum oil spill in
the Gulf of Mexico and how the cleanup was managed could be considered a failed CSR because
the public perceived British Petroleum as not acting in a timely manner to minimize the extent of
ecological damage. The company did not appropriately engage with stakeholders, both during
and after the oil spill. The accident demonstrated that British Petroleum had no focus on its
relationships with the stakeholders, because the company failed to respond effectively to the
expectations of the stakeholders and society at large.
Evaluating CSR performance. A growing number of companies are using the Global
Reporting Guidelines for sustainability reporting because of the recent financial crises and the
increasing public pressure on corporations to provide information that goes beyond standard
financial reports (Seong et al., 2012). The nonfinancial issues in sustainability reports include
environmental and community relations. The Global Reporting Initiative is an independent
global standards network that assists organizations and governments in understanding and
sharing their efforts on issues such as climate change, human rights, and corruption. Rating
agencies evaluate these reports and quantify the CSR performance of the firm.
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These nonfinancial reports are qualitative, which makes it is difficult to compare
companies based on CSR performance. To develop a more comprehensive comparison between
companies, several rating agencies such as Calvert Investments, Dow Jones Sustainability Index,
FTSE4Good, Kinder, Lydenberg, and Domini Research & Analytics Inc. Environmental Social
Governance have developed their individual rating systems for measuring a company’s CSR
performance (Seong et al., 2012). Studies have shown that CSR performance or CSR disclosure
is being used by creditors or investors to assess a company’s credibility and firms can reduce
their capital costs when they earn high CSR performance rankings because companies with high
CSR performance are attractive to investors. The increase in the number of companies that are
participating in CSR reporting indicates that companies are starting to incorporate CSR
initiatives and reporting into their business strategies.
Despite the growth in number of companies that are participating in CSR reporting, and
the numerous methods that have been proposed for measuring CSR initiatives, the measurement
of CSR remains a problem because almost all of the methods (for CSR measurement) have
limitations (Turker, 2009). Many authors suggest that measuring CSR is important to business
and society because measurement is one way to deal seriously with the important issue of CSR
performance (Turker, 2009). However, the challenge is that investigators tend to rely on
stakeholders’ opinions when measuring CSR activities because developing comprehensive
measures of corporate social initiatives that measure socially responsible performance is difficult
(Dawkins & Fraas, 2013; Turker, 2009). There is agreement among researchers that measuring
CSR is difficult and some have suggested various methods, reputation indices, behavioral and
perceptional measures, and case study (Turker, 2009). For example, the Kinder, Lydenberg, and
Domini Database, and the Fortune Index use reputation indices for evaluating CSR activities, but
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no single best way to measure corporate social activities has been established (Dawkins & Fraas,
2013; Turker, 2009). Kinder, Lydenberg, and Domini uses a variety of sources, including
government, company, nongovernmental organization, and the media to collect information on a
company in its database. Kinder, Lydenberg, and Domini rates companies on components of
CSR performance such as: (a) community relations, (b) workplace diversity, (c) employee
relations, (d) environment, and (e) product quality and safety.
Similarly, the Access to Medicine Index ranks the top 20 world’s largest pharmaceutical
corporations on seven CSR initiatives: (a) general access to medicine management; (b) public
policy and market influence; (c) research and development conducted on neglected diseases; (d)
the company’s pricing, manufacturing, and distribution practices; (e) patents and licensing
policies; (f) capacity advancement in product development and distribution; and (g) drug
donations, and philanthropic activities (Iyer, 2014; Ravi Shankar, 2013; World Health
Organization [WHO] publications and events, 2014). This study examines the impact of CSR on
financial performance in the pharmaceutical industry using the CSR performance ranking by the
Access to Medicine Index.
Implementing CSR. To implement effectively and embed CSR into its day-to-day
business, Castka et al. (2005) proposed that a company should develop a management system
that: (a) creates, delivers, and measures corporate objectives in alignment with the TBL; and (b)
reviews the effectiveness and efficiency of the business processes. In addition, the company
should be able to demonstrate through corporate reporting, that their measurement and review
processes led to improvement in its TBL. These authors propose that a company must create
appropriate strategies that incorporate the organizational objectives needed to meet their CSR
obligations (Castka et al., 2005). The company should focus on delivering these objectives by
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implementing, measuring, and continuously improving actions and business processes necessary
to achieve planned results. In other words, leaders of organizations should run their businesses
profitably and should also take responsibility for the impact of the actions of their organizations
on the stakeholders and society. Therefore, the challenge for organizations is to develop balanced
solutions that support their TBL (economic, environmental, and social aspects of the company’s
business performance) based on the communication with the stakeholders.
Maon, Lindgreen, and Swaen (2009) proposed a framework, based on Lewin’s (1951)
planned change model to help guide corporate leaders in identifying success factors necessary
for developing and implementation of CSR initiatives. Lewin’s model consists of three stages:
unfreezing, moving, and refreezing, but the model proposed by Maon et al. (2009) contains a
fourth stage: sensitizing. The authors identified a four-stage framework for successfully
developing and implementing CSR in an organization and proposed that these stages incorporate
nine steps with different roles and importance (Maon et al., 2009). In the first stage, the leaders
must unfreeze (review and reorient) past unchallenged practices and cultural assumptions about
the right way for the company to run the business. Unfreezing involves assessing corporate
purpose and current CSR status, identifying the stakeholders, establishing a vision, developing a
CSR strategic plan, and implementing the CSR in the organization. In the moving stage, the
organization incorporates a new set of cultural norms. In this stage the company implements
CSR strategic plans, evaluates the integrated strategies, and reports on the progress of the change
process. In the third stage, leaders refreeze the new cultural assumptions to consolidate the new
business paradigm. The organization develops a learning process and strategic approaches that
will ensure that the new CSR cultural values are institutionalized and anchored into the
organization’s systems. In the fourth stage, sensitizing, the corporate leaders are well aware of
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the importance of sustainability issues to corporate success. The leaders raise awareness of CSR
in the company to neutralize any attempts of employees seeking to resist the change process. The
nine steps in the four-stage framework are raising CSR awareness in the organization, evaluating
corporate purpose, developing a working definition and vision for CSR, evaluating current CSR
status, developing a strategic CSR plan, implementing the strategic CSR plan, maintaining
continuous internal and external communication, assessing CSR strategies and communications,
and institutionalizing CSR policy.
Tools and Metrics for Measuring the Impact of CSR on Corporate Financial Performance
It is becoming increasingly common for firms to publish evidence of their CSR activities
as part of their report to stockholders because investors, creditors, and financial analysts stress
the importance of CSR (Rodgers, Choy, & Guiral, 2013). Myriad reviews and meta-analyses
have suggested that CSR improves corporate financial performance (Griffin & Mahon, 1997;
Margolis & Walsh, 2001, 2003; Orlitzky, Schmidt, & Rynes, 2003; Pava & Krausz, 1996;
Rodgers et al., 2013). However, the importance of measuring CSR and the impact of CSR on
corporate financial performance is still unclear (McWilliams & Siegel 2000, 2001).
Despite the lack of agreement on the metrics or quantifiable business measures of CSR,
many agree that CSR is a critical business strategy (Santoso & Feliana, 2014). In a review of 159
published studies, Peloza (2009) evaluated the business case for CSR. The review found that the
59 studies used 39 different measures or attributes of CSR to assess the relationship between
CSR and corporate financial performance. Among the studies, 82% used a single measure
(pollution control), and 18% used environmental protection and investment in health and safety.
The CSR performance metrics used in the studies were highly diverse: some measured a firm’s
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family-friendly policies, some industry codes of ethics, while others measured corporate
environmental protection activities.
Similarly, after three decades of research on the relationship between CSR and corporate
financial performance, there exist no consistent factors for measuring CSR, and corporate leaders
use different metrics to evaluate the economic impact of CSR on corporate financial performance
(Peloza, 2009). Apart from the variation in the metrics used, it has been reported that most of the
published studies on the link between CSR and corporate financial performance relied heavily on
CSR data obtained from Kinder, Lydenberg, and Domini (McWilliams & Siegel, 2000). It has
been established that measuring CSR is quite complex because CSR has many areas or factors
such as environmental concern, business transparency, philanthropy, and employee affairs
(Margolis et al., 2009; Nollet et al., 2016). In view of the complexity of CSR, Margolis et al.
(2009) urged researchers to consider using measures different from Kinder, Lydenberg, and
Domini third-party auditors’ data to determine if the current published results are similar or
different from results obtained from the data set of other CSR reporting indexes.
There is disagreement regarding the best way to measure corporate financial performance
when evaluating the link between CSR and corporate financial performance: whether to use
accounting or market measures remains unresolved (Gama Boaventura et al., 2012; D. D. Lee &
Faff, 2009; Orlitzky et al., 2003; van Beurden & Gössling, 2008). According to a literature
review by Orlitzky et al. (2003), three measures of corporate financial performance—market,
accounting, and survey—have commonly been used in the studies of the economic impact of
CSR on corporate financial performance. Accounting measures evaluate past financial
performance and they reflect the internal efficiency of the company since accounting measures
assess the impact of corporate management policies on earnings (D. D. Lee & Faff, 2009;
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Orlitzky et al., 2003). In addition, accounting measures are indicators of the degree to which
CSR was able to affect productivity asset utilization, return on debt, and return on equity
(Orlitzky et al., 2003). Some of the accounting measures used in many studies are return on
assets, asset utilization, return on equity, sales growth, return on sales, and operating margin
(Gama Boaventura et al., 2012; Preston & O’Bannon, 1997; van Beurden & Gössling, 2008;
Waddock & Graves, 1997). Market-based measures include stock performance, market return,
market value to book value, and price per share (Orlitzky et al., 2003; van Beurden & Gössling,
2008).
Market measure is an estimate of what the market believes the firm is worth based on the
extent to which future earnings and risk are projected to impact firm value. Research has shown
that the two measures, accounting measures and market measures, if used to assess the economic
impact of CSR on financial performance, would give different findings using the same data (van
Beurden & Gössling, 2008). Some researchers have reported that market measurements provide
less significant relationship between CSR and corporate financial performance than accounting
measurements, and as such accounting measures are better than market measures for analyzing
the economic impact of CSR on corporate financial performance (van Beurden & Gössling,
2008).
CSR and Financial Performance
Scholars have been searching for the association between CSR and corporate financial
performance for more than three decades (Andonov et al., 2015; Moore, 2001; Shahzad &
Sharfman, 2015; H. Wang & Choi, 2013). The relationship between the CSR and corporate
financial performance has garnered much interest and controversy for more than five decades
(Preston & O’Bannon, 1997). In spite of this long history of research, analysis, and debate, no
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consensus on the impact of CSR on corporate financial performance has been fully established
(Griffin & Mahon, 1997; Preston & O’Bannon, 1997; Saeidi, Sofian, Saeidi, & Saeidi, 2015).
The results have not been consistent but have often been contradictory and rather misleading
(Margolis & Walsh, 2003). Although a positive relationship between CSR and corporate
financial performance has been the dominant finding in many studies (Moore, 2001; Orlitzky et
al., 2003; van Beurden & Gössling, 2008), others have reported a negative relationship
(Aupperle et al., 1985), and no relationship or inclusive relationship (Griffin & Mahon, 1997).
Many scholars have reported contradictory results on the relationship between the CSR and
corporate financial performance even within a study. In some cases, a study might suggest a
positive and no effect or a positive and negative relationship between the CSR and corporate
financial performance (Griffin & Mahon (1997). A number of researchers, including Griffin and
Mahon (1997) and Margolis and Walsh (2003) have questioned the methods used by many of the
studies, which have assessed the relationship between CSR and corporate financial performance.
These researchers argue that the contradictory results seen in these studies could be because the
relationship between the CSR and corporate financial performance may be affected by some
factors that these studies might have overlooked (Griffin & Mahon, 1997; Margolis &Walsh,
2003; Saeidi et al., 2015).
There is a considerable amount of inconsistency in the literature on the relationship
between CSR and corporate financial performance in terms of whether an association exists, and
the direction of the relationship between the CSR and corporate financial performance (Margolis
& Walsh 2003; Orlitzky et al., 2003; Salzmann, Ionescu-Somers, & Steger, 2005). Margolis and
Walsh (2003) analyzed 127 research studies that investigated the relationship between CSR and
corporate financial performance between 1972 and 2002. Their results indicated mostly positive,
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few negative, and no relationship between CSR and corporate financial performance. Some
scholars have concluded that the relationship between CSR and corporate financial performance
is complex and it is not possible to make a theoretical generalization about the effects of
corporate socially responsible practices on corporate financial performance (Margolis &Walsh,
2003; Perrini, Russo, Tencati, & Vurro, 2011; Saeidi et al., 2015). Other researchers have argued
that the exact association between CSR and corporate financial performance is simply still
unclear (Aupperle et al., 1985; Griffin & Mahon, 1997; Peloza, 2009). Therefore, the debate over
the impact of CSR and corporate financial performance remains unsettled. Although there still
exists unsettled debate about the existence of a relationship between these two concepts
(Friedman, 1970; Waddock & Graves, 1997), and in spite of the controversy about the validity of
some results (Margolis & Walsh, 2003), most studies have reported a positive association
between CSR and corporate financial performance (Orlitzky et al., 2003; H. Wang & Choi,
2013). As shown in the following studies presented, no consensus has been achieved in the
numerous studies that have evaluated the relationship between CSR and corporate financial
performance.
Studies with positive relationships between CSR and corporate financial
performance. Pava and Krausz (1996) reviewed 21 studies that examined the financial
performance of firms that are rated by the Council on Economic Priorities as being socially
responsible. They compared the financial performance of the socially responsible firms to a
control sample by size and industry (Pava & Krausz 1996). The study found that in 12 of the 21
studies there was a positive association between CSR and corporate financial performance (Pava
& Krausz 1996). One firm had a negative association, and eight had no relationship between
CSR and corporate financial performance. The researchers found that firms rated as socially
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responsible either outperformed or performed as well as other firms that did not include CSR
initiatives in their business practices (Pava & Krausz 1996).
Preston and O’Bannon (1997) conducted a study on 67 large U.S. corporations from 1982
to1992, to examine the relationship between CSR and financial performance. The study
measured CSR using three social performance ratings, including community and environment
responsibility, ability to select and retain good employees, and quality of products and services
(Preston & O’Bannon, 1997). Corporate financial performance was measured using return on
assets, return on equity, and return on investment. The study reported a strong positive
association between CSR and corporate financial performance (Preston & O’Bannon, 1997).
Waddock and Graves (1997) examined the relationship between CSR and corporate financial
performance in a study of 469 Standard and Poor’s 500 corporations. The study used the eight
CSR elements rated by Kinder, Lydenberg, Domini and Co. to measure CSR. Corporate financial
performance was measured based on return on assets, return on equity, and return on sales
(Waddock & Graves 1997). The researchers found a positive relationship between CSR and
corporate financial performance (Waddock & Graves 1997). Some have argued that the findings
of Waddock and Graves support the premise that a high level of corporate financial performance
can be achieved when there is high quality of management that relates effectively to
stakeholders, including shareholders, employees, customers, and the communities (Verschoor,
1998).
Ruf, Muralidhar, and Brown (2001) examined the impact of CSR on corporate financial
performance in a study of 496 Standard and Poor’s 500 firms. The study used the eight CSR
elements rated by Kinder, Lydenberg, Domini and Co. to measure CSR (Ruf et al., 2001).
Corporate financial performance was measured based on return on equity, return on sales, and
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growth in equity. The study showed that improving a firm’s CSR performance can generate
increased corporate financial performance (Ruf et al. 2001). In a study of 85 U.S. banks,
Simpson and Kohers (2002) categorized the banks as outstanding, satisfactory, needs to improve,
and substantial noncompliance based on 12 attributes used to measure CSR. Corporate financial
performance was measured as return on assets and ratio of loan losses to total loans. The
researchers found that the return on assets of banks rated high on CSR was almost double the
return on assets of banks rated low on CSR. Banks rated high on CSR had one half of the loan
losses when compared to banks rated low on CSR (Ruf et al., 2001).
Orlitzky et al. (2003) examined the relationship between CSR and corporate financial
performance in a meta-analysis (a study conducted on previous research) of 52 studies conducted
throughout a period of 30 years. The meta-analysis showed that there is a positive relationship
between CSR and corporate financial performance across the industries in the studies. The
researchers concluded that if CSR activities enhance corporate financial performance, then the
firm is using its resources to improve the welfare of shareholders by integrating CSR policies
into its business (Orlitzky et al., 2003). The firm is, therefore, fulfilling the economic model that
argues that a firm’s purpose is to maximize the wealth of the shareholders.
A literature review of the association between a company’s CSR and its corporate
financial performance by Margolis and Walsh (2003) found that there were 127 publications on
the relationship between CSR and financial performance between 1972 and 2002. Of these
studies, 17 were published in the 1970s, 30 in the 1980s, and 80 of the studies were published
between1990 and 2002. In 109 of the 127 studies, 54 showed a positive relationship between
CSR and corporate financial performance. Seven studies reported a negative relationship, 28
studies found nonsignificant relationships, and 20 had mixed findings. The findings from these
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127 studies suggest that there is a positive relationship between CSR and corporate financial
performance. In another study, Margolis et al. (2009) conducted a meta-analysis (performing
research on previous studies) of 251 studies on the relationship between CSR and corporate
financial performance on studies from 1972 through 2007. The results of the study indicate a
moderate positive relationship between CSR and corporate financial performance. In their metaanalysis, 59% of the firms in the studies showed a nonsignificant relationship between CSR and
corporate financial performance, 28% a positive relationship, and 2% a negative relationship
(Margolis et al., 2009).
A recent Rodriguez-Fernandez (2016) study assessed the relationship between CSR and
corporate financial performance on companies registered on the Madrid Stock Exchange in 2009.
The study found a bidirectional relationship between CSR and corporate financial performance
(Rodriguez-Fernandez, 2016). This means that engaging in socially responsible corporate
policies produce higher profits, and higher profits enhanced engagement in socially responsible
corporate policies. The author argued that increasing CSR activities improved corporate financial
performance, and when firms enjoy improved financial performance they earn improved CSR
rating, thus creating a positive feedback loop that encourages firms to incorporate CSR policies
in their business (Rodriguez-Fernandez, 2016). Kapoor and Sandhu (2010) analyzed the impact
of CSR on corporate financial performance in a study based on 93 companies operating in India
from 2005 to 2006. The study used secondary data to measure CSR and corporate financial
performance. The authors found that CSR had significant positive impact on corporate financial
performance (Kapoor & Sandhu, 2010).
Santoso and Feliana (2014) investigated the relationship between CSR and corporate
financial performance in a study of 800 companies listed on Indonesian Stock Exchange from

68
2010 to2012. The financial performance was measured based on return on assets and stockmarket returns while they measured CSR practices by corporate social disclosure index. The
study found that CSR has a positive impact on the financial performance, and, there is a
significant positive relationship between the size of a firm and CSR (Santoso & Feliana, 2014).
Von Arx and Ziegler (2014) analyzed the effect of CSR on corporate financial
performance between 2003 and 2006 by examining the effect of CSR on U.S. stock markets and
European stock markets. CSR was evaluated by comparing the environmental and social
performance of a firm compared to those of other firms within the same industry. Corporate
financial performance was measured using the average monthly stock returns. The study showed
that CSR has a positive impact on corporate financial performance (von Arx & Ziegler 2014).
Furthermore, the average monthly stock returns between 2003 and 2006 were higher in the U.S.
than in Europe. The authors argued that stock performance in the U.S. was higher because the
U.S. has a longer tradition of incorporating ethical components of CSR into its businesses than
Europe (von Arx & Ziegler 2014). For example, socially responsible investing started in the U.S.
during the 18th Century.
Studies with negative relationships between CSR and corporate financial
performance. Moore (2001) investigated the relationship between CSR and corporate financial
performance in eight of 11 firms in the U.K. supermarket industry. The CSR attributes measured
were employees, customers, shareholders, suppliers, community, and environment. Corporate
financial performance was measured using growth in turnover, profitability, return on capital,
and earnings per share. The researcher found negative relationships between CSR and corporate
financial performance, with corporate financial performance declining as CSR initiatives
increased (Moore, 2001).
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Studies with no effect or inconclusive relationships between CSR and corporate
financial performance. Aupperle et al. (1985) studied 180 firms to assess the relationship
between CSR and corporate financial performance. The study measured CSR using a survey of
the CEOs of 180 firms. Corporate financial performance was measured by return on assets
(Aupperle et al., 1985). The researchers found no association between CSR and corporate
financial performance because their study showed that engaging in CSR practices was neither
helpful nor harmful to a firm (Aupperle et al., 1985). McGuire, Sundgren, and Schneeweis
(1988) used accounting as well as stock market–based measures of firms’ financial performance
to assess the relationship between CSR and corporate financial performance. CSR data were
obtained from Fortune magazine’s annual survey of corporate reputation. Accounting-based
performance measures used were return on assets, total assets, sales growth, asset growth, and
operating income growth. The researchers found mixed results (McGuire et al., 1988). The study
showed a positive relationship between CSR and return on asset (a measure of corporate
financial performance; McGuire et al., 1988). However, CSR had a negative relationship with
operating income growth. In addition, CSR had a significant negative relationship with the ratio
of debt to assets, an accounting-based risk measure.
Sandhu and Kapoor (2005) studied 20 top companies operating in India from 2000 to
2003, to evaluate the relationship between CSR and corporate financial performance. CSR was
measured using CSR ratings from Kinder, Lydenberg, and Domini and Fortune Magazine. The
CSR attributes in the ratings include education, health care, environment, infrastructure
development, rural development, sponsorships, job opportunity, facilities available to the victims
of natural calamities, donations, employee training programs, and diversity. The study showed
that there was no relationship between CSR and corporate financial performance (Sandhu &
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Kapoor, 2005). It is interesting to note that Sandhu and Kapoor found no relationship between
CSR and corporate financial performance and yet Kapoor and Sandhu (2010) found a significant
relationship between CSR and corporate financial performance. Both studies were performed by
same authors on companies in India.
Seifert, Morris, and Bartkus (2004) investigated the relationship between the availability
of slack resources and corporate philanthropy and investigated the relationship between
corporate philanthropy and the profitability of the firm. The study measured CSR using the
philanthropy data of 157 firms chosen from the 1997 or 1998 Fortune 1,000 (Seifert et al., 2004).
Corporate financial performance was measured based on the total stock-market returns defined
as “percentage change in stock price during the year of a donation plus dividends per share as a
percentage of the beginning stock price” (p. 145). The study found that cash flow had a
significant impact on a firm’s cash donations to charitable causes, but cash donations had no
impact on corporate financial performance (Seifert et al., 2004). The findings suggest that
philanthropy, specifically cash donations, has no significant effect on corporate financial
performance (Seifert et al., 2004).
Peloza (2009) examined 128 studies concerning the relationship between CSR and
financial outcomes and found that 59% had a positive relationship, 27% had a mixed or neutral
relationship, and 14% had a negative relationship. Lu, Chau, Wang, and Pan (2014) conducted a
review of 84 studies published between 2002 and 2011, on the relationship between CSR and
corporate financial performance. The CSR practices measured included CSR disclosures, CSR
reputation ratings, social audits, CSR processes, and observable outcomes. The financial
performance attributes measured included return on assets, return on equity, return on sales, and
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earnings per share. The study found inconclusive or mixed results on the relationship between
CSR and corporate financial performance (Lu et al., 2014).
A recent Nollet et al. (2016) study examined the relationship between CSR and corporate
financial performance. The study used both return on assets and return on capital (accounting
based) as well as excess stock returns and (market-based) financial performance gauges (Nollet
et al., 2016). CSR was measured on Standard & Poor’s 500 firms for the period 2007 to 2011
using Bloomberg’s Environmental Social Governance Disclosure scores. The results showed a
U-shaped relationship between CSR and corporate financial performance, suggesting that in the
long run, CSR effects are positive. The researchers argued that their findings imply that CSR
business initiatives do not lead to financial improvement at the onset, but only after crossing a
critical point of continuous investment in CSR policies (Nollet et al., 2016). While engaging in
CSR practices impacts financial profitability negatively in the beginning, the negative effect is
reversed after crossing a critical point of CSR investment, and CSR finally helps to improve the
firm’s financial profitability. According to their findings, firms should dedicate long-term
planning and resources to CSR practices in order for CSR to maximize the wealth for the
shareholders (Nollet et al., 2016).
As discussed, there is lack of consensus on whether, and to what extent, CSR impacts a
corporation’s financial performance (Margolis et al., 2009; Margolis & Walsh, 2003; Orlitzky et
al., 2003; Shahzad & Sharfman, 2015; van Beurden & Gössling, 2008). The current literature
about the impact of CSR on corporate financial performance remains ambiguous (von Arx &
Ziegler, 2014; Waddock & Graves, 1997). There are various arguments about the relationship
between CSR and corporate financial performance. Scholars who found a positive relationship
between CSR and corporate financial performance in their studies argue that firms rated high in
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CSR have few labor problems, and customers may be attracted the firm’s products. A company’s
reputation with its stakeholders such as bankers, investors, and government may be improved if
the corporation is socially responsible. CSR can, therefore, improve a firm’s access to financial
resources, which potentially leads to a company’s financial success (Kapoor & Sandhu, 2010).
On the other hand, scholars whose studies showed negative relationships between CSR
and corporate financial performance argue that CSR puts additional financial burden on firms,
which places these companies at an economic disadvantage compared to corporations that are
less socially responsible (Sandhu & Kapoor, 2005). Arguments that propose a negative influence
of CSR on corporate financial performance emphasize that the operating costs of corporate social
activities outweigh their corporate financial benefits because CSR investments reduce corporate
financial resources. Consequently, investment in CSR can potentially reduce profits, lower
returns to shareholders, and decrease a firm’s competitive advantage (von Arx & Ziegler, 2014;
Waddock & Graves, 1997).
Many reasons have been proposed for the inconclusive evidence on whether and to what
extent CSR influences corporate financial performance. Some of the differences in the various
studies on the association between CSR and corporate financial performance arise from the
context of the studies. For example, the country, industry, size of the firm, and the differences in
the number and types of CSR elements measured can account for the inconsistencies in the
studies on the economic impact of CSR on corporate financial performance (Gregory, Tharyan,
& Whittaker, 2014; Orlitzky et al., 2003). In addition, variations in the studies have been
attributed to the different financial measures used. Some studies have used accounting measures,
including return on assets, return on equity, or return on sales, while others have used stock
returns (Margolis et al., 2009; Orlitzky et al., 2003). The value of both the accounting measures
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and the stock market measures has been disputed. Some have called accounting measures
backward looking and questioned the value of the data obtained from using these measures
(Gregory et al., 2014). Stock market measures, forward-looking measures that provide an
outlook of future cash flows, are most commonly used in assessing the impact of CSR on
corporate financial (Margolis et al., 2009).
However, others have argued that using stock market measures can produce misleading
results because it is not an efficient market in which everyone has similar information. Only
changes in corporate financial performance can truly reflect the level of CSR in the firm
(Gregory et al., 2014). A firm’s level of CSR could remain unchanged and yet the market value
(or stock value) of the firm could abruptly drop. For example, as seen in the dotcom bubble and
subsequent bust between 1997 and 2000, a market can overreact to economic changes, which can
lead to stocks becoming either overpriced or underpriced. During the dotcom bubble, many
technology companies saw unreasonably high growth in their stock prices in a bullish market
where people even invested in risky companies. The bubble burst between 1999 and 2002 when
several companies such as WorldCom that had fraudulent accounting practices filed for
bankruptcy. The market values of both the companies that had transparent accounting practices
and the fraudulent technology companies fell when the stock market crashed between 2000 and
2002. The market values of the transparent companies were not saved by high level of CSR.
Therefore, focusing on stock returns alone in determining the impact of CSR on financial
performance could be misleading.
Evolution of the Search for a Link Between CSR and Corporate Financial Performance
The search for an association between CSR and corporate financial performance has
grown immensely since the 1980s (Ameer & Othman, 2012). Two opposing views have been
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proposed. One view posits that CSR is a trade-off for corporate financial performance. The
alternative view suggests that the costs a firm incurs from CSR activities are small and that a
firm may in fact benefit from socially responsible activities (McGuire et al., 1988). There is a
growing acceptance of the latter argument for the economic benefit of CSR (Ameer & Othman,
2012). Companies in various industries are increasingly becoming engaged in socially
responsible activities that improve the welfare of society (Y. Wang & Berens, 2015).
Scholars have argued that incurring costs from CSR commitments seems to be contrary
to maximizing shareholders’ wealth because such costs may decrease a corporation’s short-term
financial performance (McWilliams & Siegel, 1997). However, the predominant argument in the
literature on CSR is that a high level of CSR is an effective strategy for establishing a good
corporate brand and reputation, which can ultimately boost a firm’s financial performance
(Orlitzky et al., 2003; Y. Wang & Berens, 2015). Corporate leaders have started to invest time
and funds into socially responsible strategies such as integrating environmental interests in their
business processes (Cheng et al., 2014). CSR became an important business practice for firms
during the last decade (Servaes & Tamayo, 2013; Y. Wang & Berens, 2015). Many firms are
posting their CSR activities on their corporate Web sites in addition to disclosing their CSR
performance in annual reports (Servaes & Tamayo, 2013). In a 2010 study of 766 CEOs from
companies worldwide by United Nations Global Compact-Accenture, it was reported that 93%
of the CEOs stated that implementing CSR is a key factor for the future success of their
corporation (Cheng et al., 2014).
Corporations did not voluntarily integrate CSR into their business practices, but they
were surprised by public responses to issues they had not considered their corporate
responsibilities. For example, there was a public outcry and call to boycott Nike products after
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the New York Times and other media outlets reported the horrible labor practices at Nike’s
Indonesia warehouses (Porter & Kramer, 2006). Nike had to acknowledge its mistakes and take
necessary steps to rectify its business practices. Activists and the media have become more
aggressive and effective at putting public pressure on corporations to run their businesses in
socially responsible ways. Increased pressure by different activist groups is one of the most
important reasons that companies are considering the consequences of their business operations
on society (Andonov et al., 2015).
Social activist groups are becoming more empowered, making it impossible for
companies not to respond to public outcry. These activists have put such enormous pressure on
companies to behave responsibly that a social climate has been created in which firms are
expected to demonstrate high-level CSR (Andonov et al., 2015). However, corporations cannot
be held responsible for all the problems in the world and, indeed, they do not have the resources
to solve all of the world’s problems. Many have called on each corporation to identify the
societal problems it is best suited to solve and from which the corporation can benefit. By putting
its resources and expertise in solving a societal problem a firm understands, and in which the
firm can benefit, the firm can produce a major social benefit, and increase shareholder value
(Porter & Kramer, 2006). Perceiving CSR as a shared value between society and corporations
requires businesses to think differently about the consequences of their activities on society.
Although CSR has gained the attention of corporate leaders and scholars (Cheng et al.,
2014), the research on the association between CSR and corporate financial performance has not
yet conclusively defined the economic influence of CSR on corporate financial performance
(Margolis & Walsh, 2003). However, just as CSR is increasingly becoming integrated into the
business strategies of firms, so is CSR reporting becoming accepted as a reporting agenda on
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firms’ annual reports. In the early 1970s, CSR reporting was at its infancy (Tschopp & Huefner,
2015). The information reported was neither consistent nor reliable, and was of little use. The
social activism of the 1990s and the subsequent demand for socially responsible investing led to
the demand and growth of the current CSR reporting.
France was the first country that made it mandatory for publicly traded companies to
include CSR data in annual reports in 2003 (Tschopp, & Huefner, 2015). Many European
countries, including Belgium and the United Kingdom, require CSR reporting. Currently,
government agencies and nongovernmental organizations are actively engaged in promoting
CSR reporting. Firms publish CSR reports to provide stakeholders information about their
socially aligned business practices. Stakeholders include employees, customers, suppliers,
shareholders, management, governments, nongovernmental organizations, media, and the public
that affect or are affected by the practices of a firm (Freeman, 1984). Governments use CSR
reports to verify that firms abide by the government regulations. The level of a firm’s CSR can
influence an investor’s decisions about investing in a company. A firm can use CSR reports to
evaluate its operations’ cost savings, for employee motivation, or to strengthen its corporate
reputation and brand (Tschopp, & Huefner, 2015). There are currently many CSR reporting
agencies, but the three most recognized are the Global Reporting Initiative’s G3 standards,
AccountAbility’s AA1000 Series, and the United Nations Global Compact’s Communication on
Progress.
The Business Case for CSR
In recent years, a growing number of corporate leaders have increasingly allocating
resources to their firms’ socially responsible strategies. For example, firms are voluntarily
integrating environmental and social practices, improved communications with stakeholders, and
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CSR reporting in their business operations (Cheng et al., 2014; Servaes & Tamayo, 2013). In the
aftermath of the recent economic downturn, the public perceives companies as prospering at the
expense of the communities in which they do businesses, and companies are blamed for being
the cause of social and economic problems (Nollet et al., 2016). Therefore, the government,
nongovernmental organizations, activists, and the public have called on businesses to operate in
a more socially responsible manner. Many scholars have observed that businesses are not only
committed to making profit, but are also getting involved in ethical and socially responsible
issues; CSR is being recognized as a relevant business strategy (Santoso & Feliana, 2014).
Despite the attention that corporations are giving to CSR, many still question whether
CSR creates value for a firm since the existing research has not provided a conclusive answer
(Cheng et al., 2014; Margolis, & Walsh, 2003; Servaes & Tamayo, 2013). Different approaches
have been proposed to support shared value creation between the firm and society to benefit the
firm and all stakeholders, but the impact of the CSR strategies on corporate financial
performance remains questionable (Perrini et al., 2011). For more than four decades, research
has focused on the social responsibilities of business, the economic argument for CSR, and the
link between CSR and corporate financial performance (Carroll, 1999; Perrini et al., 2011;
Wartick & Cochran, 1985; Wood 1991). The debate on the economic impact of CSR on
corporate financial performance has been ongoing for many decades. Yet, the business case or
rational for CSR and the association between CSR and corporate financial performance remains
controversial (D. D. Lee & Faff, 2009; Margolis & Walsh, 2003; Perrini et al., 2011).
CSR was traditionally considered a waste of a firm’s resources that conflicts with
responsibility a business owes to its shareholders (Friedman, 1970). Some scholars argue that
CSR takes resources away from the firm’s primary business, and thus conflicts with maximizing

78
shareholder value (Aupperle et al., 1985; Friedman 1970; Jensen, 2001; McWilliams & Siegel,
1997). Critics of CSR have argued that the negative relationship between CSR and corporate
financial performance is a result of the additional costs incurred when a firm invests in CSR.
They argue that investing in CSR instead of other potentially profitable business strategies
decreases economic performance (Aupperle et al., 1985; D. D. Lee & Faff, 2009). Ullmann
(1985) argued that because of the large number of variable factors that impact a firm’s CSR and
corporate financial performance, it is unreasonable to claim that there is a relationship between
CSR and the corporate financial performance.
However, CSR advocates suggest that CSR (doing good) can influence stakeholders to be
more accommodating to the business practices of a firm since a firm’s CSR helps to build the
brand and reputation (Waddock & Graves, 1997). Wood (2010) argued that CSR investments do
not only improve corporate financial performance and stakeholder value, but also enhance the
well-being of society. Proponents of CSR have tried to promote the concept of CSR by
emphasizing the “so-called business case for CSR” (Schreck, 2011, p. 167). Advocates of the
business case argue that CSR can produce many benefits that might offset its costs, and it is,
therefore, an inevitable strategy for a business (Bowen, 1953; Freeman, 1984; M. Lee & Kotler,
2010; Porter & Kramer, 2002). The business case for CSR is defined as, “a concept whereby
companies integrate social and environmental concerns in their business operations and in their
interaction with their stakeholders on voluntary basis” (Nollet et al., 2016, p. 400). Many
scholars support that the business case for CSR is the justification and rationale or the economic
and financial benefits a business gains from embedding CSR activities and initiatives in their
business strategy (Carroll & Shabana, 2010).
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The central theme of the arguments about the business case is that a high level of CSR
helps a firm develop good relationships with its stakeholders such as customers, community, and
society, which consequently improve the firm’s financial performance (Carroll & Shabana, 2010;
Ruf Muralidhar, & Brown, 2001; H. Wang & Choi, 2013). Some customers become loyal to a
corporation that takes care of its social and environmental responsibilities, and are even willing
to pay premium prices for the services or products of the firm (McWilliams & Siegel, 2001). The
CSR activities of a firm give a glimpse to people outside the company what working for such a
firm would be like, and job seekers are often attracted to such firms. Thus, corporations that are
socially responsible have an edge in selecting the best quality employees from the workforce. In
addition, the local community may be more willing to provide favorable terms when socially
responsible corporations seek to lease or buy local real estate (H. Wang & Choi, 2013). Another
advantage of high-level CSR for public companies is that CSR activities may enhance gaining a
listing on the FTSE4Good US Select Index or Dow Jones Sustainability Indexes, or other similar
indexes. These indexes rate companies on CSR criteria such as transparency, environmental and
social issues, and governance. A high rating on these indexes can increase a company’s stock
price, making shareholders wealthier and happier (Robins, 2011).
If doing good, in terms of transparency in business practices and addressing social ills,
could be associated with doing well in corporate financial performance, then companies might be
persuaded to integrate CSR in their businesses (Margolis et al., 2009; Porter & Kramer, 2006).
Businesses would be encouraged to do good even if it means sustaining additional costs, so that
they can improve their bottom lines and the well-being of society (Margolis et al., 2009). If
scholars can prove the business case for CSR, meaning that CSR and shareholder value
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maximizing could be shown to be synergistic, business leaders could justify investment in CSR
as a legitimate business expense.
Freeman’s (1984) stakeholder theory has made a valuable contribution to the importance
of a firm’s commitment to social responsibility activities (Rodgers et al., 2013; Ruf et al., 2001).
The stakeholder theory proposes that firms should not focus exclusively on the needs of
shareholders but should also be mindful of the demands of other stakeholders (Freeman, 1984).
Nevertheless, researchers disagree on whether firms pledge to do good (be socially responsible)
so that they can do well (be well off financially) or whether firms that do well are empowered to
do good. The implication of the argument that doing well facilitates doing good is that profitable
companies have abundant resources from which they can afford to devote a quota to social
responsibility activities (Preston & O’Bannon, 1997; Waddock & Graves, 1997). Scholars argue
that doing good propagates doing well, implying that a high level of CSR improves corporate
financial profitability (Ullmann, 1985; Waddock & Graves, 1997).
More studies have reported positive relationships between CSR and corporate financial
performance than negative relationships (Margolis et al., 2009). Although it might not be clear if
doing good to the stakeholders engenders doing well financially, many results inherently support
the concept. For example, Verschoor (1998) performed one of the first large-scale studies the
results of which indicate that companies that do good to the stakeholders are more well off than
those that do not do good to the stakeholders. Verschoor examined the relationship between CSR
and corporate financial performance of the 500 largest U.S. public corporations and found that
26.8% of the 500 corporations integrate CSR into their businesses. The CSR activities reported
in the annual reports of the corporations consisted mostly of the corporations’ ethical conduct to
stakeholders. The financial performance of those corporations that disclose their CSR activities
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was found to be significantly higher than those of corporations that do not. Another study similar
to that of Verschoor (1998) was conducted by van Beurden and Gössling (2008), where they
reviewed 34 studies on the relationship between CSR and financial performance. Van Beurden
and Gössling reported that the majority of the studies found a positive relationship between CSR
and corporate financial performance. Out of the 34 studies reviewed, 68% reported a positive
relationship, 26% reported no relationship, while 6% (two studies) reported a negative
relationship between CSR and corporate financial performance (van Beurden & Gössling, 2008).
In a recent study of the relationship between CSR and corporate financial performance,
Kang, Germann, and Grewal (2016) examined 4,500 firms throughout a period of 19 years. The
study reported that firms that participate in CSR do well financially because of their investment
in CSR activities (Kang et al., 2016). Similar to other studies, their findings suggested that firms
engage in CSR for various reasons. Some firms adopt socially responsible initiatives because
they are doing well financially and because they believe that being socially responsible is the
right corporate strategy. Other firms participate in CSR as a kind of penance to compensate for
their past corporate social irresponsibility (Kang et al., 2016; Orlitzky et al., 2003). Kang et al.
(2016) found that the firms that engaged in CSR for philanthropic reasons gained significant
financial performance from investing in CSR. On the other hand, firms that engaged in CSR
merely as repentance for their past corporate irresponsibility obtained little or no positive
financial performance from investing in CSR. These studies seem to support the notion that firms
that do good (invest in CSR) also do well financially. These findings that substantiate the
business case for CSR could motivate corporations to be more socially responsible.
Factors That Influence the Relationship Between CSR and Corporate Financial
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Performance
Industry effects. The relationship between CSR and corporate financial performance is
affected by many factors, such as firm size, industry, economic conditions, and regulatory
environment (Peloza, 2009). Although a large number of studies that have shown a positive
relationship give hope to the business case of CSR, scholars are concerned about the
inconsistency in these results. Griffin and Mahon (1997) posited that industries operate under
very different situations and are faced with different stakeholder interests, social and
environmental issues, and levels of activism. Research has shown that studies that fail to account
for the differences between industries and use multiindustry data may mask specific industry
effects and the real CSR impact on corporate financial performance. In order words, results
obtained from analyzing data from a cross section of industries may be masked by the different
CSR or corporate financial performance elements ranked and/or the different methods used for
measuring CSR and corporate financial performance. Each industry is unique because each
industry has different competencies and internal and external pressures. Therefore, the internal
and external pressures in an industry, such as governmental regulations and consumer issues, are
likely to be similar within each industry (Griffin & Mahon, 1997). Researchers have argued that
a study should focus on a single industry to allow the scholar to determine if similar issues
within the industry are treated in like manner (Griffin & Mahon, 1997) because “the issues
change and they differ for different industries” (Carroll, 1979, p. 501). Griffin and Mahon (1997)
strongly advocate that scholars should concentrate on studying the link between CSR and
corporate financial performance within a specific industry because of the “uniqueness of internal
competencies or external pressures inherent in an industry, the degree of public visibility, the
different configurations of stakeholders and their differing degrees of activism on particular
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issues” (p. 10). The type of social responsibility activities a firm chooses to engage in is uniquely
related to the nature of the demands by its stakeholder, its corporate competencies, and industry
environment (Baird, Geylani, & Roberts, 2012; Griffin & Mahon 1997; Simpson & Kohers,
2002).
Firm size. Another significant factor that researchers have found to influence the
relationship between CSR and corporate financial performance is firm size (Moore, 2001). Many
studies that have either tested or controlled for firm size found firm size to be significantly
associated with CSR disclosure. Moore’s (2001) findings suggest that the larger the firm, the
more visible it is to the public, and, hence, larger firms are more likely to be exposed to greater
public scrutiny. Therefore, if larger firms are not socially responsible, their reputation is more
likely to suffer than the reputation of the less visible smaller firms. To prevent loss of reputation,
the larger firms are often more likely to engage in socially responsible initiatives. Pava and
Krausz (1996) also found that larger firms were significantly more socially responsible than
smaller firms.
Firm risk. Scholars have argued that firm risk influences the relationship between CSR
and corporate financial performance (Moore, 2001; R. W. Roberts, 1992). R. W. Roberts (1992)
reported that firms with a low level of risk (stocks that consistently perform well) are more prone
to devote their resources to social responsibility activities. The study also found that financial
performance is associated with the level of corporate social disclosure (R. W. Roberts, 1992).
Trotman and Bradley (1981) also examined the effects of firm risk on corporate disclosure of
social responsibility performance and they found that firms with a good reputation of investing in
CSR activities had lower firm risk. The Trotman and Bradley (1981) study is in agreement with
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R. W. Roberts’ (1992) argument that firms with low risk are more prone to provide their
corporate responsibility information, and low risk yields higher financial performance.
Summary
Chapter 2 provides a brief discussion of the evolution of the pharmaceutical industry and
CSR. The growing understanding that corporations have an obligation to work for social
improvement was shown to be one of the causes of the increasing pressure on companies to
practice and demonstrate their commitment to CSR. The lack of consensus on the impact of CSR
on corporate financial performance after a long history of research, analysis, and debate, was
discussed. Different theories were proposed in the literature review about the lack of consistent
metrics for evaluating the economic impact of CSR on corporate financial performance. The
challenge and complexity of measuring CSR and financial performance despite the growth in the
number of companies that participate in CSR reporting was underscored. As discussed in
Chapter 2, most studies to date have reported a positive association between CSR and corporate
financial performance, even though the debate about the relationship between CSR and corporate
financial performance remains unsettled.
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Chapter 3: Methodology
Overview of Chapter Content and Organization
This chapter explains the methodology used to conduct this research study. The
subsections discuss the methodology and rational, the research design, population, sample and
sampling procedures, instruments, validity and reliability, study limitations, human subject
consideration, data collection, data management, and analysis.
There is hardly any pharmaceutical company that can operate without an annual
sustainability or CSR report (Nussbaum, 2009). The “idea that firms need to take account of the
interests and concerns of multiple stakeholders, not just shareholders” (Googins et al., 2007, p.
126), is one of the many pressures driving business practices and decision making in
organizations. Many firms have integrated CSR as a prominent business strategy in an attempt to
go above and beyond increasing shareholder value and also contribute to the well-being of
society (Turker, 2009). In spite of the increasing amount of literature on CSR, corporate leaders
continue to disagree about how to balance CSR and their shareholders’ wealth (Leisinger, 2009).
This study uses the Global Leadership Network framework to assess the impact of CSR
on the financial performance in the pharmaceutical industry. Definitions and terminology of CSR
are still unclear, and corporations’ social responsibility performance metrics are still being
developed (Googins et al., 2007). The Global Leadership Network Framework assessment
presents concepts and criteria to help corporations account for their social responsibility
performance. The Global Leadership Network framework is a benchmarking tool designed to
assist companies in defining their CSR strategies and in measuring corporate performance by
focusing on issues that meet the needs of the business.
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If a significantly positive relationship between CSR and financial performance is shown,
businesses may be influenced to pay attention to, not only their corporate financial profits, but
also their social, ethical, and environmental activities such as improving the access to medicine,
reducing poverty, and contributing to the improvement of their communities. The Global
Leadership Network framework provides corporations beneficial and socially responsible
strategies “to conceptualize and to monitor their triple bottom line performance” (Googins et al.,
2007, p. 126).
Restatement of Study Purpose
The purpose of this quantitative study is to analyze the impact of CSR on financial
performance in the pharmaceutical industry. The aim of the study is to ascertain if CSR leads to
better financial performance in the pharmaceutical industry. Therefore, correlations were
computed to examine the relationship between CSR (independent variables), and the 2011–2014
financial performance (dependent variable). The strength of association between the dependent
variable and independent variables was assessed through linear correlation (using the Spearman
correlation coefficient) to determine whether a significant correlation exists. This study intended
to analyze the impact of CSR on financial performance of the 20 global pharmaceutical
companies that are rated by the Access to Medicine Index. However, the researcher studied 18 of
the 20 pharmaceutical companies that participated in the 2012 and 2014 Access to Medicine
CSR rating because: (a) Only 19 of the 20 pharmaceutical companies participated in both the
2012 and 2014 Access to Medicine CSR ranking. The 20th company rated by the Access to
Medicine in 2012 was different from the 20th company rated in 2014; (b) One of the 19
companies that was ranked by the Access to Medicine in both 2012 and 2014 is a private
company and was eliminated from this study because it is not a publicly traded company. The
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financial data of the private company that were eliminated from this study are not publicly
available unlike the financial data of the 18 publicly traded pharmaceutical companies. This
study aimed to evaluate the world’s largest, publicly traded pharmaceutical companies so that the
findings of the study could be generalized to other publicly traded pharmaceutical companies.
The study is expected to influence a change in the contribution of pharmaceutical companies to
the welfare of society at large by inspiring global pharmaceutical industry leaders to invest in
CSR to generate positive collective benefits for society.
Restatement of Research Questions
For more than three decades, many researchers have been trying to figure out if
companies that have integrated CSR in their business policy perform better financially than
companies that have not integrated CSR (Cheng et al., 2014; Robins, 2011). This study examines
the impact of CSR on financial performance in the pharmaceutical industry. CSR is measured by
ratings from the Access to Medicine Index, and corporate financial performance is measured by
EVA. The research question that this study proposes to answer is: What is the financial
performance in the pharmaceutical companies that have embraced CSR?
Population: Industry Studied
The population that was used in the study is composed of companies within the same
industry: the pharmaceutical industry. Pharmaceutical companies face similar issues, problems,
government regulatory restraints, enforcement procedures, and stakeholder activism. Research
has shown that in a multiindustry study, the differences between industries can mask specific
industry effects and the real CSR impact on corporate financial performance (Griffin & Mahon,
1997). Using a single industry allows the researcher to determine the impact of CSR on financial
performance in the pharmaceutical industry. The population of this study consists of 20 of the
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world’s largest pharmaceutical companies. The pharmaceutical manufacturing sector in the study
consists of companies primarily engaged in the manufacturing and processing of biological and
medical pharmaceutical products for internal and external consumption.
The 20 pharmaceutical companies listed in this study (APPENDIX A) were selected
because they are the only pharmaceutical companies currently participating in the Access to
Medicine Index’s CSR assessment. The 20 pharmaceutical companies selected for the study
account for more than 50% of the global pharmaceutical market capitalization (Iyer, 2014). The
study focuses on the pharmaceutical industry because of the investigator’s experience working
the industry. The pharmaceutical corporations evaluated in this study are industry leaders and
they have global scope of operations. These companies are ideal candidates for studying
economic impact of CSR on corporate financial performance because multinational CSR
activities are represented in the study. The financial and CSR data of these companies are
available publicly. Limited by the number of pharmaceutical companies participating in the
Access to Medicine Index ranking, the study evaluated the CSR and financial performance of top
18 global pharmaceutical companies. The study examined the impact of CSR on the financial
performance in the pharmaceutical industry from 2011 to 2014.
Research Design
A quantitative method is used to show a quantifiable result related to the numerical
changes that arise from the study groups or population being studied (Holton & Burnett, 2005).
A quantitative research method examines the relationship between variables, in this case, CSR
and financial performance (Creswell, 2014). This study uses a quantitative correlational
nonexperimental research method to test whether, and to what degree, a relationship exists
between CSR (independent variables) and financial performance (dependent variable). A
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quantitative nonexperimental research uses existing data (data obtained from a secondary source)
to study a phenomenon (Holton & Burnett, 2005). A quantitative research method includes
experimental, quasiexperimental (less rigorous experiments), correlational, and descriptive
methods (Creswell, 2014). In experimental research, the researcher wants to find out if a specific
treatment would produce an outcome. The researcher specifically treats one group while
withholding the same treatment from another, and then evaluates how the two groups scored on
the measured outcome. The interest of the researcher in a correlational research study is
assessing the degree of association or relationship between two or more variables. An
independent variable is construed to be the cause of the resulting outcome in a study. Changes in
the independent variable cause changes in the dependent variable (Martin & Bridgmon, 2012).
The dependent variable is the ensuing behavior or outcome that is measured in response to an
independent variable.
In evaluating the relationship between CSR and financial performance, this study
employed a quantitative correlational study design using publicly available records to collect
financial data and CSR data. Quantitative research method was the method of choice for this
study because it is difficult to compare companies’ CSR performance based on qualitative CSR
data (Seong et al., 2012). Consequently, CSR rating organizations, including Calvert
Investments, Dow Jones Sustainability Index, FTSE4Good, and Kinder, Lydenberg, and Domini
Research & Analytics Inc., have generated their own systems for rating a company’s CSR
performance. Similarly, the Access to Medicine Index developed its seven categories for
evaluating the CSR performance of pharmaceutical industries (Iyer, 2014). Because there is a
wide variation in the level of CSR in pharmaceutical companies, this quantitative study
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examined changes in financial performance (dependent variable) that were caused by CSR
(independent variables) in the pharmaceutical industry.
Instrument Validity-Reliability
Validity indicates the extent to which a measure or tool precisely represents the concept
in the study that it alleges to measure (P. Roberts, Priest, & Traynor, 2006). Measures in a study
are deemed valid if they measure what they are supposed to measure (Holton & Burnett, 2005).
Reliability refers to the extent to which a protocol or tool consistently produces similar results in
different circumstances such as if the tool is used by different researchers or if used at different
times (P. Roberts et al., 2006). A measure is considered reliable if it yields consistent results over
time (Creswell, 2014). A measure could be very reliable (consistent) but not valid. For example,
an employee’s self-assessment of job performance can be very reliable but may not be valid.
Three common types of validity are content validity, criterion validity, and construct
validity (Creswell, 2014). Content validity indicates that the items measured in the study are the
items that the researcher intended to measure (Creswell, 2014; Holton & Burnett, 2005).
Criterion validity tests whether the measure can predict the dependent variable it is supposed to
predict (Holton & Burnett, 2005; Twycross & Shields, 2004). Construct validity denotes the
ability of a measurement tool to measure the underlying theory or concept. Reliability and
validity demonstrate the rigor of the research study and the trustworthiness of the research
findings (P. Roberts et al., 2006).
The researcher chose to demonstrate the content validity of the study by examining the
same measures (the one dependent and seven independent variables) that were evaluated in
Berete’s (2011) study and shown to have an effect on the research question in this study. Berete
analyzed 18 pharmaceutical companies to assess the relationship between CSR and financial
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performance of pharmaceutical industry throughout a two-year period before, and one year after
the first publication of the Access to Medicine Index. The CSR of pharmaceutical companies
was scored by the Access to Medicine Index for the first time in 2008. The study evaluated the
financial performance by the EVA and used the average sum of 2006 and 2007 as the financial
performance of the company before the publication of Access to Medicine Index and the
financial performance of 2009 as the financial performance after the publication of the Access to
Medicine Index (Berete, 2011). In Berete’s study, the Pearson correlation was performed on the
2008 CSR scores of the firms and the corporate financial performances before and after the
publication of the Access to Medicine Index.
Of the 18 pharmaceutical companies that participated in this study, 13 are the same
companies in Berete’s (2011) study. This study’s methodology is similar to Berete’s to the extent
that it used the same Access to Medicine Index for scoring CSR and EVA to measure financial
performance. The 18 pharmaceutical companies examined in this study integrated CSR, but there
is a wide variation of the level of CSR in these companies. Therefore, this quantitative study
examines the economic impact of CSR (independent variables) on financial performance
(dependent variable) in the pharmaceutical industry. This study differs from Berete’s (2011)
study because it evaluated the correlation between eight dimensions of CSR and financial
performance while Berete’s study only correlated overall CSR with financial performance. The
study correlated the CSR scores of 2012 and 2014 with corporate financial performances of
2011, 2012, 2013, and 2014 because the Access to Medicine Index is published every two years.
Reliability
The reliability of this study is assessed by employing validated quantitative research
methods similar to Berete’s (2011) study and public third-party data. The seven CSR categories
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used in this study were previously used in Berete’s study. The CSR categories are general access
to medicine management, public policy and market influence, research and development
conducted on neglected diseases, the company’s pricing, manufacturing and distribution
practices, patents and licensing policies, capacity advancement in product development and
distribution, drug donations, and philanthropic activities (Iyer, 2014). Similar to Berete’s (2011)
study, this study uses publicly available data to measure the financial performance of the
pharmaceutical companies using the EVA.
Berete (2011) found a significantly positive relationship between CSR and financial
performance and proposed that a case could be made that a high level of CSR could result in a
high level of corporate financial performance. By evaluating the 2012 and 2014 CSR scores of
companies with varying levels of CSR and the corporate financial performances throughout a
four-year period (2011–2014), this study determined if indeed doing good (a high level of CSR)
could engender doing well (a high level of corporate financial performance).
Study Limitations
One limitation related to the research on the relationship between CSR and corporate
financial responsibility to date is that there are no established or consistent indicators for the
measurements of CSR or corporate financial performance (Moore, 2001). For example, in the 51
different studies that Griffin and Mahon (1997) reviewed, they reported that 80 indicators had
been used for measuring corporate financial performance. The 80 criteria used for corporate
financial performance measurement included profitability, asset utilization, growth, liquidity,
and risk, and market measures. Griffin and Mahon found that return on assets, return on equity,
and return on sales were the most commonly used for measuring corporate financial
performance. The researchers posited that accounting-based measures were better for assessing
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corporate financial performance than market-based measures because market-based measures
may be evaluating more than just the financial performance (Griffin & Mahon, 1997). Many
studies have used market-based measures of performance, including stock market returns, but
McGuire et al. (1988) argued that accounting-based measures, such as return on assets, were
better gauges of CSR than market-based measures.
Griffin and Mahon (1997) found that many of the 51 studies they reviewed used a single
indicator or attribute to measure CSR, despite “the need for multiple sources of corporate social
performance” (p. 14). It is important to use many indicators to measure CSR, because CSR is a
complex concept that refers to the extent to which a corporation meets the needs, demands, and
expectations of not only its shareholders, but also of society at large. Therefore, Ullmann (1985)
argued that to study the complex issue of CSR, researchers would need to use a variety of criteria
to measures CSR. Ullmann further argued that measuring CSR implies creating a list of the
firm’s stakeholders, measuring their rate of satisfaction using different criteria, and developing
“an overall index that encompasses these different criteria so that organizations can be ranked in
terms of their overall social performance” (p. 544).
This study examines the influence that the CSR initiatives of pharmaceutical corporations
have on the firms’ financial performance. CSR corporate rankings are obtained from the Access
to Medicine Index. The Access to Medicine Index ranks the top 20 world’s largest
pharmaceutical corporations on seven CSR initiatives: (a) management of general access to
medicine programs; (b) public policy and market influence; (c) research and development on
neglected diseases; (d) pricing, manufacturing, and distribution practices; (e) patent and licensing
policies; (f) capacity advancement in product development and distribution; and (g) product
donations and philanthropic activities (Iyer, 2014; Ravi Shankar, 2013; WHO publications and
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events, 2014). This study is limited to the world’s 20 largest pharmaceutical companies and the
stated CSR initiatives because only these pharmaceutical companies have so far agreed to
participate in the Access to Medicine Foundation’s rating (Ravi Shankar, 2013; WHO
publications and events, 2014). Furthermore, the Access to Medicine Foundation, a not-for-profit
organization, is the one and only international company dedicated to finding ways to improve
access to medicines worldwide by encouraging pharmaceutical companies to promote drug
donations and access to medicine. The Access to Medicine Index is transparent in its business
practices, and starting in 2012, it adopted a more refined methodology that incorporates
stakeholder feedback in ranking the social responsibility activities of pharmaceutical companies
(Ravi Shankar, 2013).
Other researchers have used indexes such as Dow Jones Sustainability Index or the
FTSE4Good Index to identify and select U.S. corporations committed to CSR development
(Berger, 2013), but this study has found no literature on any rating agency apart from the Access
to Medicine Index that participates in ranking pharmaceutical companies on all the CSR
performance activities that will be examined in this study. Droppert and Bennett (2015) argued
that even though the “Dow Jones Sustainability Index is the best established of the various CSRrelated indices discussed but its focus is more on corporate sustainability than public health
concerns. The Access to Medicines Index provides a much stronger focus on public health” (p.
7). Hunt and Khosla (2010) suggested that the Access to Medicine Index offers “a firm
information base for monitoring the conduct of pharmaceutical companies” (p. 3). For example,
Kinder, Lydenberg, and Domini Research & Analytics Inc., a firm based in Boston, ranks
companies’ CSR performance on categories including community, corporate governance,
environment, employee relations, and diversity (Seong et al., 2012). These categories do not
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fulfill the requirements of this study because they do not include the major CSR categories that
are crucial to this study. The management of the access to medicine, drug donations, R & D on
neglected drugs, and the other four CSR categories evaluated by the Access to Medicine Index
are central to this study. The researcher has not found any other organization that ranks CSR
performance categories similar to those of the Access to Medicine Index. This study is limited to
examining the financial performance and CSR initiatives of the world’s 20 largest
pharmaceutical corporations to improve global access to drugs. The sample was chosen because
the CSR scores of all the 20 pharmaceutical companies are available on one rating index
company. The same metrics are used by the company to score and rank the CSR performance of
all the companies.
Human Subject Consideration
The study does not use human subjects. Therefore, it is not necessary to provide
documents that protect the rights of the participants, for example, confidentiality agreements and
consent forms. The financial data sources selected are from publicly available database
information collected from company annual reports to governmental agencies. Written
permission to use the Access to Medicine Index data of the participating pharmaceutical
companies was requested because Access to Medicine Index is copyrighted.
Instrumentation
When choosing an instrument in a quantitative research study, the researcher seeks the
instrument that best allows him or her to quantify ideally the theoretical and conceptual
framework (Hagan, 2014). Publicly available financial and CSR data of 20 pharmaceutical
companies are used in this study. EVA is used to evaluate the financial data gathered from the
annual reports of pharmaceutical companies. The CSR data is obtained from Access to Medicine
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Foundation, a nonprofit international corporation. The Access to Medicine Index evaluates the
CSR of the 20 world’s largest pharmaceutical corporations and assigns each corporation scores
on a relative scale of 0 to 5. The corporations are assessed and scored on the seven categories of
socially responsible corporate performance, consisting of: management of general access to
medicine programs; public policy and market influence; research and development on neglected
diseases; pricing, manufacturing and distribution practices; patent and licensing policies;
capacity advancement in product development and distribution; and product donations and
philanthropic activities (Iyer, 2014; Ravi Shankar, 2013; WHO publications and events, 2014).
Validity
There are two measures of validity in a study design: internal and external validity.
Internal validity is the degree to which the results are attributable to the independent variable and
not some other rival explanation; the confidence that we can place in the cause and effect
relationship in a study (P. Roberts et al., 2006; Twycross & Shields, 2004). To establish the
validity of a construct, the new measure must be related to other established or previously
verified measures (Gunter & Jensen, 2002).
The results of a study could be invalidated if the measurements failed to portray the
concepts relevant to the research question (Hagan, 2014). To establish internal validity of the
study, the researcher examined the measures (the dependent variable and seven independent
variables) that have been evaluated in Berete’s (2011) study and found to have an effect on the
research question in this study.
Berete (2011) analyzed 18 pharmaceutical companies to assess the relationship between
CSR and financial performance of pharmaceutical industry throughout a two-year period before,
and one year after the first publication of the Access to Medicine Index. The CSR of
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pharmaceutical companies was scored by the Access to Medicine Index for the first time in 2008.
The study evaluated the financial performance by the EVA, and used the average sum of 2006
and 2007 as the financial performance of the company before the publication of Access to
Medicine Index and the financial performance of 2009 as the financial performance after the
publication of the Access to Medicine Index (Berete, 2011). In Berete’s study, the Pearson
correlation was performed on the 2008 CSR scores of the firms and the corporate financial
performances before and after the publication of the Access to Medicine Index. Berete’s study
showed that CSR has a positive impact on financial performance in the pharmaceutical industry.
Of the 20 pharmaceutical companies participating in this study, 13 are the same
companies in Berete’s (2011) study. The methodology of this study is similar to that of Berete’s
to the extent that it will use the same Access to Medicine Index for scoring CSR and EVA for
measuring financial performance. The 20 pharmaceutical companies examined in this study have
integrated CSR, but there is a wide variation of the level of CSR in these companies. Therefore,
this quantitative study examines the economic impact of CSR (independent variables) on
financial performance (dependent variable) in the pharmaceutical industry. This study is different
from Berete’s (2011) study because it aims to determine if there is a correlation between the
level of CSR and financial performance. Because the Access to Medicine Index is published
every two years, the study correlates the CSR scores of 2012 and 2014 with corporate financial
performances of 2011, 2012, 2013, and 2014.
External validity is the extent to which the results of a study can be generalized from a
small sample group to make predictions about the entire population (P. Roberts et al., 2006;
Twycross & Shields, 2004). The participants in this study are from the same industry and they
face similar social, political, economic, legal, intercultural, and technical driving forces such as
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strict government regulations and increased cost of developing a new drug. Thus, the results of
this study, which evaluates the top world’s largest, publicly traded pharmaceutical companies,
could be generalized to other publicly traded pharmaceutical companies. However, the results
may not be generalizable beyond publicly traded pharmaceutical companies in the industry.
Reliability
Reliability refers to the consistency of a measure and the probability that if the measure
were retested or duplicated, the same results would be obtained. The measurement is said to be
reliable if the same result can be achieved on repeated occasions or at different time points
(Ameer & Othman, 2012). If reliable, the researcher can assume the results of the measurements
for the sample are consistent and could be generalized to a larger population (Hagan, 2014).
Although there is a growing body of literature on CSR, the measurement of CSR is still
challenging. Many methods for measuring socially responsible activities are offered in the
literature, but these methods all have some limitations (Turker, 2009).
This quantitative study uses public, third-party numerical data and validated quantitative
research methods similar to Berete’s (2011) study to assess reliability. The financial data used in
the study are publicly available. The CSR data are evaluated and scored by a third party (Access
to Medicine Index), thus eliminating the possibility of the researcher’s bias and the potential for
corporate favoritism or coercion. The Access to Medicine Index has become an internationally
known nonprofit organization dedicated to helping to promote access to medicine worldwide by
examining the CSR activities of 20 of the world’s largest pharmaceutical companies (Ravi
Shankar, 2013; WHO publications and events, 2014). The study evaluates over an extended
period representative of the timeframes necessary to test the independent variables on the
dependent variable.
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Data Collection Procedures
The study uses publicly available records to collect financial data and CSR data for the
period 2011 through 2014. Financial data (annual revenues) were collected from the annual
reports of the pharmaceutical companies. The annual report is the most characteristic instrument
of corporate disclosure because it is the principal source of information for investors, it is an
important communication between a company and its stakeholders, and it is considered highly
credible because it is similar to audited financial statements (Dawkins & Fraas, 2013). The
Securities and Exchange Commission, as mandated by the Sarbanes-Oxley Act, requires
companies to provide transparent financial and internal controls, verified by independent
auditors, in their annual reports, and to disclose quarterly, any substantial changes in these
controls (Guerra, 2004; Rockness & Rockness, 2005). The Sarbanes-Oxley Act, enacted in 2002,
is a United States federal law also known as the corporate auditing and accountability, and
responsibility act, but it is commonly called SOX. The act is designed to enforce transparent
financial governance and internal controls in corporations (Rockness & Rockness, 2005). The
internal controls are the controls related to the preparation of financial statements for external
purposes that conform to the generally accepted accounting principles. The Sarbanes-Oxley Act
was enacted in response to major corporate and accounting scandals, including those that
involved Enron, Tyco International, Adelphia, Peregrine, and WorldCom.
This study’s financial data are derived from the following sources: Hoover’s full business
database, Securities Data Corporation, and Standard and Poors 500 Index, and Factiva online
database for news articles. The concept of Economic Value-Added developed by Stern Stewert
and Co. in the early 1990s, is used to evaluate financial performance (Kyriazis & Anastassis,
2007; Madhavi & Prasad, 2015a; Poornima et al., 2015). When evaluating a company’s
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performance, the Economic Value-Added model considers a company as creating value for its
shareholders only if the company generates returns that are in excess of the cost of capital. The
introduction of the Economic Value-Added concept has equipped companies with the ability to
gauge better their performance on a global standard because Economic Value-Added measures
the profit generated by an organization over its cost of capital (Kyriazis & Anastassis 2007;
Madhavi & Prasad, 2015a). Economic Value-Added is computed by deducting the cost of capital
from the net operating profit after tax. Many researchers consider Economic Value-Added one of
the best performance measurements that captures the economic profit of a corporation (Madhavi
& Prasad, 2015a). Many companies, including Coca Cola, AT&T, Briggs & Stratton, and
Quaker Oats, have adopted Economic Value-Added as a financial management system to
monitor performance (Kyriazis & Anastassis, 2007). The Economic Value-Added method makes
it possible to assess how efficiently capital is being used in a firm compared to traditional
approach, which is based on the concept of accounting profits and the relevant ratios, such as the
return on equity and the return on assets (Kvach & Il’ina, 2013). The traditional performance
measurements do not consider the cost of invested capital in order to determine the profits a
company has made, whereas Economic Value-Added does (Kyriazis & Anastassis, 2007). For
example, under the traditional approach, if two companies have the same return on equity, they
would be considered equally successful, whereas under the Economic Value-Added approach, a
different conclusion would be reached if the economic profit (Economic Value-Added) or
residual income of these two companies were different.
The data for CRS activities are garnered from the Web site of Access to Medicine Index.
The Access to Medicine Foundation is a Netherlands-based not-for-profit company that is
dedicated to promoting access to medicine worldwide (WHO publications and events, 2014).
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The Access to Medicine Foundation has been gathering CSR data on the pharmaceutical
companies since 2008. The Access to Medicine Index, published every two years, scores
pharmaceutical companies on seven areas, and provides information about what these companies
are doing to improve their social responsibilities (Ravi Shankar, 2013; WHO publications and
events, 2014). The Access to Medicine Foundation is funded by the Bill and Melinda Gates
Foundation, the Dutch Foreign Affairs Ministry, and the United Kingdom Department for
International Development (WHO publications and events, 2014). The goal of the Access to
Medicine Foundation is to encourage pharmaceutical companies to make their products more
available, affordable, and accessible to people worldwide.
The eight categories of CSR for which corporations are evaluated and scored by Access
to Medicine Index include management of general access to medicine programs; public policy
and market influence; research and development on neglected diseases; pricing, manufacturing
and distribution practices; patent and licensing policies; capacity advancement in product
development and distribution; product donations, and philanthropic activities; and overall CSR
(Iyer, 2014; Ravi Shankar, 2013; WHO publications and events, 2014). The metrics used by the
Access to Medicine Index to evaluate social responsibility fall within the Googins’s et al. (2007)
four areas of the Global Leadership Network framework: (a) business strategy, (b) leadership, (c)
operational excellence, and (d) engaged learning. The metrics are not necessarily legal
definitions of CSR, but instead they are the strategic decisions, corporate moral ethics, and
values that help to shape the culture of a responsible organization. Researchers, pharmaceutical
companies, investors, governments, and nongovernmental organizations consider the Access to
Medicine Index as a useful tool with impartial information for benchmarking the CSR of
pharmaceutical companies (Ravi Shankar, 2013; “Sanofi’s initiatives,” 2012).
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Methodological Assumptions
This study assumes that the secondary data that are gathered from publicly available
records provide beneficial understanding about the impact of CSR on financial performance in
the pharmaceutical industry (Holton & Burnett, 2005). It is also assumed that CSR data collected
by the Access to Medicine Index from the participating pharmaceutical companies engaged in
socially responsible practices are reliable. The researcher argues that the CSR data are reliable
because of the SOX-like laws that govern Netherlands, the country in which the Access to
Medicine Foundation is based. When other countries, including the Netherlands, France, and
Germany, realized the need for stricter financial governance in corporations after the SOX was
enacted in the United States, they enacted similar laws (Rockness & Rockness, 2005). The SOXlike laws in these countries function to regulate and mandate accurate corporate reporting.
Data Management
The study uses publicly available records to collect financial data and CSR data for the
period from 2011 to 2014. The data collected from each company were organized in a Microsoft
Office Excel spreadsheet in columns representing the name of the company, the year, financial
data (dependent variable), and each of the eight categories of CSR scores for the company
(independent variables). The data entry into the spreadsheet was performed with great focus on
accuracy to ensure that accurate data were transferred to the SPSS analysis software. Both the
financial data and the CSR scores used in the study were saved in an electronic folder that is
protected by a password known only by the study’s author. Five years after the study is
completed, the stored data will be erased with CyberShredder (a software that permanently
deletes confidential files and directories from the computer).
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Calculation of EVA
The concept of EVA developed by Stern Stewart and Co. in the early 1990s, is used to
evaluate financial performance (Kyriazis & Anastassis, 2007; Madhavi & Prasad, 2015a;
Poornima et al., 2015). EVA is computed by deducting the cost of capital from the net operating
profit after tax. EVA = Net Operating Profit After Tax – (Capital Invested x the Weighted
Average Cost of Capital). As presented in the formula, there are three elements necessary to
calculate EVA: Net Operating Profit After Tax, Invested Capital, and Weighted Average Cost of
Capital. Net Operating Profit After Tax is defined as “the profits derived from company’s
operations after taxes but before financing costs and non-cash bookkeeping entries” (Madhavi &
Prasad, 2015b, p. 53). The capital invested is the amount of money that was used to fund a
project. The weighted-average cost of capital was calculated because the information is not
provided on the income statements of the 18 pharmaceutical companies. EVA was calculated as
shown below because it was not found in any of the balance sheets of the corporations in the
study:
EVA = Net Operating Profit after Tax- (Invested Capital*WACC)
NOPAT = Net operation Profit After Tax
NOPAT = Operating income – Income tax expense + Interest
Invested Capital = Total Assets – Noninterest bearing current liabilities + leases
Noninterest bearing current liabilities = Accounts payable + Taxes payable + Accrued
liabilities + other current liabilities
WACC = Weighted Average Cost of Capital
WACC = Weighted Cost of Debt + Weighted Cost of Equity
WACC = Rd (1-Tc) x (Dt/V) + Re x (E/V)
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Where:
Dt = Total debt
E = Total equity
V = E + Dt = Firm value
Tc = corporate tax rate
Rm = Historical market return (1966-2015 stocks and government bond yield)
Rf = Expected Risk free rate of return in market (1966–2015 stocks and government bond
yield)
β (Beta) = A measure of the risk of a stock compared to the market
Rd = Cost of Debt (an after-tax rate of interest a company pays for its debt)
Re = Cost of Equity (market rate of return that equity investors, such as shareholders,
expect to be paid as compensation for the risk they took for investing their capital in the
company).
Rd = I/(Dt) x (1 – tc)
Re = Rf + β (Rm – Rf)
EVA is a more comprehensive financial performance metric than other financial
performance metrics such as earnings per share, return on asset, and return on investment
because it measures the entire cost of running a business including operating and financing cost
(Ehrbar, 1998). In his 1995 Harvard Business Review article, Peter Drucker (as cited in Ehrbar,
1998) stated:
EVA is based on something we have known for a long time: What we call profits, the
money left over to service equity, is usually not profit at all. Until a business returns a
profit that is greater than its cost of capital, it operates at a loss. Never mind that it pays
taxes as if it had a genuine profit. The enterprise still returns less to the economy than it
devours in resources.…Until then it does not create wealth; it destroys it. (p. 2)
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Data Analysis
The data analysis was done using SPSS statistics analysis software based on its
standardized, comprehensive statistical features for data manipulation, graphics, regression
models, and summary statistics. Descriptive statistics (means, standard deviations, coefficients of
variation, and medians) were calculated for each of the study variables to describe the impact of
CSR on enhancement or erosion of shareholder value. The link between CSR and financial
performance were evaluated in this study with the Spearman correlation coefficient, which is
used to analyze the relationship between two variables (Martin & Bridgmon, 2012). A
correlation coefficient that denotes a relationship between two or more variables is called a
multiple correlation. The values for the Spearman correlation coefficients range from -1.0 to
+1.0. Multiple correlations have positive values while the negative values reflect negative
relationship. The two variables in the study were the dependent (corporate financial
performance) and the independent variables (eight categories of CSR activities).
Multiple regression analysis is used to analyze the extent to which two or more
independent variables are related to a dependent variable (Martin & Bridgmon, 2012). The study
performed multiple regression analyses to evaluate the relationship between the dependent
variable (corporate financial performance) and each of the eight independent variables (eight
categories of CSR), and to determine whether stakeholder value is enhanced or eroded.
Regression analysis was also used to estimate the statistical value of the dependent variable for a
given value of the independent variable to confirm that the independent variables individually or
collectively explain a change in the dependent variable.
Institutional Review Board Approval
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This study does not involve human subjects, but it uses publicly available existing data.
Before collecting and analyzing their research data, doctoral students at the Pepperdine
University are obliged to obtain approval from the university’s institutional review board (IRB)
after successfully passing the preliminary oral dissertation examination. At Pepperdine
University, students must get approval from the university IRB regardless of whether their
dissertation research involves or doesn’t involve human subjects. The IRB is designed to protect
the rights and welfare of the participants in the research. The IRB ensures that the research is
ethical and conducted in a manner that complies with federal, state, or local laws and regulations.
Researchers are expected to address any ethical issues that may be involved in their research.
Because this study does not involve human subjects, the researcher submitted an application of
exempt review status to the IRB, stating purpose, research questions, the study procedure, study
population, the design, data analysis, the risks, and the benefits of this study to the subjects and
society. In addition, the researcher submitted a Human Subject Training Certificate and a copy of
the dissertation proposal to the IRB.
Summary
The research study methodology discussed the study purpose, research questions, the
population studied, the research design, instrument validity and reliability, instrumentation, study
limitations, human subject considerations, data collection procedures, methodological
assumptions, data management, and data analysis. The aim of this quantitative study is to
examine the relationship between CSR and corporate financial performance in the
pharmaceutical industry.
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Chapter 4: Results
Overview of Chapter Content and Organization
Chapter 4 summarizes the results of the statistical analyses performed on the publicly
available data collected from the 18 pharmaceutical companies that participated in this research
study. The subsections discuss the analysis of results, answering the research questions, and
contain additional findings and the conclusion. The purpose of this study is to determine the
financial performance in the pharmaceutical industry among pharmaceutical companies that
have embraced CSR. The aim of this quantitative, nonexperimental, correlative research study
is to ascertain if CSR leads to better financial performance in the pharmaceutical industry.
The research question in this study was fully addressed using descriptive and inferential
statistical analyses. Financial performance was measured as EVA. Correlations were performed
on the eight hypotheses in the study. Wilcoxon matched pairs test was used to compare
changes in CSR and EVA scores from 2012 to 2014. Correlations were computed to examine
the relationship between CSR (independent variables), and the 2011 to 2014 financial
performance (dependent variable). The study correlated the CSR scores of 2012 and 2014 with
corporate financial performances of 2011, 2012, 2013, and 2014. Because the Access to
Medicine Index is published every two years, the CSR scores of 2012 were correlated with the
average of the sum of 2011 and 2012 financial performances while the CSR scores of 2014
were correlated with the average of the sum of 2013 and 2014 financial performances. The
study is expected to influence a change in the contribution of pharmaceutical companies to the
welfare of society by inspiring global pharmaceutical industry leaders to invest in CSR to
generate positive collective benefits for society. A significantly positive relationship between
CSR and financial performance should influence businesses to pay attention to not only their
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corporate financial profits, but also their social, ethical, and environmental activities such as
improving the access to medicine, reducing poverty, and contributing to the improvement of
their communities. The study evaluated the financial performance and CSR engagement of 18
leading worldwide pharmaceutical companies with headquarters in seven countries depicted in
Table 1.
Six of the pharmaceutical companies in this study have their headquarters in the United
States, four in Japan, two in Great Britain, two in Germany, two in Switzerland, one in
Denmark, and one in France. The study intended to evaluate the pharmaceutical companies
listed in Table1 because they are the only pharmaceutical companies currently participating in
the Access to Medicine Index’s CSR assessment and ranking. Although the study aimed to
analyze the impact of CSR on financial performance of 20 global pharmaceutical companies
that are rated by the Access to Medicine Index, the researcher studied 18 of the 20
pharmaceutical companies because: (a) Only 19 of the 20 pharmaceutical companies
participated in both the 2012 and 2014 Access to Medicine CSR ranking. The 20th company
rated by the Access to Medicine in 2012 was Abbott Laboratories Inc., while the 20th company
rated in 2014 was AbbVie Inc.; (b) Boehringer Ingelheim GmbH, a private company, was one
of the 19 companies ranked by the Access to Medicine in both 2012 and 2014, but it was
eliminated from this study because it is not a publicly traded company. The financial data of
Boehringer Ingelheim GmbH are not publicly available, unlike the financial data of the 18
publicly traded pharmaceutical companies.
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Table 1.
Companies on the Access to Medicine Index CSR Ranking
Company

Year

Country

Abbott Laboratories Inc.

2012

USA

AbbVie Inc.

2014

USA

Astellas Pharma Inc.

2012 and 2014

Japan

AstraZeneca plc

2012 and 2014

Great Britain

Bayer AG

2012 and 2014

Germany

Bristol-Myers Squibb Co.

2012 and 2014

USA

Daiichi Sankyo Co. Ltd.

2012 and 2014

Japan

Eisai Co. Ltd.

2012 and 2014

Japan

Eli Lilly & Co.

2012 and 2014

USA

Gilead Sciences Inc.

2012 and 2014

USA

GlaxoSmithKline plc

2012 and 2014

Great Britain

Johnson & Johnson

2012 and 2014

USA

Merck & Co. Inc.

2012 and 2014

USA

Merck KGaA

2012 and 2014

Germany

Novartis AG

2012 and 2014

Switzerland

Novo Nordisk A/S

2012 and 2014

Denmark

Pizer Inc.

2012 and 2014

USA

Roche Holding AG

2012 and 2014

Switzerland

Sanofi

2012 and 2014

France

Takeda Pharmaceutical Co. Ltd.

2012 and 2014

Japan

This study aimed to evaluate the world’s largest, publicly traded pharmaceutical
companies so that the findings of the study could be generalized to other publicly traded
pharmaceutical companies. The quantitative study used archival data from annual reports of 18
pharmaceutical companies to answer the research question. The annual reports of the 18
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companies were collected for the years of 2011 through 2014. The financial data were gathered
from the income statements and balance sheets of each of the 18 pharmaceutical companies for
the period 2011 through 2014. Griffin and Mahon (1997) and Pava and Krausz (1996)
established that publicly disclosed financial information that satisfies the mandate of the U.S.
Securities Exchange Commission, including 10k filings, is adequate for analyzing the impact of
CSR on financial performance. EVA or economic profit was calculated from the information
obtained from the annual reports. EVA is a more comprehensive performance metric than other
performance metrics such as earnings per share, return on asset, and return on investment
because it measures the entire cost of running a business including operating and financing cost
(Ehrbar, 1998). In his 1995 Harvard Business Review article, Peter Drucker (as cited in Ehrbar,
1998) stated:
EVA is based on something we have known for a long time: What we call profits, the
money left over to service equity, is usually not profit at all. Until a business returns a
profit that is greater than its cost of capital, it operates at a loss. Never mind that it pays
taxes as if it had a genuine profit. The enterprise still returns less to the economy than it
devours in resources.…Until then it does not create wealth; it destroys it. (p. 2)
The CSR data were gleaned from the 2012 and 2014 reports of the Access to Medicine
Index. The analysis of the data to determine the impact of CSR on financial performance in the
pharmaceutical industry was performed using SPSS. Table 2 displays the descriptive statistics
(Mean [M], standard deviation [SD], minimum value [Low], and maximum value [High]) for the
companies’ CSR scores and EVA for 2012 and 2014.
Analysis of Results
Table 2 provides the descriptive statistics (Mean [M], standard deviation [SD], minimum
value [Low], and maximum value [High]) for the 2012 and 2014 CSR scores and EVA score.
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Table 2.
Descriptive Statistics for 2012 and 2014 CSR Scores and EVA
Score
2012 Overall CSR Score
2012 General Access to Medicine
Management
2012 Public Policy & Market Influence
2012 Research & Development
2012 Pricing, Manufacturing, &
Distribution
2012 Patents & Licensing
2012 Capability Advancement in Product
Development & Distribution
2012 Product Donations & Philanthropic
Activities
2014 Overall CSR Score
2014 General Access to Medicine
Management
2014 Public Policy & Market Influence
2014 Research & Development
2014 Pricing, Manufacturing, &
Distribution
2014 Patents & Licensing
2014 Capability Advancement in Product
Development & Distribution
2014 Product Donations & Philanthropic
Activities
2012 EVA
2014 EVA
n = 18

M
2.36

SD
0.87

Low
0.90

High
3.80

2.90
2.99
2.63

1.26
0.68
0.99

0.50
1.80
1.20

4.90
3.90
4.70

1.79
1.68

0.98
0.91

0.20
0.70

3.20
4.10

2.28

1.04

0.60

4.20

3.18
2.36

1.05
0.56

1.30
1.45

4.60
3.29

2.94
1.57
2.44

1.36
0.63
0.53

0.70
0.40
1.60

4.90
2.80
3.70

2.57
1.68

0.77
0.62

1.10
0.60

3.80
2.80

2.73

0.83

1.20

3.90

2.57
-3,052.40
-15,620.15

0.74
28,332.54
66,407.70

1.30
3.60
-113,153.74 15,552.43
-275,675.42 20,664.70

As shown in Table 2, the Overall CSR scores increased slightly from 2012 (M = 2.36, SD
= 0.87) to 2014 (M = 2.36, SD = 0.56), while EVA decreased from 2012 (M = -3,052.40, SD =
28,332.54) to 2014 (M = -15,620.15, SD = 66,407.70). The highest CSR score for 2012 was
product donations and philanthropic activities (M = 3.18, SD = 1.05), while the lowest score for
2012 was patents and licensing (M = 1.68, SD = 0.91). The highest CSR score for 2014 was
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general access to medicine management (M = 2.94, SD = 1.36), while the lowest score for 2014
was public policy and market influence (M = 1.57, SD = 0.63).
Answering the Research Question
The research question asked: What is the financial performance in the pharmaceutical
industry among companies that have embraced CSR? The related null hypotheses predicted that
there would be no correlations between any of the eight CSR scores and financial performance.
Specifically, the Alternative Hypothesis predicted positive correlations between financial
performance (EVA) and CSR as follows:
Alternative Hypothesis 1. There is a positive correlation between incorporation of general
access to medicine management (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 2. There is a positive correlation between incorporation of public
policy and market influence (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 3. There is a positive correlation between incorporation of
research and development conducted on neglected diseases (independent variable) in the
business strategy, and financial performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 4. There is a positive correlation between incorporation of
pricing, manufacturing, and distribution practices (independent variable) in the business strategy,
and financial performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 5. There is a positive correlation between incorporation of patent
and licensing policies (independent variable) in the business strategy, and financial performance
(dependent variable) in the pharmaceutical industry.
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Alternative Hypothesis 6. There is a positive correlation between incorporation of
capacity advancement in product development and distribution (independent variable) in the
business strategy, and financial performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 7. There is a positive correlation between incorporation of
product donations and philanthropic activities (independent variable) in the business strategy,
and financial performance (dependent variable) in the pharmaceutical industry.
Alternative Hypothesis 8. There is a positive correlation between incorporation of CSR
(overall independent variables) in the business strategy, and financial performance (dependent
variable) in the pharmaceutical industry.
Table 3.
Spearman Correlations for CSR Scores with EVA in 2012 and 2014
Correlations for 2012 Data
Correlations for 2014 Data
CSR Scores
EVA CSR Scores
EVA
General Access to Medicine
General Access to Medicine
Management
.26 Management
.59
Public Policy & Market Influence
.29 Public Policy & Market Influence
.28
Research & Development
.33 Research & Development
.08
Pricing, Manufacturing, &
Pricing, Manufacturing, &
Distribution
.28 Distribution
.37
Patents & Licensing
.33 Patents & Licensing
.38
Capability Advancement in
Capability Advancement in
Product Development &
Product Development &
Distribution
.17 Distribution
.52
Product Donations &
Product Donations &
Philanthropic Activities
.15 Philanthropic Activities
.50
Overall CSR Score
.16 Overall CSR Score
.63
n = 18
* p < .05. ** p < .01. *** p < .005. **** p < .001.
To answer the research question posed in this study, Table 3 displays the Spearman
correlations for the 2012 and 2014 CSR scores with the 2012 and 2014 EVA. Spearman

**

*
*
***
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correlations were used instead of Pearson correlations because of sample size (n = 18). Below are
the results of the hypothesis testing.
Test of Hypothesis 1
Null Hypothesis 1 was: There is no correlation between incorporation of general access
to medicine management (independent variable) in the business strategy, and financial
performance (dependent variable) in the pharmaceutical industry. This hypothesis was addressed
using Spearman’s correlations. As shown in Table 3, General access to medicine management
was not significantly correlated with EVA in 2012 (rs = .26, p = .28), but was significantly
correlated in 2014 (rs = .59, p = .008), providing partial support to reject this null hypothesis. The
results showed a positive and significant relationship between general access to medicine
management and financial performance in 2014, but general access to medicine management
was not significantly correlated with financial performance in 2012. This finding partially
supports alternative hypothesis 1, which postulates that there is a positive correlation between
incorporation of general access to medicine management in the business strategy, and financial
performance in the pharmaceutical industry.
Test of Hypothesis 2
Null Hypothesis 2 was: There is no correlation between incorporation of public policy
and market influence (independent variable) in the business strategy, and financial performance
(dependent variable) in the pharmaceutical industry. This hypothesis was addressed using
Spearman’s correlations. Table 3 displays the Spearman correlations for the 2012 and 2014 CSR
scores with that year’s EVA score to answer the research question. As shown in Table 3, Public
policy and market influence was not significantly correlated with EVA in 2012 (rs = .29, p = .22)
nor in 2014 (rs = .28, p = .25), providing no support to reject this null hypothesis. This finding
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supports the null hypothesis 2 that there is no correlation between incorporation of public policy
and market influence in the business strategy and financial performance in the pharmaceutical
industry.
Test of Hypothesis 3
Null Hypothesis 3 was: There is no correlation between incorporation of research and
development conducted on neglected diseases (independent variable) in the business strategy,
and financial performance (dependent variable) in the pharmaceutical industry. This hypothesis
was addressed using Spearman’s correlations. As shown in Table 3, Research and development
conducted on neglected diseases was not significantly correlated with EVA in 2012 (rs = .33, p =
.16) nor in 2014 (rs = .08, p = .75), providing no support to reject this null hypothesis. This
finding supports the null hypothesis 3 that there is no correlation between incorporation of
research and development conducted on neglected diseases in the business strategy, and financial
performance in the pharmaceutical industry.
Test of Hypothesis 4
Null Hypothesis 4 was: There is no correlation between incorporation of pricing,
manufacturing, and distribution practices (independent variable) in the business strategy, and
financial performance (dependent variable) in the pharmaceutical industry. This hypothesis was
addressed using Spearman’s correlations. As shown in Table 3, Pricing, manufacturing, and
distribution practices was not significantly correlated with EVA in 2012 (rs = .28, p = .24) nor in
2014 (rs = .37, p = .12), providing no support to reject this null hypothesis. This finding supports
the null hypothesis 4 that there is no correlation between incorporation of pricing,
manufacturing, and distribution practices in the business strategy, and financial performance in
the pharmaceutical industry.
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Test of Hypothesis 5
Null Hypothesis 5 was: There is no correlation between incorporation of patent and
licensing policies (independent variable) in the business strategy, and financial performance
(dependent variable) in the pharmaceutical industry. This hypothesis was addressed using
Spearman’s correlations. As shown in Table 3, patents and licensing policies was not
significantly correlated with EVA in 2012 (rs = .33, p = .17) nor in 2014 (rs = .38, p = .11),
providing no support to reject this null hypothesis. This finding supports the null hypothesis 5
that there is no correlation between incorporation of patent and licensing policies in the business
strategy, and financial performance in the pharmaceutical industry.
Test of Hypothesis 6
Null Hypothesis 6 was: There is no correlation between incorporation of capacity
advancement in product development and distribution (independent variable) in the business
strategy, and financial performance (dependent variable) in the pharmaceutical industry. This
hypothesis was addressed using Spearman’s correlations. As shown in Table 3, Capability
advancement in product development and distribution was not significantly correlated with EVA
in 2012 (rs = .17, p = .50), but was significantly correlated in 2014 (rs = .52, p = .02), providing
partial support to reject this null hypothesis. The results showed a positive and significant
relationship between capability advancement in product development and distribution and
financial performance in 2014, but capability advancement in product development and
distribution was not significantly correlated with financial performance in 2012. This finding
partially supports alternative hypothesis 6, which postulates that there is a positive correlation
between incorporation of capacity advancement in product development and distribution in the
business strategy, and financial performance in the pharmaceutical industry.
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Test of Hypothesis 7
Null Hypothesis 7 was: There is no correlation between incorporation of product
donations and philanthropic activities (independent variable) in the business strategy, and
financial performance (dependent variable) in the pharmaceutical industry. This hypothesis was
addressed using Spearman’s correlations. As shown in Table 3, product donations and
philanthropic activities was not significantly correlated with EVA in 2012 (rs = .15, p = .54), but
was significantly correlated in 2014 (rs = .50, p = .03), providing partial support to reject this null
hypothesis. The results showed a positive and significant relationship between product donations
and philanthropic activities and financial performance in 2014, but product donations and
philanthropic activities was not significantly correlated with financial performance in 2012. This
finding partially supports alternative hypothesis 7, which postulates that there is a positive
correlation between incorporation of product donations and philanthropic activities in the
business strategy, and financial performance in the pharmaceutical industry.
Test of Hypothesis 8
Null Hypothesis 8 was: There is no correlation between incorporation of overall CSR
(overall independent variables) in the business strategy, and financial performance (dependent
variable) in the pharmaceutical industry. This hypothesis was addressed using Spearman’s
correlations. As shown in Table 3, overall CSR score was not significantly correlated with EVA
in 2012 (rs = .16, p = .53) but was significantly correlated in 2014 (rs = .63, p = .003), providing
partial support to reject this null hypothesis. The results showed a positive and significant
relationship between overall CSR (overall independent variables) and financial performance in
2014, but overall CSR (overall independent variables) was not significantly correlated with
financial performance in 2012. This finding partially supports alternative hypothesis 8, which
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postulates that there is a positive correlation between incorporation of overall CSR in the
business strategy, and financial performance in the pharmaceutical industry.
Additional Findings
Table 4 provides the results of the Wilcoxon matched pairs tests comparing CSR and
EVA scores in 2012 with 2014. Wilcoxon matched pairs tests were used instead of paired
samples t tests because of the sample size (n = 18). Inspection of the table found that significant
changes occurred in four out of the nine pairs. Specifically, CSR public policy and market
influence scores significantly declined (z = 3.73, p = .001), and CSR pricing, manufacturing, and
distribution scores significantly gained (z = 3.60, p = .001). CSR capability advancement in
product development and distribution scores significantly gained (z = 2.75, p = .006), and CSR
product donations and philanthropic activities scores significantly declined (z = 3.13, p = .002).
Table 4.
Comparison of 2012 and 2014 Selected Variables Wilcoxon Matched Pairs
Variable
Overall CSR Score

Year

n

M

SD

2012
2014

18
18

2.36
2.36

0.87
0.56

General Access to Medicine
Management
2012
2014

18
18

2.90
2.94

18
18

2.99
1.57

18
18

2.63
2.44

18
18

1.79
2.57

.78

3.73

.001

1.40

.16

3.60

.001

0.99
0.53

Pricing, Manufacturing, & Distribution
2012
2014

0.29

0.68
0.63

Research & Development
2012
2014

p
.98

1.26
1.36

Public Policy & Market Influence
2012
2014

z
0.02

0.98
0.77
continued
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Variable
Patents & Licensing

Year

n

M

SD

2012
2014

18
18

1.68
1.68

0.91
0.62

Capability Advancement in Product
Development & Distribution
2012
2014

18
18

2.28
2.73

1.04
0.83

2012
2014

18
18

3.18
2.57

1.05
0.74

2012
2014

18
18

-3052.40
-15620.15

28332.54
66407.70

Product Donations & Philanthropic
Activities

EVA

z
0.39

p
.70

2.75

.006

3.13

.002

1.50

.13

n = 18
As shown in Table 4 using Wilcoxon test statistic (z-score) to compare changes in CSR
and EVA scores from 2012 to 2014, no significant changes were found in five out of the nine
pairs. Specifically, overall CSR scores were not significantly different from 2012 to 2014 (z =
0.02, p = .98). As shown in Table 4, CSR general access to medicine management scores were
not significantly different from 2012 to 2014 (z = 0.29, p = .78). CSR research and development
of neglected diseases scores were not significantly different from 2012 to 2014 (z = 1.40, p =
.16). CSR patent and licensing scores were not significantly different from 2012 to 2014 (z =
0.39, p = .70). Corporate financial performance (EVA) was not significantly different from 2012
to 2014 (z = 1.50, p = .13).
The 2012 and 2014 CSR scores of eight CSR categories and the 2012 and 2014
financial performance data of the 18 pharmaceutical companies are shown as:
Overall CSR scores and EVA (see Appendix E1); CSR general access to medicine
management scores and EVA (see Appendix E2); CSR public policy & market influence
scores and EVA (see Appendix E3); CSR research & development scores and EVA (see
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Appendix E4); CSR pricing, manufacturing & distribution scores and EVA (see Appendix E5);
CSR patents & licensing scores and EVA (see Appendix E6); CSR capability advancement in
product development & distribution scores and EVA (see Appendix E7); and CRS product
donations & philanthropic activities scores and EVA (see Appendix E8).
Summary
In Chapter 4, archival data from 18 pharmaceutical companies for the period 2011
through 2014, were used to evaluate the impact of CSR on financial performance in the
pharmaceutical industry among companies that have embraced CSR. The purpose of the
quantitative analysis is to ascertain if CSR leads to better financial performance in the
pharmaceutical industry.
The descriptive statistical analysis showed that the mean overall CSR scores increased
slightly from 2012 to 2014, while the mean EVA decreased from 2012 to 2014. Product
donations and philanthropic activities was the highest CSR score for 2012, while patents and
licensing was the lowest score for 2012. The highest mean CSR score for 2014 was general
access to medicine management, while the lowest mean CSR score for 2014 was public policy
and market influence.
Spearman’s correlations of the 2012 and 2014 CSR scores with the 2012 and 2014 EVA
were used to answer the research question, which asked: What is the financial performance in the
pharmaceutical industry among companies that have embraced CSR? They were also used to
answer the related null hypotheses, which predicted that there would be no correlations among
any of the eight CSR scores and financial performance. Four of the eight hypotheses received
partial support based on significant correlations between 2014 CSR and 2014 financial
performance.
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This study found no correlation among the eight dimensions of CSR and corporate
financial performance in 2012. The results showed a positive and significant relationship
between general access to medicine management and financial performance in 2014, but general
access to medicine management was not significantly correlated with financial performance in
2012. This finding partially supports alternative hypothesis 1, which postulates that there is a
positive correlation between incorporation of CSR general access to medicine management in the
business strategy, and financial performance in the pharmaceutical industry.
The findings showed a positive and significant relationship between CSR capability
advancement in product development and distribution and financial performance in 2014, but
CSR capability advancement in product development and distribution was not significantly
correlated with financial performance in 2012. This finding partially supports alternative
hypothesis 6, which postulates that there is a positive correlation between incorporation of
capacity advancement in product development and distribution in the business strategy, and
financial performance in the pharmaceutical industry.
A positive and significant relationship was found between CSR product donations and
philanthropic activities and financial performance in 2014, but CSR product donations and
philanthropic activities was not significantly correlated with financial performance in 2012. This
finding partially supports alternative hypothesis 7, which postulates that there is a positive
correlation between incorporation of product donations and philanthropic activities in the
business strategy, and financial performance in the pharmaceutical industry.
A positive and significant relationship was found between overall CSR (overall
independent variables) and financial performance in 2014, but overall CSR (overall independent
variables) was not significantly correlated with financial performance in 2012. This finding
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partially supports alternative hypothesis 8, which postulates that there is a positive correlation
between incorporation of CSR in the business strategy, and financial performance in the
pharmaceutical industry.
The Wilcoxon matched pairs tests were used to compare the changes in CSR and EVA
scores from 2012 to 2014. The results showed that significant changes occurred in four out of the
nine pairs that were compared. CSR public policy and market influence scores significantly
declined from 2012 to 2014. CSR pricing, manufacturing, and distribution scores significantly
gained from 2012 to 2014. CSR capability advancement in product development and distribution
scores significantly gained from 2012 to 2014, and CSR product donations and philanthropic
activities scores significantly declined from 2012 to 2014. In the final chapter, these findings are
compared to the literature, conclusions and implications are drawn, and recommendations are
suggested.
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Chapter 5: Discussion
Introduction and Summary of Key Findings
Chapter 5 provides an overview of this study, compares the findings to the literature,
draws conclusions and implications, and makes some recommendations. More than 2 billion
people still do not have access to medicines for treatable health conditions (Arnold & Valentin,
2013; M. Lee & Kohler, 2010). Gaining access to medicine depends on a variety of stakeholders,
including governments and the pharmaceutical industry. Pharmaceutical companies play a
crucial role in society because they have the expertise to develop and manufacture life-saving
therapeutic products. Pharmaceutical companies would be motivated to embed CSR in their
governance structures and develop strategies to manage access to medicine and address the needs
of the poor if provided a justifiable business case for CSR. Although the study of CSR and its
impact on corporate financial performance has grown immensely throughout the past 40 years, it
is still uncertain if CSR creates value for a firm since the existing research has not provided a
conclusive answer (Cheng et al., 2014; Margolis, & Walsh, 2003; Servaes & Tamayo, 2013).
The purpose of this quantitative study is to analyze the impact of CSR on corporate
financial performance in the pharmaceutical industry. The aim of the study is to ascertain if CSR
leads to better financial performance in the pharmaceutical industry. Therefore, correlations were
computed to examine the relationship between CSR (independent variables), and the 2011–2014
financial performance (dependent variable). The strength and direction of association between
the dependent variable and independent variables was assessed through correlation (using the
Spearman correlation coefficient) to determine whether a significant correlation exists. This
study intended to analyze the CSR performance of the leading 20 global pharmaceutical
companies that are ranked by the Access to Medicine Index but because of unavailability of CSR
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data for the contiguous years, the researcher studied 18 of the 20 pharmaceutical companies that
participated in the 2012 and 2014 Access to Medicine CSR rating. The study assesses the
world’s largest, publicly traded pharmaceutical companies and the findings could be generalized
to other publicly traded pharmaceutical companies. This study is expected to influence a change
in the contribution of pharmaceutical companies to the welfare of society by inspiring global
pharmaceutical industry leaders to invest in CSR to generate positive collective benefits for
society.
This study uses the Global Leadership Network Framework to evaluate the financial
performance in the pharmaceutical industry among companies that have embraced CSR. The
Global Leadership Network Framework shown in Figure 1, focuses on four areas: business
strategy (evaluating business priorities and alignment of CSR with business policies and
processes), engaged learning (defining corporate CSR policy through interaction and
consultation with stakeholders), leadership (commitment of the corporation to take leadership on
social and environmental issues that are important to the business), and operational excellence
(embedding CSR through coordination of processes, practices, policies, and relationships with
the stakeholders to ensure alignment between the business strategy and the corporate goal).
The research question that this study answers is: What is the financial performance in the
pharmaceutical industry among companies that have embraced CSR? The related null
hypotheses predicted that there would be no correlations between any of the eight CSR scores
and financial performance. Specifically, the alternative hypotheses predicted positive
correlations between the dependent variable, financial performance and the eight independent
variables: incorporation of general access to medicine management in the business strategy
(Alternative hypothesis 1), incorporation of public policy and market influence in the business
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strategy (Alternative hypothesis 2), incorporation of research and development conducted on
neglected diseases in the business strategy (Alternative hypothesis 3), incorporation of pricing,
manufacturing, and distribution practices in the business strategy (Alternative hypothesis 4),
incorporation of patent and licensing policies in the business strategy (Alternative hypothesis 5),
incorporation of capacity advancement in product development and distribution in the business
strategy (Alternative hypothesis 6), incorporation of product donations and philanthropic
activities in the business strategy (Alternative hypothesis 7), and incorporation of overall CSR in
the business strategy (Alternative hypothesis 8).
The Null Hypotheses predicted no correlations between the dependent variable, financial
performance and the eight independent variables: incorporation of general access to medicine
management in the business strategy (Null Hypothesis 1), incorporation of public policy and
market influence in the business strategy (Null hypothesis 2), incorporation of research and
development conducted on neglected diseases in the business strategy (Null hypothesis 3),
incorporation of pricing, manufacturing, and distribution practices in the business strategy (Null
hypothesis 4), incorporation of patent and licensing policies in the business strategy (Null
hypothesis 5), incorporation of capacity advancement in product development and distribution in
the business strategy (Null hypothesis 6), incorporation of product donations and philanthropic
activities in the business strategy (Null hypothesis 7), and incorporation of overall CSR in the
business strategy (Null hypothesis 8).
Archival data from 18 global pharmaceutical companies were used to determine the
financial performance in the pharmaceutical industry among companies that have embraced
CSR. Four of the eight hypotheses received partial support based on significant correlations in
2014. Specifically, significant 2014 relationships with financial performance (EVA) were
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observed for general access to medicine management (Alternative hypothesis 1), capacity
advancement in product development and distribution (Alternative hypothesis 6), product
donations and philanthropic activities (Alternative hypothesis 7) as well as the overall CSR
(Alternative hypothesis 8).
Descriptive statistics was used to evaluate the 2012 and 2014 CSR and financial
performance (measured as EVA) of 18 pharmaceutical companies. The mean overall CSR scores
increased slightly from 2012 to 2014 while the mean financial performance (EVA) decreased
from 2012 to 2014. The highest mean CSR score for 2012 was product donations and
philanthropic activities, while patents and licensing was the lowest CSR score for 2012. The
highest mean CSR score for 2014 was general access to medicine management, while the lowest
CSR score for 2014 was public policy and market influence.
The changes in CSR scores and EVA from 2012 to 2014 were compared using Wilcoxon
matched pairs test, and significant changes were found in four out of the nine matched pairs.
Specifically, CSR public policy and market influence scores significantly declined; CSR pricing,
manufacturing, and distribution scores significantly gained; CSR capability advancement in
product development and distribution scores significantly gained; and CSR product donations
and philanthropic activities scores significantly declined.
Comparison of Results to Earlier Studies
The relationship between the CSR and corporate financial performance has garnered
much interest and controversy for more than five decades (Preston & O’Bannon, 1997). Despite
this long history of research, analysis, and debate, no consensus on the impact of CSR on
corporate financial performance has been fully established (Griffin & Mahon, 1997; Preston &
O’Bannon, 1997; Saeidi et al., 2015). The results have not been consistent but have often been
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contradictory and rather misleading (Margolis & Walsh, 2003). Although the study of CSR and
its impact on corporate financial performance is growing, it is still unknown whether high profits
enable greater spending on CSR, or if it is that CSR creates higher profits (Robins, 2011).
This study builds on Berete’s (2011) study by testing the strength of the correlations
between CSR and corporate financial performance as predictors of value creation for
stakeholders. Berete’s study evaluated the relationship between overall CSR and financial
performance but did not examine the effects of each of the eight dimensions of CSR on financial
performance. In addition to correlating corporate financial performance with overall CSR, this
study examines the relationship between corporate financial performance and each of the seven
CSR categories: (a) general access to medicine management; (b) public policy and market
influence; (c) research and development conducted on neglected diseases; (d) pricing,
manufacturing, and distribution practices; (e) patent and licensing policies; (f) capacity
advancement in product development and distribution; and (g) drug donations and philanthropic
activities, and (h) overall CSR. Berete’s (2011) study found positive correlation between overall
CSR and financial performance in the pharmaceutical industry. This study found no correlation
between the eight dimensions of CSR and corporate financial performance in 2012. However,
this study found positive and significant relationship between four of eight categories of CSR
and corporate financial performance in 2014. Specifically, significant 2014 relationships with
financial performance (EVA) were observed for general access to medicine management
(Alternative hypothesis 1), capacity advancement in product development and distribution
(Alternative hypothesis 6), product donations and philanthropic activities (Alternative hypothesis
7), and overall CSR (Alternative hypothesis 8). The findings in this study of significant 2014
overall CSR positive relationship with 2014 corporate financial performance support Berete’s
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(2011) findings. Unlike Berete’s findings, the results of this study did not show any effect of
2012 overall CSR on 2012 corporate financial performance in the pharmaceutical industry.
A majority of studies on the relationship between CSR and corporate financial
performance have reported a positive association between CSR and corporate financial
performance (Orlitzky et al., 2003; H. Wang & Choi, 2013), but some have reported negative
relationships. Moore (2001) investigated the relationship between CSR and corporate financial
performance in 8 of 11 firms in the U.K. supermarket industry. The CSR dimensions measured
were employees, customers, shareholders, suppliers, community, and environment while
financial performance metrics were growth in turnover, profitability, return on capital, and
earnings per share. The researcher found negative relationships between CSR and corporate
financial performance, with corporate financial performance declining as CSR initiatives
increased (Moore, 2001).
Some studies in the literature on the link between CSR and financial performance showed
no effect, inconclusive, or mixed relationships between CSR and corporate financial
performance. Aupperle et al. (1985) studied 180 firms to assess the relationship between CSR
and corporate financial performance. The study measured CSR using a survey of the CEOs of
180 firms. The researchers found no association between CSR and corporate financial
performance because their study showed that engaging in CSR practices was neither helpful nor
harmful to a firm (Aupperle et al., 1985). McGuire et al. (1988) assessed the relationship
between CSR and corporate financial performance and they reported mixed results. Their study
showed a positive relationship between CSR and return on asset, a negative relationship between
CSR and operating income growth, and a significant negative relationship between CSR and
ratio of debt to assets (McGuire et al., 1988). Peloza (2009) examined 128 studies concerning the
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relationship between CSR and financial outcomes and reported mixed results. Peloza found that
59% of the studies reviewed reported a positive relationship between CSR and financial
performance, 27% had a mixed or neutral relationship, and 14% had a negative relationship
between CSR and financial performance.
There are inconsistencies in the findings on the relationship between CSR and corporate
financial performance. Sandhu and Kapoor (2005) studied 20 top companies operating in India
from 2000 to 2003, to evaluate the relationship between CSR and corporate financial
performance. The study showed that there was no relationship between CSR and corporate
financial performance (Sandhu & Kapoor, 2005). However, when these same authors replicated
the study on the same companies using same CSR measures and financial performance measures,
they found a significant relationship between CSR and corporate financial performance (Kapoor
& Sandhu, 2010).
Several researchers, including Griffin and Mahon (1997) and Margolis and Walsh (2003)
questioned the methods used by many of the studies that have assessed the relationship between
CSR and corporate financial performance. These researchers argue that the contradictory results
seen in these studies could be because the relationship between the CSR and corporate financial
performance may be affected by some factors that these studies might have overlooked (Griffin
& Mahon, 1997; Margolis &Walsh, 2003; Saeidi et al., 2015). This study builds on Berete’s
(2011) study by evaluating the impact of CSR on corporate financial performance, but the
methodology of this study is quite different from Berete’s study. Because the Access to Medicine
Foundation publishes its CSR ranking of the largest 20 global pharmaceutical companies every
two years, this study correlated the mean value of each two-year financial performance to the
corresponding CSR score. Berete’s study correlated 2008 overall CSR scores with the mean
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financial performance of 2006 and 2007, and the financial performance of 2009 in the
pharmaceutical industry. This study correlated the 2012 scores of each of eight CSR dimensions
with 2012 financial performance (mean financial performance of 2011 and 2012) in the
pharmaceutical industry, and correlated the 2014 scores of each of the eight CSR dimensions
with 2014 financial performance (mean financial performance of 2013 and 2014) in the
pharmaceutical industry.
After decades of research on the relationship between CSR and corporate financial
performance, there exist no consistent factors for measuring CSR, and corporate leaders use
different metrics to evaluate the economic impact of CSR on corporate financial performance
(Peloza, 2009). There is lack of agreement on the metrics or quantifiable measures of CSR
(Santoso & Feliana, 2014). In a review of 159 published studies, Peloza (2009) found that 59
studies used 39 different dimensions or attributes of CSR to assess the relationship between CSR
and corporate financial performance. The CSR performance metrics used in the studies were
highly diverse; some measured a firm’s family-friendly policies, some industry codes of ethics,
while others measured corporate environmental protection activities.
There is disagreement regarding the best way to measure corporate financial performance
when evaluating the link between CSR and corporate financial performance; whether to use
accounting or market-based measures remains unresolved (Gama Boaventura et al., 2012; D. D.
Lee & Faff, 2009; Orlitzky et al., 2003; van Beurden & Gössling, 2008). Researchers have
shown that the two measures (accounting measures and market measures), if used to assess the
economic impact of CSR on financial performance on the same data, would give different
findings (van Beurden & Gössling, 2008). Some researchers have argued that accounting
measures are better than market measures for analyzing the economic impact of CSR on
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corporate financial performance because market-based measurements provide less significant
relationship between CSR and corporate financial performance (van Beurden & Gössling, 2008).
There is controversy about the inconclusive or mixed evidence on whether and to what
extent CSR influences corporate financial performance. Some have argued that the
inconsistencies in the studies’ findings on the economic impact of CSR on corporate financial
performance arise from the context of the studies, such as the country, industry, size of the firm,
and the differences in the number and types of CSR elements measured (Gregory et al., 2014;
Orlitzky et al., 2003). In addition, variations in the studies have been attributed to the different
financial measures used. Some studies have used accounting measures including return on assets,
return on equity, or return on sales while others have used stock returns (Margolis et al., 2009;
Orlitzky et al., 2003). The value of both the accounting measures and the stock market measures
has been disputed. Some have called accounting measures backward looking and questioned the
value of the data obtained from using these measures (Gregory et al., 2014). Others argue that
stock market measures are forward-looking measures that provide an outlook of future cash
flows (Margolis et al., 2009), but some researchers contend that using stock market measures can
produce misleading results on the relationship between CSR and corporate financial performance
(Gregory et al., 2014).
The debate over the impact of CSR and corporate financial performance remains
unsettled because no consensus has been achieved in the numerous studies that have evaluated
the relationship between CSR and corporate financial performance. Margolis and Walsh (2003)
analyzed 127 research studies that investigated the relationship between CSR and corporate
financial performance between 1972 and 2002. Their results showed mostly positive, few
negative, and no relationship between CSR and corporate financial performance. Some scholars
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have concluded that the relationship between CSR and corporate financial performance is a
complex puzzle and it is not possible to make a theoretical generalization about the effects of
corporate socially responsible practices on corporate financial performance (Margolis &Walsh,
2003; Perrini et al., 2011; Saeidi et al., 2015).
Critics of CSR have argued that investing in CSR instead of other potentially profitable
business strategies decreases economic performance (Aupperle et al., 1985; D. D. Lee & Faff,
2009). Ullmann (1985) argued that because of the large number of variable factors that impact a
firm’s CSR and corporate financial performance, it is unreasonable to claim that there is a
relationship between CSR and the corporate financial performance. The findings of this
quantitative study on the impact of CSR on financial performance in the pharmaceutical
company do not support the assertion that the costs incurred when a firm invests in CSR decrease
corporate financial performance. At the minimum, this study found that investment in CSR does
not decrease corporate financial performance, but instead CSR investment has moderate positive
relationship with corporate financial performance based on the 2014 significant relationship
between four of eight CSR dimensions with corporate financial performance, and no 2012
relationship between eight CSR dimensions with corporate financial performance.
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This study makes new contributions to the understanding of the economic impact of CSR
on corporate financial performance by broadening an earlier study. Berete’s (2011) study only
evaluated the relationship between a single dimension of CSR (overall CSR) and financial
performance in the pharmaceutical industry. This study assessed the relationship between overall
CSR and corporate financial performance in the pharmaceutical industry. In addition, this study
examined the relationship between corporate financial performance and each of the seven CSR
categories: (a) general access to medicine management; (b) public policy and market influence;
(c) research and development conducted on neglected diseases; (d) pricing, manufacturing, and
distribution practices; (e) patent and licensing policies; (f) capacity advancement in product
development and distribution; (g) drug donations and philanthropic activities, and (h) overall
CSR. This study found partial correlation between four of the eight dimensions of CSR and
corporate financial performance based on significant positive correlations found between the
four categories of CSR and corporate financial performance in 2014 but not in 2012. Significant
2014 positive relationships with financial performance were observed for general access to
medicine management, capacity advancement in product development and distribution, product
donations and philanthropic activities, and overall CSR. The significant 2014 overall CSR
positive relationship with 2014 corporate financial performance partially supports Berete’s
(2011) findings. The findings in this study of no negative relationship between any of the eight
categories of CSR and corporate financial performance in the pharmaceutical industry is an
important contribution to the understanding of the relationship between CSR and financial
performance in the pharmaceutical sector.
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Alignment with Theoretical Framework
This study uses the Global Leadership Network Framework to assess how focused
companies that have embrace CSR are on the four corporate domains: business strategy, engaged
learning, leadership, and operational excellence. The CSR data in this study were collected from
the public data of Access to Medicine Index, a rating company whose ranking criteria align with
the four domains of the Global Leadership Network Framework. The Access to Medicine Index
scores and ranks the CSR performance of 20 global pharmaceutical corporations on: (a) general
access to medicine management CSR scores; (b) public policy and market influence CSR scores;
(c) research and development conducted on neglected diseases CSR scores; (d) pricing,
manufacturing, and distribution practices CSR scores; (e) patent and licensing policies CSR
scores; (f) capacity advancement in product development and distribution CSR scores; (g) drug
donations and philanthropic activities; and (h) overall CSR scores. This study evaluated the
impact of CSR on the financial performance in the pharmaceutical industry on 18 pharmaceutical
companies that have embraced CSR.
The Access to Medicine Index provides guidance to companies and reports on what all
the pharmaceutical companies in the index are already doing well, and where solutions are still
lacking (Access to Medicine Index, 2012, 2014). The Access to Medicine Index reports on how
companies integrate CSR into their business strategies, and examines how they engage and share
knowledge with stakeholders. In addition, the Index addresses access to medicines-related risks,
opportunities and challenges, and explores innovative business models that improve access to
medicine in a cost-effective way (Access to Medicine Index, 2012, 2014). The Index provides
insight for companies, the global health, and investors to facilitate cooperation among all
stakeholders working to improve human health globally (Access to Medicine Index, 2012, 2014).

135
The Global Leadership Network Framework focusses on: (a) business strategy
(evaluating business priorities and alignment of CSR with business policies and processes), (b)
engaged learning (defining corporate CSR policy through interaction and consultation with
stakeholders), (c) leadership (commitment of the corporation to take leadership on social and
environmental issues that are important to the business), and (d) operational excellence
(embedding CSR through coordination of processes, practices, policies, and relationships with
the stakeholders to ensure alignment between the business strategy and the corporate goal). The
following analyses of the eight dimensions of CSR reported by Access to Medicine show
evidence that the rating of the 20 pharmaceutical companies is consistent with the four domains
(business strategy, engaged learning, leadership, and operational excellence) of the theoretical
framework of this study. The Access to Medicine Index analyzes different areas of the eight CSR
dimensions on which they rate the 20 pharmaceutical companies as shown below.
2012 and 2014 Access to Medicine Index CSR Report
General access to medicine management. The Access to Medicine Index analyzes the
business strategies of pharmaceutical firms by evaluating how access to medicine is embedded in
corporate governance and the processes for reviewing access to medicine strategies and
initiatives. It reports on the transparency of companies’ strategies and motives. In addition, the
index assesses the operational excellence and engaged learning practices of the companies and
reports on the extent and quality of stakeholder engagement, and whether the viewpoints of
stakeholders are incorporated in the business strategies. The index encourages innovation and
reports on whether companies are developing new business models to meet the needs of poor
patients. The index reports on the leadership of the management units responsible for
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developing, managing, and implementing access to medicine strategies and initiatives (Access to
Medicine Index, 2012, 2014).
Public policy and market influence. The Access to Medicine Index evaluates strategic
business activities of the pharmaceutical companies such as lobbying activities, ethical
marketing, anticorruption, antibribery, and competitive behavior. The index reports on how
companies regulate their behavior, and reports on lobby activities and any breach of laws and
standards in all countries in which the companies operate (Access to Medicine Index, 2012,
2014). The index reports on unethical marketing practices such as improper marketing practice,
bribery and corruption, and company’s initiatives to counter these corporate malpractices. In
addition, the index reports any innovative training or enforcement mechanisms to ensure ethical
behavior in company operations.
Research and development conducted on neglected diseases. Because of the lack of
access to medicine for poor people, especially for people living in developing countries, there is
great demand for R & D that targets communicable and non-communicable diseases, neglected
diseases, maternal diseases, and neonatal diseases (Access to Medicine Index, 2012, 2014). The
Index examines how company pipelines target diseases in these categories. The Index reports on
companies’ commitment to take leadership on product development programs that target
diseases covered by the Index. It reports on ethical clinical trials conduct and transparency of
clinical trials. The Access to Medicine Index also reports any innovative strategic business
models that focus on current gaps in product development for diseases covered by the Index.
Pricing, manufacturing and distribution practices. There is public outcry that
pharmaceutical drugs are too expensive and that the high prices of drugs deny access to
medicines for the poor. The Access to Medicine Index measures companies’ operational
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excellence (embedding CSR through coordination of processes, practices, policies, and
relationships with the stakeholders to ensure alignment between the business strategy and the
corporate goal) to determine if these firms consider patients’ ability to pay when developing their
pricing, manufacturing, and distribution strategies (Access to Medicine Index, 2012, 2014). The
index reports on how companies certify that their products are priced equitably, especially for the
poor patients, and how manufacturing and distribution practices of the companies help to
guarantee product quality.
Patent and licensing policies. Patents are the life blood of pharmaceutical companies
because it is the company’s intellectual property. A patent on a drug reduces competition and
gives a company monopoly rights, but monopoly can limit access to affordable medicine. The
Access to Medicine Index asks companies a series of questions about the business strategies they
use to limit the impact of patent monopolies on low income patients, and the firm’s efforts to
support the entry of generic medicine manufacturers into the market (Access to Medicine Index,
2012, 2014). The Index also questions the pharmaceutical companies about steps taken to lower
drug prices where generic medicine markets are absent.
Capacity advancement in product development and distribution. The Access to
Medicine Index analyzes capacity advancement in product development and distribution by
examining long-standing corporate engagement with local stakeholders that is aligned with the
needs and aims of the local population, and designed to improve the skills of people in the
communities in which the pharmaceutical company is operating (Access to Medicine Index,
2012, 2014). Capacity advancement in product development and distribution essentially analyzes
the four domains of the Global Leadership Network Framework: leadership, engaged learning,
business strategy, and operational excellence. The Access to Medicine Index evaluates how
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companies engage with local stakeholders to build capabilities in clinical research. The Index
reports on how companies are improving quality management skills and competencies of the
people in the community to make sure that drugs produced locally meet international standard of
quality. The Index reports on companies’ actions on improving pharmacovigilance systems
(monitoring the effects drugs sold to the community to identify and evaluate any adverse
reactions). In addition, it reports on how companies are building other local capacities, such as
training health care workers, encouraging healthy living, and building health infrastructure.
Drug donations and philanthropic activities. The Access to Medicine Index
emphasizes that companies take a strategic and structured business approach toward donations
and philanthropic activities by focusing corporate business strategies on neglected diseases on a
long-term basis rather than a one-time emergency donation of products (Access to Medicine
Index, 2012, 2014). The Index reports on companies’ product donations that target eradication,
or control of a disease, and on philanthropic activities that support national and international
health. The Index also reports on novel philanthropic activities that can improve the impact and
efficiency of donations and philanthropic activities. As shown above, the process for ranking the
CSR of 20 pharmaceutical companies is aligned with the four domains (business strategy,
engaged learning, leadership, and operational excellence) of the theoretical framework of this
study.
Many companies are in the business of rating the CSR performance of firms but to the
best of the researcher’s knowledge, no other rating index ranks companies on the same CSR
dimensions as those of Access to Medicine Index. Researchers agree that measuring CSR is
difficult and some have suggested various methods, including reputation indices, behavioral and
perceptional measures, and case study (Turker, 2009). Despite the growth in number of
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companies that are participating in CSR reporting, and the numerous methods that have been
proposed for measuring CSR initiatives, the measurement of CSR remains a problem because
almost all the methods for measuring CSR have limitations (Turker, 2009). Droppert and Bennett
(2015) conducted an exploratory qualitative study of CSR on six large multinational
pharmaceutical firms to understand why global pharmaceutical companies incorporate CSR in
their business strategies and promote ways to leverage CSR to improve human health worldwide.
The seven multinational pharmaceutical companies evaluated in Droppert and Bennett’s (2015)
study—GlaxoSmithKline, Johnson and Johnson, Merck & Co., Novartis, Pfizer, Roche, and
Sanofi—are also among the 18 pharmaceutical companies in this quantitative study of the impact
of CSR on financial performance in the pharmaceutical industry. Droppert and Bennett reported
that out of all the current indices that score CSR, track the development, implementation, and
effects of CSR strategies in the pharmaceutical industry, “Access to Medicines Index is best
aligned with public health interests, but needs more work in terms of garnering attention,
promoting transparency and ensuring that the indicators truly reflect existing priorities and
concerns” (p. 7). This study supports the findings of Droppert and Bennett because to the best of
the researcher’s knowledge, there are no other indices with CSR dimensions that are better
aligned to human health than the Access to Medicine’s eight CSR dimensions evaluated in this
study.
Another framework that could be used for evaluating the relationship between CSR and
corporate financial performance is the pyramid of CSR (Figure 2). The pyramid of CSR
proposed by Carroll (1991) provides a framework for understanding how a firm can reconcile its
role of maximizing shareholders’ profits with its social responsibilities to stakeholders. The
pyramid of CSR proposed that in addition to economic and legal obligations, a corporation also
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has ethical and philanthropic responsibilities (Carroll, 1991). Carroll’s four-part CSR pyramid
complements the current trend in corporate management where there is a growing acceptance of
the relationship between the economic role of the firm and its obligations to the society (Gupta,
2012).
Final Summary of the Literature
Some scholars and corporate leaders have questioned if corporations should be involved
in philanthropy especially after the economic arguments by Milton Friedman in a 1970 New York
Times article and in his 1962 book Capitalism and Freedom. Friedman (1962) wrote in his book
that the corporation is owned by its stockholders. The corporation should not make any
charitable contributions. If the corporation makes a charitable contribution, it denies the
individual stockholders the right to decide how to use his or her funds. Friedman’s argument
assumes that goals directed to helping society and corporations’ economic goals are quite
different, so that when a corporation spends on social issues, the corporation is depriving itself of
its economic goals (Friedman, 1962, 1970). Although this study found no correlation between
2012 product donations and philanthropic activities and 2012 corporate financial performance in
the pharmaceutical industry, product donations and philanthropic activities did not negatively
impact financial performance in 2012. The findings in this study of significant positive
relationship between 2014 product donations and philanthropic activities and 2014 corporate
financial performance in the pharmaceutical industry, do not support Friedman’s (1962, 1970)
argument against corporate philanthropic activities.
Conclusions and Implications
This study evaluated the long debated, unresolved relationship between CSR and
corporate financial performance. This study sheds new light on the economic link between CSR
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and financial performance in the pharmaceutical industry by evaluating eight dimensions of
CSR, seven of which to the best of the researcher’s knowledge, have not been explored up to
date. The study contributes to the literature on CSR-financial performance in a couple of ways.
First the study measured the link between CSR and financial performance in the Pharmaceutical
industry to collaborate earlier studies. This study focused on a single industry supporting Griffin
and Mahon (1997) who argued that to increase the internal validity of studies on the relationship
on the link between CSR and financial performance future research should focus on companies
from the same industry rather than multiple companies in various industries.
Second, this study contributes to the literature by exploring the impact of eight different
dimensions of CSR on financial performance in a single industry. The study correlated financial
performance with: CSR scores of general access to medicine management, CSR scores of public
policy and market influence, CSR scores of research and development conducted on neglected
diseases, CSR scores of pricing, manufacturing, and distribution practices, CSR scores of patent
and licensing, CSR scores for capacity advancement in product development and distribution,
CSR scores of product donations and philanthropic activities, and overall CSR scores. Because
this study was able to differentiate the economic impact of eight dimensions of CSR on financial
performance, the results would benefit future studies on the economic effects of CSR on
pharmaceutical companies that have embraced CSR and those that have not.
Third, the results of earlier studies on the impact of CSR on corporate financial
performance have not been consistent but have often been contradictory and misleading. This
study found a moderate positive relationship (25% positive relationship) between CSR and
corporate financial performance in the pharmaceutical industry based on a significant 2014
positive relationship between four dimensions of CSR and 2014 corporate financial performance.
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The results of this study suggest at the minimum, that CSR does not negatively impact financial
performance in the pharmaceutical industry. That this study did not find evidence of a negative
correlation between CSR and corporate financial performance in the pharmaceutical industry, is
a significant result in itself.
Recommendations for Future Study
This study uses Googins’s et al. (2007) Global Leadership Network framework as the
theoretical framework to evaluate the impact of CSR on financial performance in the
pharmaceutical industry. The Global Leadership Network framework focuses on business
strategy, engaged learning, leadership, and operational excellence. It provides corporations
beneficial and socially responsible strategies to assist companies “to conceptualize and to
monitor their triple bottom line performance” (Googins et al., 2007, p. 126). The researcher
recommends that as many pharmaceutical companies are developing and restructuring their CSR
strategies, future studies should define CSR more succinctly to help corporate leaders develop
their business strategies as they align their CSR policies. Droppert and Bennett’s (2015)
qualitative study of CSR in seven of the highest earning multinational pharmaceutical firms,
found that CSR meant different things for each firm. Each firm defined CSR differently,
managed CSR differently, was involved in different CSR activities, and had different
motivations for engaging in CSR. The dimensions of CSR to be measured should be
standardized (Droppert & Bennett, 2015).
The researcher supports Griffin and Mahon (1997), who called on researchers to focus
their studies of the relationship between CSR and financial performance on a single industry to
allow the scholar to determine if similar issues within the industry are treated in like manner.
Each industry is unique because each industry has different competencies and internal and
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external pressures. Therefore, the internal and external pressures in an industry, such as
governmental regulations and consumer issues, are likely to be similar within each industry.
Scholars should concentrate on studying the link between CSR and corporate financial
performance within a specific industry because of the “uniqueness of internal competencies or
external pressures inherent in an industry, the degree of public visibility, the different
configurations of stakeholders and their differing degrees of activism on particular issues”
(Griffin & Mahon, 1997, p. 10). The type of social responsibility activities a firm chooses to
engage in is uniquely related to the nature of the demands by its stakeholder, its corporate
competencies, and industry environment (Baird et al., 2012; Griffin & Mahon 1997; Simpson &
Kohers, 2002). Researchers should focus their studies of the relationship between CSR and
financial performance on a single industry to determine if similar issues within the industry are
treated in like manner, and thus, potentially eliminate or reduce the current inconsistencies in the
literature on the link between CSR and financial performance.
In support of Castka et al. (2005), a company should develop a management system that:
(a) creates, delivers, and measures corporate objectives in alignment with its TBL; and (b)
reviews the effectiveness and efficiency of the business processes to implement effectively and
embed CSR into its day-to-day business. The concept of the TBL is often called the three Ps:
people, planet, and profits. It proposes that firms should pay attention not only to maximizing
their wealth or financial bottom line, but also to the welfare of all their stakeholders (Meijer &
Schuyt, 2005; Rogers & Hudson, 2011; Slaper & Hall, 2011). In other words, leaders of
organizations should run their businesses profitably and should also take responsibility for the
impact of the organizations’ actions on the stakeholders and society. Pharmaceutical companies
should develop balanced solutions that support their TBL (economic, environmental, and social
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aspects of the company’s business performance) based on communications with the stakeholders.
Rodriguez-Fernandez’s (2016) study assessed the relationship between CSR and
corporate financial performance on companies registered on the Madrid Stock Exchange in 2009.
The study found that engaging in socially responsible corporate policies produced higher profits
and higher profits enhanced engagement in socially responsible corporate policies. The author
argued that increasing CSR activities improved corporate financial performance, and when firms
enjoy improved financial performance they earn improved CSR rating, thus creating a positive
feedback loop that encourages firms to incorporate CSR policies in their business (RodriguezFernandez, 2016). The researcher posits that companies might be encouraged to incorporate
consistently CSR policies in their business strategies by the moderate positive relationship
between CSR and corporate financial performance in the pharmaceutical industry in this study,
and Rodriguez-Fernandez’s (2016) findings showing that increasing CSR activities improves
corporate financial performance and creates a positive feedback loop that perpetuates corporate
financial well-being.
The body of literature on CSR contains myriad definitions of the CSR concept (Swaen &
Chumpitaz, 2008), and as such, some have termed CSR a tortured concept (Godfrey et al., 2010).
Most CSR definitions emphasize the voluntary actions of business designed to improve society’s
social or environmental conditions (Mackey et al., 2007; Margolis & Walsh, 2001). Because the
search for a common definition of CSR is still elusive, the researcher supports that a clear
definition of CSR be developed for each industry. There are differences in internal competencies
of each industry, demand from stakeholders, and issues that are important to the industry.
Therefore, defining CSR relevant to each industry might help to eradicate the inconsistencies in
current literature, help cooperate leaders design CSR strategies that meet the needs of their
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industry and society, and provide a better understanding about the link between CSR and
financial performance.
The 18 pharmaceutical companies that participated in this study have integrated CSR in
their business strategies, but there is a wide variation in the level of CSR among these
companies. Many have argued that a high level of CSR performance can be a strategic
investment that could ultimately increase a firm’s profits and thus lead to increase in shareholder
returns (Nollet et al., 2016). However, it is still unknown whether high profits enable greater
spending on CSR, or if it is that CSR creates higher profits (Robins, 2011). To shed more light
on the relationship between CSR and corporate financial performance in the pharmaceutical
industry, future quantitative studies could categorize companies as follows: (a) Based on level of
CSR scores—high, medium or low CSR scores,—correlate the mean CSR score of each group
with the corporate financial performance of that group; (b) Based on level of financial
performance—high, medium or low financial performers—correlate the mean CSR score of each
group with the corporate financial performance of that group. This could advance the
comprehension of the impact of CSR on financial performance in the pharmaceutical industry.
Such a study could clarify if high levels of CSR increase financial performance or if high levels
of financial performance increase investment in CSR.
Pharmaceutical companies should consistently incorporate CSR in their business
strategies because it has been reported that consistent practice of CSR improves financial
performance, although this study showed a moderate positive relationship between CSR and
financial performance in the pharmaceutical industry. Nollet et al. (2016) examined the
relationship between CSR and corporate financial performance. The researchers found that while
engaging in CSR practices impacts financial profitability negatively in the beginning, the

146
negative effect is reversed after crossing a critical point of continuous investment in CSR
policies, and CSR ultimately helps to improve the firm’s financial performance. Pharmaceutical
companies should engage long-term planning about their CSR activities and continuously
commit resources to CSR practices, so that CSR can help improve their financial profitability,
access to medicines, human health, and society.
Summary
For more than four decades, research has focused on the social responsibilities of a
business, the economic argument for CSR, and the link between CSR and corporate financial
performance (Carroll, 1999; Perrini et al., 2011; Wartick & Cochran, 1985; Wood, 1991).
Although the debate on the economic impact of CSR on corporate financial performance has
been ongoing for many decades, the business case or rational for CSR and the association
between CSR and corporate financial performance remains controversial (D. D. Lee & Faff,
2009; Margolis & Walsh, 2003; Perrini et al., 2011).
The search for an association between CSR and corporate financial performance has
grown immensely since the 1980s (Ameer & Othman, 2012). While CSR has gained the
attention of corporate leaders and scholars (Cheng et al., 2014), the research on the association
between CSR and corporate financial performance has not yet conclusively defined the economic
impact of CSR on corporate financial performance (Margolis & Walsh, 2003). The concept of
CSR has been evolving since the early 1930s (Carroll, 1979), and throughout the past decades,
CSR has grown from a marginalized concept into a complex one that is increasingly becoming
central in business decision making (Cochran, 2007). Companies in various industries are
increasingly becoming engaged in socially responsible activities that improve the welfare of
society (Y. Wang & Berens, 2015). Despite the attention that corporations are giving to CSR,
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many still doubt that CSR creates value for a firm since the existing research has not provided a
conclusive answer (Cheng et al., 2014; Margolis, & Walsh, 2003; Servaes & Tamayo, 2013).
The 18 pharmaceutical companies evaluated in this study have all incorporated CSR in
their business strategies. The pharmaceutical industry has a highly complex set of stakeholders to
balance, including patients; government regulators; the health and scientific community; patient
advocates; the media; activists, including antivivisectionists; politicians; and the public. The
pharmaceutical industry is admired because it provides medicines that cure life-threatening
diseases, but the industry is also much criticized because it does not provide everyone a cure at
affordable prices (Nussbaum, 2009). Over time, many people grew to distrust the pharmaceutical
industry and the glowing public image of the industry has been tarnished by various reports in
the media of unethical and illegal behavior such as not disclosing negative results in clinical
trials, high drug prices, and companies enticing doctors with gifts to use their drugs (Nussbaum,
2009).
To rebuild trust, it behooves all pharmaceutical companies to include CSR activities in
their business strategies because businesses are not measured on their profitability alone (Kessel,
2014). The pharmaceutical industry is different from other industries because it is in a business
designed to improve the health of people while concurrently increasing shareholders’ profits. It is
important for pharmaceutical companies to engage CSR in their business strategies because the
pharmaceutical industry is different from other sectors since its business decisions have direct
impact on human lives (Droppert & Bennett, 2015). The public perceives the pharmaceutical
industry differently from other sectors because the industry discovers and develops drugs that
can save human lives. Therefore, the pharmaceutical industry is perceived as having a distinct
ethical responsibility to the public such as providing access to drugs to all patients. It can be
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argued that pharmaceutical companies are primarily loyal to shareholders and not to their
products’ consumers (Kessel, 2014).
The pharmaceutical industry cannot afford to deemphasize patients’ needs. Access to
medications in the early 20th century was considered a luxury that only the affluent could afford,
but today, access to medicine is regarded as a human right (Kessel, 2014). Because the industry
has the ability to provide access to medicines, it has a moral obligation to do so. Developing
CSR strategies that focus on transparent policies and procedures for drug development and
clinical trials, drug pricing, and marketing will go a long way toward helping the industry
balance its responsibilities to its stakeholders. This study did not find any negative correlations
between CSR and financial performance in the pharmaceutical industry. This study found a
partial support for significant positive relationships among four dimensions of CSR and financial
performance in the pharmaceutical industry. The finding of partial support for the economic
impact of CSR on financial performance, and no negative impact of CSR on financial
performance in the pharmaceutical industry, should encourage corporate leaders in this sector to
increase their investment in CSR to provide access to medicines and improve society.
To the best of the researcher’s knowledge, this study is the first of the small number of
studies that have examined the relationship between CSR and financial performance in the
pharmaceutical industry and that evaluated the economic effect of each of the eight categories of
CSR on financial performance in the pharmaceutical industry. Because of the inconsistency that
still exists about the economic impact of CSR on financial performance, evaluation of the eight
dimensions of CSR in this study contributes to the body of literature on CSR and advances the
comprehension of the impact of CSR on financial performance in the pharmaceutical industry.
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More studies have reported positive relationships between CSR and corporate financial
performance than negative relationships (Margolis et al., 2009). This study found partial support
for the correlation of CSR with corporate financial performance. Although it might not be clear if
doing good to the stakeholders engenders doing well financially, many results inherently support
the concept that investment in CSR improves financial performance. If scholars can prove that
doing good, in terms of transparency in business practices and addressing social ills, could be
associated with doing well in corporate financial performance, then companies might be
persuaded to incorporate CSR in their business strategies. Pharmaceutical companies would be
encouraged to do good even if it means sustaining additional costs, so that they can improve their
financial performance, increase access to medicines, and improve the well-being of society. If
scholars can prove the business case for CSR, meaning that CSR and shareholder value
maximizing could be persuasively shown to be synergistic, business leaders could justify
investment in CSR as a legitimate business expense.
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APPENDIX E1:
Overall CSR Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
Overall
CSR
Scores
0.9
1.6
2.4

2012
EVA
(million)
4402
5840
-820

2014
Overall
CSR
Scores
1.56
1.94
2.51

2.1
0.9
1.9
2.0
3.0
3.8

1750
-16452
14563
2808
2009
4867

2.23
1.50
2.47
1.73
2.81
3.29

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

3.6
3.1
2.5
2.9
3.0
2.2
2.3
3.2

6439
762
33
9597
15552
1072
7415
-1628

2.84
2.64
2.77
2.84
3.01
1.93
2.30
2.57

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

1.1

-113154

1.45

-275675

2014
EVA
(million)
-2989
-379
-636

Corporate
Headquarter
s
Japan
Great Britain
Germany

Japan
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APPENDIX E2:
CSR General Access to Medicine Management Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Co.

2012 2012
2014 2014
CSR EVA
CSR EVA
Scores (million) Scores (million)
0.5
4402
1.0
-2989
2.6
5840
2.1
-379
3.9
-820
2.7
-636

Corporate
Headquarters
Japan
Great Britain
Germany

Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences

2.4
0.9
2.6
2.1
3.4

1750
-16452
14563
2808
2009

1.6
0.7
3.3
2.6
2.9

828
-50609
-8175
1756
6235

GlaxoSmithKline

4.9

4867

4.9

3954

Great Britain

Johnson & Johnson

4.8
3.7
2.8
3.4
4.1
2.4
2.5
4.1
1.1

6439
762
33
9597
15552
1072
7415
-1628
-113154

4.4
4.3
3.8
4.8
4.7
2.1
2.7
3.3
1.0

9122
-2597
103
8913
20665
2169
8008
-1855
-275675

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France
Japan

Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda Pharmaceutical

USA
Japan
Japan
USA
USA
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APPENDIX E3:
CSR Public Policy & Market Influence Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
2.1
1.8
2.9

2012
2014 2014
EVA
CSR EVA
(million) Scores (million)
4402
1.6
-2989
5840
1.7
-379
-820
1.7
-636

Corporate
Headquarters
Japan
Great Britain
Germany

3.6
1.9
3.0
3.5
3.1
3.8

1750
-16452
14563
2808
2009
4867

2.4
0.4
1.8
0.8
2.8
2.1

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

3.5
3.2
2.9
3.4
3.6
2.4
3.3
3.9

6439
762
33
9597
15552
1072
7415
-1628

1.1
1.3
1.3
1.4
2.7
1.4
1.4
1.0

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

2.0

-113154

1.3

-275675

Japan
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APPENDIX E4:
CSR Research & Development Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
1.2
2.3
1.8

2012
2014 2014
EVA
CSR EVA
(million) Scores (million)
4402
1.6
-2989
5840
2.5
-379
-820
2.1
-636

Corporate
Headquarters
Japan
Great Britain
Germany

1.9
1.2
2.8
2.7
2.1
4.7

1750
-16452
14563
2808
2009
4867

2.2
2.2
2.4
2.0
2.1
3.7

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

3.8
3.7
2.8
3.6
2.7
2.4
2.4
3.8

6439
762
33
9597
15552
1072
7415
-1628

3.3
2.5
3.0
3.0
2.4
2.0
1.8
2.5

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

1.4

-113154

2.6

-275675

Japan
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APPENDIX E5:
CSR Pricing, Manufacturing & Distribution Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
0.2
0.7
2.0

2012
2014 2014
EVA
CSR EVA
(million) Scores (million)
4402
2.3
-2989
5840
1.3
-379
-820
3.2
-636

Corporate
Headquarters
Japan
Great Britain
Germany

2.0
0.4
0.8
1.1
3.2
2.9

1750
-16452
14563
2808
2009
4867

2.6
1.7
2.9
1.5
3.8
3.0

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

2.7
2.5
1.8
2.5
2.7
2.1
2.0
2.5

6439
762
33
9597
15552
1072
7415
-1628

3.2
3.1
2.9
2.6
3.3
1.8
2.9
3.0

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

0.2

-113154

1.1

-275675

Japan
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APPENDIX E6:
CSR Patents & Licensing Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
0.8
1.4
1.5

2012
2014
EVA
CSR 2014 EVA
(million) Scores (million)
4402
0.8
-2989
5840
1.2
-379
-820
1.8
-636

Corporate
Headquarters
Japan
Great Britain
Germany

1.5
0.7
0.8
1.4
4.1
2.6

1750
-16452
14563
2808
2009
4867

2.6
1.7
1.9
1.4
2.8
2.8

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

3.2
2.6
1.3
1.7
1.8
0.9
1.7
1.5

6439
762
33
9597
15552
1072
7415
-1628

1.3
0.9
1.9
1.9
1.5
1.6
1.8
1.7

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

0.8

-113154

0.6

-275675

Japan
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APPENDIX E7:
CSR Capability Advancement in Product Development & Distribution Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
0.8
1.3
2.8

2012
2014 2014
EVA
CSR EVA
(million) Scores (million)
4402
1.5
-2989
5840
3.1
-379
-820
3.0
-636

Corporate
Headquarters
Japan
Great Britain
Germany

1.2
0.6
1.6
1.4
2.2
4.2

1750
-16452
14563
2808
2009
4867

1.8
1.2
2.0
2.0
2.5
3.5

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

3.7
2.7
2.9
2.8
3.0
1.9
2.7
3.7

6439
762
33
9597
15552
1072
7415
-1628

3.3
3.3
3.0
3.8
3.9
2.9
2.6
3.8

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

1.6

-113154

2.0

-275675

Japan
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APPENDIX E8:
CRS Product Donations & Philanthropic Activities Scores and EVA

Company
Astellas Pharma
AstraZeneca plc
Bayer AG
Bristol-Myers
Squibb Co.
Daiichi Sankyo
Eisai Co. Ltd.
Eli Lilly & Co.
Gilead Sciences
GlaxoSmithKline
Johnson &
Johnson
Merck & Co.
Merck KGaA
Novartis AG
Novo Nordisk
Pfizer Inc.
Roche Holding
Sanofi
Takeda
Pharmaceutical

2012
CSR
Scores
1.5
2.3
3.4

2012
2014 2014
EVA
CSR EVA
(million) Scores (million)
4402
1.4
-2989
5840
2.5
-379
-820
2.8
-636

Corporate
Headquarters
Japan
Great Britain
Germany

3.0
1.3
3.1
2.4
3.0
4.6

1750
-16452
14563
2808
2009
4867

1.7
1.3
2.7
2.0
2.4
3.4

828
-50609
-8175
1756
6235
3954

USA
Japan
Japan
USA
USA
Great Britain

4.4
4.1
4.0
3.7
4.1
3.8
2.3
4.5

6439
762
33
9597
15552
1072
7415
-1628

3.1
3.5
3.4
3.3
3.6
2.1
2.8
2.6

9122
-2597
103
8913
20665
2169
8008
-1855

USA
USA
Germany
Switzerland
Denmark
USA
Switzerland
France

1.8

-113154

1.7

-275675

Japan
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